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ABSTRACT 
 
ALISON P. SANDERS: Environmental metals and birth defects: 
New approaches to understanding the role of metals in congenital heart defects 
(Under the direction of Rebecca C. Fry) 
 
Birth defects are a leading cause of infant mortality, and cardiac defects are 
among the most fatal. The majority of birth defects have no known cause whether 
environmental, genetic, or a combination of these factors. Toxic metals are likely 
contributors to birth defects in humans, yet the biological pathways that underlie these 
relationships remain largely unknown. The objective of this research was to assess the 
contributions of environmental metals to congenital heart defects using i) an ecologic 
study to evaluate the relationship between metals and birth defects in North 
Carolina and ii) an in vitro cardiomyocyte model to identify underlying metal-
altered molecular pathways. This research evaluated the associations between arsenic, 
cadmium, manganese, and lead levels in private well water with the prevalence of 
specific birth defects using six years of data collected by the North Carolina Birth Defects 
Monitoring Program. Prevalence ratios (PR) with 95% confidence intervals (CI) were 
calculated to estimate the association between the prevalence of birth defects in census 
tracts with the highest average metal levels compared to the lowest average metal levels, 
adjusted for maternal age, race, and education status. We identified relationships between 
the highest category of arsenic exposure and the prevalence of conotruncal heart defects 
(PR: 1.3 95%CI: 0.9-1.8) as well as the highest category of manganese exposure and the 
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prevalence of atrioventricular septal heart defects (PR: 1.8 95% CI: 1.1-3.1). The findings 
suggest an ecologic association between concentrations of metals in drinking water and 
the prevalence of specific birth defects. Next, we applied an in vitro approach to identify 
biological pathways that underlie metal-altered signaling in the heart. We exposed 
human-derived cardiomyocytes to low-level cadmium chloride (0.5 µM) and assessed 
changes in genome-wide microRNA (miRNA) and messenger RNA (mRNA) expression 
levels. We identified 8 miRNAs and 31 genes that were differentially expressed in 
cardiomyocytes exposed to cadmium compared to unexposed controls. A subset of 8 
mRNAs were predicted targets of the cadmium-associated miRNAs. We identified 
miRNA-dependent signaling pathways that were enriched for gene expression, 
embryonic development, and organismal development. Taken together, the findings 
contribute to the understanding of potentially preventable environmentally-mediated birth 
defects. 
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CHAPTER 1: INTRODUCTION 
 
 
The global burden of birth defects  
 Birth defects affect approximately 3% of all live births and are the leading cause 
of infant mortality in the US [1]. The estimated cost of US hospital stays due to birth 
defects was $2.6 billion in 2004 [2], and birth defects are the 10th leading cause of global 
Disability Adjusted Life Years [3]. Despite the serious physiological and economic 
impacts of births defects, roughly 60-70% of birth defects have no known environmental 
or genetic cause [4]. Collectively, birth defects include a spectrum of structural 
malformations at birth including musculoskeletal, reproductive, gastrointestinal, 
craniofacial, neural tube, and cardiac anomalies. Each of these broad classifications is 
further divided into specific phenotypes that range in severity and may be diagnosed from 
before birth to later in life.  
  
 Congenital heart defects (CHDs) 
 Congenital heart defects (CHDs) are the most common type of birth defects, 
occurring in nearly 1 in 100 live births [5], and are the leading cause of defect-related 
deaths [6]. CHDs consist of a heterogeneous group of structural malformations affecting 
structures of the heart including the valves, chambers and walls, and outflow tracts. The 
most common CHDs include septal defects such as ventricular septal defects (VSD) and 
atrial septal defects (ASD), conotruncal defects such as Tetralogy of Fallot (TOF) and 
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transposition of the great arteries (TGA), and outflow tract obstructions such as 
hypoplastic left heart syndrome (HLHS) and coarctation of the aorta [7]. Many infants 
born with CHDs undergo surgery in the first six months of life, which may fully repair a 
defect; however, diagnosis of a CHD in some cases may require life-long healthcare and 
multiple reparative surgeries [8]. Approximately 34% of birth defect hospitalizations in 
the US are due to cardiac and circulatory anomalies, and there is substantial economic 
burden of CHDs, estimated at nearly $1.4 billion in 2004 [2]. 
 Many CHDs arise from genetic origins such as chromosomal abnormalities or 
single gene mutations. For example, of infants born with Edwards Syndrome, a genetic 
disorder that is caused by an additional copy of the 18th chromosome, 90-100% are 
estimated to develop a CHD [9]. An increasing number of genetic factors or syndromes 
have been identified for many of the cardiac phenotypes [9, 10]; however, it’s estimated 
that 80% of CHD cases originate from other or unknown causes [11]. 
  
 Environmental factors that contribute to CHDs  
 Even with the identification of some genetic risk factors, the biological 
mechanisms of CHD remains poorly understood. As with other complex diseases, it is 
hypothesized that a combination of genetic and environmental factors contribute to 
CHDs, rather than a single component in isolation. Potential environmental exposures of 
interest in CHD etiology have included maternal diet (including alcohol and tobacco 
products), maternal health conditions (diabetes, influenza, or rubella), medication use 
(including retinoic acid and anti-seizure medications), maternal stress, air pollution, 
pesticides, disinfection byproducts, solvents, and heavy metals [6, 12-14]. Notably, toxic 
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metal exposure has been associated with birth defects (reviewed by [15]), yet limited 
studies have directly assessed this relationship or mechanism of action. Given the large 
economic and societal impacts of birth defects and specifically the contributions of 
cardiac defects, the studies presented herein examine the links between early life 
exposure to toxic metals and CHDs at the population and mechanistic levels.  
 
Toxic metals as ubiquitous environmental contaminants  
Toxic metals are elements that have no known biological role in human 
physiology. The research presented in Chapter 2 prioritized four heavy metals for study 
based on their environmental relevance in North Carolina: arsenic, cadmium, lead, and 
manganese. Arsenic, cadmium, lead, and manganese are toxic metals ranked by the 
ATSDR as priority contaminants of concern and are known carcinogens and/or 
neurodevelopmental toxicants [16-19].  
Toxic metals are present in environmental reservoirs including air, water, and 
soil; and human exposure is widespread in populations worldwide and in the US. 
Specifically, diet and drinking water are common sources of exposure to each of these 
metals. Among pregnant women participating in the Fourth National Report on Human 
Exposure to Environmental Chemicals (NHANES IV), 66%, 89%, and 94% had 
detectable levels of cadmium, mercury, and lead in whole blood [20]. Blood levels of 
arsenic were not examined. The global prevalence of toxic metals in the environment 
combined with their well-documented health effects represents a public health concern on 
a global scale.  
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Sources and routes of potential toxic metal exposure  
Arsenic is the 20th most abundant element in the Earth’s crust [21]. 
Approximately 70% of environmental arsenic is naturally-occurring and 30% is created 
as a result of anthropogenic sources [22]. Human exposure to arsenic primarily occurs 
through consumption of contaminated drinking water or food products including rice, 
apples, [16, 23]. For example, it is estimated that more than 30 million individuals in 
Bangladesh are potentially exposed to arsenic through contaminated drinking water wells 
[24].  
Cadmium exposure commonly occurs through diet via consumption of shellfish 
and leafy greens and through exposure to tobacco products [19]. Minor exposure can also 
occur from byproducts of industrial processes [19]. Blood levels of cadmium among 
smokers are up to five times higher than blood levels detected in nonsmokers [25], and 
cadmium levels in pregnant women exposed to second–hand smoke have been shown to 
be double that of nonsmokers [26].  
Exposure to lead can result from various environmental sources such as 
contaminated dust or soil, drinking water, lead-based paint, cigarette smoke, as well as 
byproducts of industrial processes [17]. Due to the removal of lead from gasoline in the 
1970s and 80s, environmental lead levels have steadily declined. Drinking water is a 
potential route of lead exposure as a result of lead leaching from lead-soldered pipes [27] 
and rural counties may experience additional risk factors for environmental lead exposure 
such as older housing and lower socioeconomic status that may increase an individual’s 
likelihood of exposure [28].  
Manganese is typically considered an essential metal, but excess levels of 
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manganese are known to result in neurotoxic effects in humans [18]. Manganese is 
typically encountered through diet; however, drinking water may be a significant source 
of manganese ingestion [29]. Inhalation exposure to manganese aerosols can occur 
through showering and occupational exposure to welding fumes [18, 30].  
 
Drinking water metal exposure 
Arsenic, cadmium, and lead are regulated in public water supplies under the Safe 
Drinking Water Act at levels of 10 µg/L, 5 µg/L, and 15 µg/L [31]. It should be noted 
that lead is regulated according to a Treatment Technique (TT) which requires that no 
more than 10% of samples can exceed 15 µg/L; arsenic and cadmium regulatory 
standards are set as the Maximum Contaminant Level (MCL) allowed in public 
distribution systems. Manganese, largely due to issues associated with taste and odor, is 
regulated at a Secondary Maximum Contaminant Level (SMCL) of 50 µg/L that is not 
federally enforced in public distribution systems [31]. Detectable levels of metals in 
public drinking water can range up to the MCL and may potentially contribute to low-
level exposure in the general population; however, MCLs in public water distribution 
systems are largely considered protective of human health.  In contrast, millions of US 
residents rely on drinking water supplies known as private domestic wells that are not 
regulated by federal government regulations, and there are currently no regulatory 
standards for domestic well waters. In areas where there a high proportion of private well 
use is compounded by underlying geology predisposed to elevated metal levels, 
individuals may unknowingly consume drinking water with contaminant levels in excess 
of EPA guideline levels.   
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Approximately 14% (about 42 million people) of the U.S. population and 26% of 
North Carolinians (2.3 million), use federally unregulated private wells as a primary 
drinking water source [32]. Private well water consumption in the U.S. is associated with 
an excess lifetime risk of bladder and lung cancer due to arsenic ingestion that is five 
times higher than that estimated for public well users [33] (Kumar 2010). Previously, we 
showed that arsenic levels in North Carolina private wells ranged as high as 806 ppb - a 
level that is 80 times the current EPA MCL in public distribution systems [34] (see 
Appendix One) and exceeds a level associated with known cancer risks. This initial study 
also demonstrated spatial and temporal trends of naturally-occurring arsenic across the 
state. These data support that ingestion of metal-contaminated drinking water may be a 
public health concern in North Carolina. Identifying regions of contamination through 
studies like the one above, can help to shape state and local water monitoring policies 
[35] as well as assist in developing cost-effective monitoring programs that target at risk 
populations. Moreover, there is a need to better understand potential health effects 
associated with private well metal exposure, particularly among susceptible populations, 
in North Carolina.   
 
Prenatal exposure, susceptibility, and development  
The widespread occurrence of environmental metals indicates a public health 
need to monitor and protect susceptible populations from toxic metal exposures in North 
Carolina. Pregnant women and children are considered susceptible populations due to 
their developmental status and/or compromised immune systems. Heavy metals including 
arsenic, cadmium, lead, and manganese are known human carcinogens and/or 
	   7	  
developmental toxicants [16-19].  The known neurotoxic and developmental impacts of 
toxic metals make these priority contaminants of concern for the protection of population 
health. Of concern, these metals are able to cross the placental barrier potentially 
resulting in in utero exposure during a critical period of developmental susceptibility [36-
38]. Prenatal metal exposure has been implicated in numerous adverse health outcomes in 
newborns including increased infant mortality, lower birth weight, and intrauterine 
growth restriction (reviewed by [15]). Prenatal biomonitoring programs would serve to 
protect pregnant women and the developing fetus, yet these remain limited in number.  
 
Prenatal biomonitoring of toxic metals 
Toxic metal exposures in utero and during childhood may result in significant 
health effects to individuals that manifest cumulatively to the detriment of populations. 
US annual economic losses due to decreased productivity from environmental exposure 
to mercury and lead were estimated as $8.7 and $43.4 billion respectively [39, 40]. In 
pregnant women, maternal blood levels of 3.5 µg/L mercury and 5.0 µg/dL lead are 
recommended for the protection of fetal health [41-43]. However, currently Minnesota, 
New York City, and New York State are the only jurisdictions that have active guidelines 
for monitoring maternal blood lead levels in the US [43], in spite of strong evidence to 
indicate the adverse health effects of metals to susceptible populations such as newborns.  
While North Carolina has established a successful program for childhood lead 
screening [44], we recently showed that in a sample of pregnant women from North 
Carolina (n=211), more than 57% had a detectable blood levels of more than one toxic 
metal including arsenic, cadmium, mercury, or lead [45]  (see Appendix Two). 
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Specifically, arsenic (65.7%), cadmium (57.3%), mercury (63.8%), and lead (100%) 
levels were detected in maternal blood samples. The findings also suggest that factors 
related to maternal county of residence and race may impact maternal exposure levels. 
Moreover, some women exceeded the guideline levels of mercury and lead during 
pregnancy. No reference guideline levels currently exist for prenatal levels of arsenic or 
cadmium. 
Targeted national, statewide, and community level programs promoting mothers’ 
awareness of metals exposure and in utero effects would help to protect human health 
and lessen the economic burden of metal exposure. Biomonitoring programs in North 
Carolina and other targeted populations can help to protect the health of expectant 
mothers and their children by reducing prenatal exposures and subsequently the potential 
for future adverse developmental effects [45].  
 
In utero and developmental susceptibility  
Prenatal biomonitoring represents a step towards protecting the health of 
developing newborns. The first trimester of pregnancy is considered a critical period of 
fetal susceptibility to maternal exposure to environmental contaminants. Specifically, one 
month prior to conception and three months after conception is known as the 
periconceptional period. Environmental exposures during the periconceptional period are 
of greatest concern to the developing fetus. In birth defect etiology, each major organ 
system has a more sensitive period during development, which overlaps with the 
pregnancy/developmental timeline for specific organs. The most sensitive time period for 
cardiac development occurs in the first through third weeks of pregnancy. 
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The heart is the first major organ to develop and function in an embryo. The heart 
arises out of the primary and the secondary heart fields, which originate the left ventricle 
or the right ventricle, respectively [46]. The two fields converge to form the heart tube, 
which then loops and bends to begin to form the four-chambered heart [46]. On 
approximately day 21 after conception, electrophysiological factors induce spontaneous 
orchestrated contraction of cardiac cells and the human heart begins to beat [47]. The 
process of heart formation is a highly controlled and time-dependent process [48]. Proper 
development and function of the cardiovascular system is crucial for embryonic survival 
and health. Defects in cardiac development may result in fetal loss or congenital heart 
defects. Physiologically, there are still many unknowns about the processes that control 
and regulate embryonic heart development. The highly regulated, precise coordination 
and timing of cardiac development stages in early gestation potentially prior to pregnancy 
detection means that cardiac organ development is particularly susceptible to 
environmental influences [46].  
 
Relationships of environmental metals to birth defects  
 There are many detrimental health outcomes associated with developmental metal 
exposure including spontaneous abortion, stillbirth, low birth weight, preterm birth, 
reduced fetal growth, impaired neurodevelopment, and congenital malformation [15, 49-
55]. Despite the known developmental effects of metals and susceptible periods of fetal 
development in pregnancy, few epidemiologic studies have examined the link between 
maternal metal exposure and the occurrence of structural defects. Exposure to metals, 
such as arsenic, cadmium, mercury, and lead, is associated with detrimental birth 
	   10	  
outcomes in humans [56-61]. Further, epidemiological data suggest there may be links 
between environmental exposure to metals and birth defects in humans including birth 
defects [15, 62-69]. These findings are demonstrated in animal models, which clearly 
show that exposure to toxic metals cause birth defects [70-73], yet epidemiological 
studies investigating these effects in human populations remain limited in number and 
study quality. 
 
Epidemiologic evidence of the relationship between drinking water metals and 
birth defects 
 
This section reviews the literature regarding the four prioritized heavy metals that 
will be discussed in Chapter 2, namely arsenic, cadmium, lead, and manganese. Metals in 
drinking water including arsenic and lead have been associated with the occurrence of 
CHDs [62, 64, 69] as well as NTDs [63, 68]. No studies have examined manganese 
exposure in drinking water and the relationship to birth defects, and only a single study 
has analyzed cadmium levels in drinking water with the occurrence of NTDs [63].  
Studies that have examined the association between drinking water metal levels 
and birth defects reported conflicting findings. One study in Bangladesh reported an 
elevated odds of any birth defect (odds ratio (OR): 1.005, 95% CI: 1.001-1.010) with 
exposure to environmental arsenic in drinking water, but did not differentiate between 
types of birth defects [66]. The finding was a small but statistically significant association 
and the authors recommended future examination of the association with NTDs. A 
second study investigated the association between arsenic in drinking water as well as 
occupational metal exposures and the risk of NTDs (lumped spina bifida, anencephaly, 
and encephalocele) [63]. This case-control study found that environmental metals in 
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drinking water including arsenic, cadmium, mercury and lead were not strong risk factors 
for NTDs. Zierler et al. conducted a case-control study in of drinking water arsenic levels 
and cardiovascular defects in Massachusetts [69]. The authors reported an association 
between publicly supplied drinking water arsenic levels and the prevalence of congenital 
heart defects, specifically that of coarctation of the aorta (prevalence odds ratio (POR): 
3.4, 95% CI: 1.3-8.9).  In an ecologic study of mortality from circulatory diseases in the 
US, Engel and Smith reported an elevated standardized mortality ratio of 2.0 (95% CI: 
1.1-3.4) among female infants with circulatory system anomalies [64]. A case-control 
study in Massachusetts reported crude and adjusted ORs of 1.8 and 2.2 (no 95% CIs were 
reported) of grouped cardiovascular defects associated with detectable lead levels in 
drinking water [62]. A single study, conducted in Scotland, reported no association 
between lead in drinking water and NTDs and did not assess the relationship with other 
defects [67]. 
The association between manganese exposure through drinking water and birth 
defects has not been previously studied. However, one study reported that exposure to 
water manganese levels greater than 0.4 mg/L was associated with an elevated risk of all-
cause infant mortality compared to unexposed controls (OR: 1.8, 95%CI: 1.2-2.6) [74]. 
The authors recommended that future studies be conducted to replicate the findings and 
examine more specifically defined mortality outcomes. 
 
Limitations of epidemiological studies of birth defects 
The dearth of epidemiological studies investigating the relationship between 
environmental metal exposures and birth defects is in part due to methodological hurdles 
	   12	  
that impact studies of rare outcomes. Given the nature of birth defect etiology, 
population-based studies examining environmental causes of disease must be 
retrospective since it is not known in advance whether a fetus will develop a defect. This 
results in several major hurdles in studies of birth defects including poor exposure 
assessment and subsequent issues of temporality, limited sample sizes or poor case 
ascertainment, and unmeasured confounding.  
Among the studies examining drinking water metal exposures, exposure was 
assigned based on average levels in community or public water supplies. Temporal 
fluctuations were accounted for in two of the studies by assigning maternal exposure 
based on public water samples closest to the date of conception [63, 69]. Samples were 
averaged if the distribution system was unknown or multiple water tests were performed 
within the periconceptional period. In other instances, samples were obtained from the 
mother’s primary water source up to one year after pregnancy [66]. Ideally, maternal 
exposure assessment would be performed near the time of conception, however this is not 
feasible with the preferred case-control design used to study birth defects. Direct 
biological monitoring of maternal and fetal exposures during the periconceptional period 
would greatly improve potential exposure misclassification issues in studies of 
environmental causes of birth defects. This approach is particularly difficult in the study 
of birth defects due to the low prevalence of defects and the associated cost of monitoring 
a large number of individuals to detect a small proportion of cases. Moreover, exposure 
monitoring during the critical period of susceptibility may differ greatly based on the 
defect of interest. Commonly, information on environmental exposures is obtained 
through questionnaire or maternal interview. Direct exposure assessment may be less of a 
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concern for geographically stable contaminants. For instance, in arsenic endemic regions 
evidence indicates that levels of arsenic in groundwater tend to remain stable for several 
years [75]. 
Notwithstanding possible exposure misclassification, these studies were largely 
hampered by insufficient sample sizes and case enrollment (n<30) for analyses. Studies 
investigating the effects of any exposure on birth defects should separate defect etiologies 
as outcome as much as possible, preferably to individual phenotype classifications or 
groups based on similar etiology. Lumping cases into large groups of defects (as by [63, 
66] can obscure interpretation of the findings due to outcome misclassification since there 
are a wide variety of congenital malformation etiologies.  
Additional factors that affect metal-defect relationships include prenatal nutrition 
[76], maternal age [77], race [78], socioeconomic status [68, 79], infant sex [80], and 
family history [81]. For example, in the U.S. non-Hispanic Black infants compared with 
non-Hispanic white infants, had a significantly higher birth prevalence of Tetralogy of 
Fallot [78]. CHDs are also more common among families of lower socioeconomic classes 
[79] and among families with a previous CHD occurrence [81]. Limited sample sizes or 
use of retrospective data (e.g. collected through birth defects registries) may prevent 
adequate adjustment for confounding variables.  
The biological mechanism by which toxic metals may induce birth defects is not 
well understood and is underrepresented in the literature. Studies may be lacking due to 
the well-documented ability of arsenic and other metals to induce spontaneous abortion 
[49, 82] that may ultimately prevent the true proportion of incident cases of congenital 
malformations from being detected. The use of in vivo and in vitro models has enabled 
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more direct study of the mechanisms that drive metal-defect associations and largely 
eliminates the limitations encountered by population-based studies.  
 
Understanding biological mechanisms that link metals to CHDs 
As discussed above, CHDs are associated with metal exposures including arsenic 
and lead [62, 64, 69, 83]. A preponderance of evidence from epidemiological, in vivo and 
in vitro studies has provided substantial knowledge of genetic and environmental factors 
that contribute to CHDs. Toxic metals are known to impact cell function at a molecular 
level that can result in cancer and non-cancer endpoints [84, 85], however, the role of 
molecular factors in metal-associated birth defects in humans remain largely unknown. 
Molecular factors including gene expression and epigenetic processes that ultimately 
control gene expression may underlie metal-associated CHDs.  
 
Toxicological findings: in vivo and in vitro studies 
Given the number of ethical and technical limitations associated with studying 
environmentally-mediated causes of birth defects in humans, alternative in vivo and in 
vitro models provide controlled situations and have enabled substantial advances in the 
understanding of defect etiology. There is extensive evidence from animal models 
suggesting that toxic metal exposure is associated with structural malformations [73, 86-
94]. For example, metals including arsenic, cadmium, lead, and mercury have been 
shown to induce structural defects in the chick embryo affecting development of the 
neural tube, limbs, gut, and heart among other structures [70, 73, 91, 95, 96]. Notably, 
there is extensive research and debate on the role of arsenic in NTDs as animal models 
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consistently demonstrate teratogenicity but epidemiologic studies inconsistently report an 
association [68, 87, 97]. Thus, animal models are useful to better understand molecular 
mechanisms and pathways involved in the interplay between metal exposure and birth 
defects [97, 98].    
In vivo models present several advantages including that cardiac development is 
largely conserved cross vertebrate species, animal models provide shorter developmental 
timelines and the ability to model maternal conditions. In vivo models allow researchers 
to differentiate between the effects of pre- and postnatal exposures and enable direct 
assessment of exposures during critical windows of susceptibility. Advances in 
understanding mechanisms of CHD etiology have been made possible through the use of 
genetically modified animals such as knock-out models. For example, there are a number 
of candidate genes (e.g, connexin40 and connexin45) that upon deletion from the genome 
result in septal defects in animal models, including VSDs [99-101]. Further, there is 
evidence that prenatal metal exposure, for example to cadmium, can lead to long-term 
alterations in cardiac function in adult rats [102].  
The results from in vivo experiments are currently curated in publicly accessible 
databases of genes and environmental contaminants with known associations. Together 
these have enabled novel computational predictions that allow for relatively quick survey 
of the role of molecular factors in metal-associated birth defects. We have previously 
used toxicogenomic approaches to identify biological pathways perturbed by metal 
exposure using an in ovo whole chick embryo model [95]. Specifically, we 
computationally predicted key biological pathways that were metal-associated and altered 
during development. Using an in ovo approach we validated that blockade of a prioritized 
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pathway, the glucocorticcoid pathway, reverted arsenic-induced neural tube defects in the 
chick embryo. The results demonstrated the application of a novel systems biology 
strategy by which biological pathways can be predicted and subsequently tested to 
increase our understanding of pathophysiological mechanisms related to birth defects 
[95]. 
In vitro models offer the advantage of studying relevant tissue types (eg, human 
cell types) under highly controlled environments that further reduce the influence of 
confounding factors in animal studies. In vitro studies also benefit from relatively quick 
experimental time, and ease of collection of biological samples for molecular analyses. 
Few studies, however, have investigated the toxicogenomic and epigenetic effects of 
metals in heart cells. Identification of genomic and epigenetic effects of metals levels in 
metal-perturbed heart function using in vitro culture of cardiomyocytes has not been 
previously described.   
  
Biological signaling pathways related to CHDs 
The exact mechanisms contributing to CHDs remain elusive, however key gene 
families are involved in cardiac development [99, 103-108]. There is growing evidence 
that prenatal environmental exposure may influence the burden of disease in adult life, 
and that this relationship is associated with epigenetic modifications altered during the 
prenatal period [109-112]. It is hypothesized that many key cardiac development genes 
have upstream regulators that may be modified by metal exposure perhaps through 
epigenetic processes, leading to altered heart development and function in adulthood 
[113, 114].  
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Epigenetic mediators: DNA methylation and microRNAs 
Epigenetics is the study of heritable changes that occur “above” the genome that 
do not directly alter the genetic sequence. Epigenetic factors include DNA methylation, 
histone modification, microRNAs (miRNA) which have functional consequences in the 
cell such as modifying gene expression or protein translation without changes in DNA 
sequence [115, 116]. DNA methylation refers to the addition of a methyl group that can 
be reversibly added to cytosine bases typically occurring in cytosine-guanine (CpG) rich 
areas of the DNA. Changes in DNA methylation are potentially transcriptional-regulating 
and can have profound impacts, particularly during development. The addition or 
removal of methyl groups from 5-methylcytosine (5-meC), or DNA methylation, is an 
epigenetic mechanism that may play a key role in mediating biological processes [110], 
possibly contributing to subsequent health effects resulting from environmental toxicant 
exposure.  
Metals are known modifiers of DNA methylation [84, 117-119]. We recently 
investigated the effects of cadmium exposure on fetal and maternal patterns of DNA 
methylation in a cohort of mother-baby pairs from North Carolina. We found that 61 and 
92 genes in fetal and maternal DNA were differentially methylated and showed that these 
genes were enriched for biological pathways involved in transcriptional regulation and 
apoptosis [120] (See Appendix Three).   
miRNAs are short single-stranded RNAs approximately 20 nucleotides in length 
that post-transcriptionally regulate gene expression through silencing. miRNAs are 
involved in a number of cell proliferation, apoptosis, and developmental processes [111, 
112]. miRNAs are small non-coding RNA segments that selectively bind segments of 
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messenger RNA (mRNA) and prevent translation of proteins, ultimately resulting in gene 
silencing. The first miRNA, lin-4, was discovered in 1993 in C. elegans and is involved 
in regulation of key genes in organism development. Currently over 1,100 human 
miRNAs have been identified and are believed to target approximately 60% of genes 
[121]. Multiple miRNAs may bind to and/or control downstream translation of proteins. 
Likewise, a single miRNA can bind multiple mRNA targets. The implications of miRNA 
post-transcriptional processes include the potential to inhibit biological pathways even in 
the presence of increased gene expression (mRNA transcripts).  
miRNAs are known regulators of gene expression during cardiovascular 
development (reviewed by [114, 122]). Specifically, miR-133, miR-22, and miR-1 are 
involved in cell proliferation and maintenance processes that dictate gene expression and 
cardiac development and/or dysfunction. Of note, miR-1 overexpression negatively 
regulates cardiac growth, in part by targeting and downregulating heart and neural crest 
derivatives-expressed protein 2 (Hand2), a transcription factor that promotes 
cardiomyocyte expansion [123]. It has also be shown that mice deficient in miR-17~92 
developed fatal ventricular septal defects [124].  
Numerous studies have assessed miRNA expression with respect to arsenic 
exposure and are reviewed in [125], while only three studies have examined or cadmium-
associated miRNA changes in human tissues or cell lines [126-128]. Occupational 
cadmium exposure was associated with increased expression of miR-146a in peripheral 
blood leukocytes [126]. In Chinese children, increased levels of urinary arsenic and lead, 
but not cadmium were associated with decreased levels of miR-21 and miR-221 [127]. 
Finally, human hepatoblastoma cells exposed to 10 µM cadmium showed decreased 
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expression levels of 12 miRNAs, four of which belonged to the let-7 family of tumor 
suppressors [128].  
Both DNA methylation and miRNA expression are proposed epigenetic processes 
that contribute to CHDs [114, 129, 130]. Given that metals alter miRNA expression, it is 
plausible that metal-induced miRNA alterations in heart cells, may affect a large number 
of cell division and maintenance processes, which contribute to aberrant gene expression 
and dysregulated cardiac function and/or development. The research presented in Chapter 
3 examines miRNAs as a potential epigenetic mechanism of metal-induced perturbed 
cardiac gene expression. Epigenetic processes may likely be the “missing link” in 
previous studies of genetic and environmental factors that influence birth defect etiology.  
 
Research gaps and specific aims 
Metal exposure continues to be an important area of public health concern for 
both maternal and child health. There are knowledge gaps in population-based studies of 
toxic metals exposure and birth defect outcomes as well as understanding the underlying 
biological processes that potentially mediate metal-induced defects. The identification of 
metal-defect relationships as well as the underlying genetic and epigenetic components 
will lead the way in understanding potentially preventable environmentally-mediated 
defect etiology. 
While studies investigating the relationship between metals in drinking water and 
the risk of birth defects show putative evidence of a positive association with CHDs, 
there is room for methodological improvement and need for further studies. Bias due to 
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possible exposure misclassification, insufficient sample sizes, and issues regarding case 
identification and ascertainment largely hampered previous studies. In addition, all US 
studies that have examined the association between drinking water arsenic and birth 
defect outcomes have referenced populations supplied by public drinking water. Public 
drinking water is federally regulated for most toxic metals. Since millions of Americans 
obtain their water from unregulated domestic private wells and private wells and these 
wells are federally unregulated, studies of private well water and birth defect outcomes 
are needed. The area of environmental metal exposure and birth defect outcomes has 
room for methodological improvement and an essential need for additional study to 
investigate potential associations in potential metal-exposed populations such as North 
Carolina private well users.  
 The research presented in Chapter 2 assesses the contributions of environmental 
metals to the prevalence of CHDs using an ecologic study to evaluate the relationship 
between private well drinking water metals and CHDs in North Carolina. We analyzed 
North Carolina private well monitoring data and birth defect registry data to identify 
associations between environmental metals the prevalence of birth defects. This research 
investigated epidemiologic relationships between specific birth defects, including CHDs, 
and a panel of environmental metals (e.g. arsenic, cadmium, manganese, and lead) using 
statewide birth defect registry data from 2003 to 2008. We hypothesized that private well 
levels of arsenic, cadmium, manganese, and lead were associated with the prevalence of 
specific birth defects in North Carolina.  
In addition to understanding metal-defect associations at the population level, 
there is a need to mechanistically understand biological pathways that lead to disease. In 
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vitro models enable highly-controlled experimental conditions to investigate the cellular 
mechanisms underlying biological responses and pathways in metal-exposed human 
cells. miRNA expression is clearly involved in embryonic cardiac development and is 
implicated in response to metal exposure, but is previously unexplored as a potential 
mechanism of metal-induced birth defects. There is a need to understand the mechanistic 
impact of metals on cardiomyocyte miRNA expression and subsequent control of gene 
expression. Identification of genomic and epigenetic modifiers in metal-perturbed heart 
function using in vitro culture of human cardiomyocytes has not been previously 
described.   
 The research presented in Chapter 3 assesses the potential contributions of 
environmental metals to the etiology of CHDs using an in vitro cardiomyocyte model to 
identify underlying metal-altered molecular pathways. We used in vitro heart cell culture 
to assess genome-wide gene expression and miRNA expression levels in human 
cardiomyocyte cells. This research toxicogenomically identified pathways that are 
dysregulated in human heart cells as a result of exposure to an environmentally relevant 
cadmium dose. We hypothesized that in vitro metal exposure would alter cardiomyocyte 
contractility and gene expression through an epigenetic mechanism, namely miRNA 
expression and key signaling pathways were identified using a systems biology approach.  
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CHAPTER 2: ASSOCIATION BETWEEN ARSENIC, CADMIUM, 
MANGANESE, AND LEAD LEVELS IN PRIVATE WELLS AND BIRTH 
DEFECTS PREVALENCE IN NORTH CAROLINA: AN ECOLOGIC STUDY 
 
Overview 
Heavy metals including arsenic, cadmium, lead, and manganese are known 
human carcinogens and/or developmental toxicants that are able to cross the placental 
barrier from mother to fetus. In this population-based study, we assess the association 
between metal concentrations in private well water and birth defect prevalence in North 
Carolina. We conducted a semi-ecologic study including 20,151 infants born between 
2003 and 2008 with selected birth defects (cases) identified by the North Carolina Birth 
Defects Monitoring Program, and 668,371 non-malformed infants (controls). We 
geocoded maternal residences at delivery and over 20,000 well locations measured for 
metals by the North Carolina Division of Public Health. The average level of each metal 
was calculated among wells sampled within North Carolina census tracts. Individual 
exposure was assigned as the average metal level of the census tract that contained the 
geocoded maternal residence. Prevalence ratios (PR) with 95% confidence intervals (CI) 
were calculated to estimate the association between the prevalence of birth defects in the 
highest category (≥90th percentile) of average census tracts metal level and compared to 
the lowest category (≤50th percentile). Statewide, private well metal levels exceeded the 
EPA Maximum Contaminant Level in 2.2, 0.1, 3.9, and 21 percent of wells tested for 
arsenic, cadmium, lead, and manganese, respectively. The highest category of arsenic 
exposure was weakly associated with a higher prevalence of conotruncal heart defects 
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(PR: 1.3 95% CI: 0.9-1.8). The highest category of manganese exposure was significantly 
associated with a higher prevalence of atrioventricular septal heart defects (PR: 1.8 95% 
CI: 1.1-3.1) and was modestly associated with conotruncal heart defects (PR: 1.3 95% CI: 
1.0-1.9). These findings suggest an ecologic association between concentrations of 
certain metals in drinking water and specific birth defects.   
 
Introduction 
Heavy metals including arsenic, cadmium, lead, and manganese are known 
human carcinogens and/or developmental toxicants [1-4]. These metals are able to cross 
the placental barrier potentially resulting in in utero exposure during a critical period of 
developmental susceptibility [5-7]. There are many detrimental developmental health 
outcomes potentially associated with metal exposure including spontaneous abortion, 
stillbirth, low birth weight, preterm birth, reduced fetal growth, impaired 
neurodevelopment, and congenital malformation [8-15]. 
Birth defects are a leading cause of infant mortality in the U.S. [16, 17], yet 60-
70% have no known cause [18]. In epidemiologic studies, toxic metals including arsenic, 
cadmium, and lead have been associated with congenital structural malformations 
(reviewed by [9]). Metal exposure from arsenic- and lead-contaminated drinking water 
has been associated with an increased occurrence of congenital heart defects (CHDs) [19-
21] as well as neural tube defects (NTDs) in human populations [22, 23]. The 
teratogenicity of arsenic, cadmium, manganese, and lead has been demonstrated in 
animal models, specifically affecting cardiac, limb, musculoskeletal, craniofacial, and 
central nervous system development [10, 24-26]. It is clear from animal studies that metal 
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exposure can result in structural malformation; however, limited population-based human 
studies have examined such relationships.  
Diet and drinking water are common sources of metal exposure in non-
occupationally exposed individuals. In North Carolina, 2.3 million residents use private 
wells for drinking water [27], and the water quality of these wells is not federally 
regulated [28]. Notably, several statewide assessments of North Carolina private wells 
have indicated geographical regions with naturally-occurring arsenic [29-31], with levels 
in some wells as high as 806 ppb - a level that is 80 times the current EPA Maximum 
Contaminant Level (MCL) standard (10 ppb) in public distribution systems [29]. These 
data support that ingestion of metal-contaminated drinking water may be a public health 
concern in North Carolina. To date, no studies that examined the association between 
metals in private wells and birth defect prevalence have been carried out in North 
Carolina.  
In the present study we examined private well water levels of arsenic, cadmium, 
manganese, and lead across North Carolina, and used an ecologic study design to assess 
the association between metal levels and specific birth defect phenotypes. Individual 
level data on maternal water consumption were not available; therefore, we conducted a 
semi-ecologic study by assigning maternal drinking water metal exposure based on 
geocoded residence within a census tract. We compared the prevalence of twelve specific 
defect types or groups of defects in census tracts with the highest average metal levels to 
the prevalence in census tracts with the lowest average metal levels. This work represents 
the first effort to assess the association between statewide levels of metals in North 
Carolina wells with birth defects. 
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Methods 
 
Study design and study population 
We conducted a statewide semi-ecologic study including 20,151 eligible cases 
and 668,371 non-malformed controls in North Carolina born between 2003 and 2008. To 
be eligible for this study, participants were liveborn singleton infants born between 2003 
and 2008, with a geocoded residence at delivery within a North Carolina census tract. In 
addition, eligible case infants could not have any known chromosomal abnormalities. 
Infants from non-singleton births (n=25,069), without a geocoded residence at delivery 
(n=38,216), or case infants with known chromosomal abnormalities (n=1,305) were 
excluded from this study.  
Individual-level data regarding maternal source of drinking water and frequency 
of consumption were not available; therefore our ecologic study used the census tract as 
the unit of analysis. Our analysis included 797 census tracts across North Carolina. 
Private well water data were provided by the North Carolina Department of Health and 
Human Services within the Division of Public Health. The well water database contained 
metal concentrations collected from private wells across the state between 1998 and 2010 
measured by inductively coupled plasma-mass spectrometry. This database contains 
historical records of well water samples collected by and analyzed at the State Laboratory 
of Public Health in Raleigh, North Carolina as we have previously described [29].  
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Outcome classification 
The following twelve structural defects or groups of defects were included in this 
study: (1) spina bifida without anencephaly (n=218); (2) anotia and microtia (n=94); (3) 
conotruncal defects including common truncus, Tetralogy of Fallot (TOF), and 
transposition of the great arteries (TGA) (n=435); (4) atrioventricular septal defects 
(AVSD) and endocardial cushion defects (ECD) (n=150); (5) hypoplastic left heart 
syndrome (HLHS) (n=142); (6) cleft palate (CP) (n=351); (7) cleft lip (CL) with or 
without CP (n=516); (8) esophageal atresia (EA) and tracheo-esophageal fistula (TEF) 
(n=140); (9) pyloric stenosis (n=1,204); (10) reduction defects of the upper and lower 
limbs (n=255); (11) gastroschisis (n=215); and (12) hypospadias (n=1,994).  
Case infants with selected birth defects were identified by the North Carolina 
Birth Defects Monitoring Program (BDMP). The BDMP is a statewide active 
surveillance program covering all 100 North Carolina counties [32]. Cases were liveborn 
infants identified through systematic review and abstraction of medical records by BDMP 
field staff. Diagnoses were confirmed by supporting documentation in the medical 
record, such as surgical or autopsy reports, medical imaging, and physical exams. 
Selected birth defects in this analysis included a spectrum of phenotypes comprising 
NTDs, CHDs, gastrointestinal, genitourinary, and musculoskeletal defects. Non-
malformed controls infants were identified from birth certificate records during the same 
years. 
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Exposure assessment 
Environmental metals of interest included arsenic, cadmium, manganese, and 
lead. We analyzed over 20,000 measurements of metal concentrations in private wells 
collected by the North Carolina Department of Health and Human Services across the 
state between 1998 and 2010. Only private wells with a corresponding GPS coordinate or 
with a complete geocoded address were considered in this study (~67% of wells sampled 
statewide). GPS coordinates were standardized to a decimal degree format and private 
well locations were geocoded according to previously described methods [29]. The 
number of geocoded wells varied by metal where 46,286 had arsenic measures, 22,915 
had cadmium measures, 70,671 had manganese measures, and 76,387 had lead 
measurements. Geocoded well locations were then assigned to North Carolina census 
tracts corresponding to the 2000 census using ESRI ArcGISTM 9.3 (Redlands, CA).  
The average level of each of the four metals (arsenic, cadmium, manganese, and lead) 
was calculated within each census tract across the state. The distributions of average 
metal levels were mapped using ESRI ArcGISTM 9.3 software (Redlands, CA). Census 
tracts with fewer than ten well measures for each contaminant over the total time period 
were excluded from further analysis (n=352, 44%).  
Maternal residence at delivery for cases and controls was geocoded by the North 
Carolina State Center for Health Statistics. Cases and controls were assigned to census 
tracts in North Carolina based on geocoded maternal residence at delivery using ESRI 
ArcGISTM 9.3 (Redlands, CA). 
A dichotomous exposure contrast was developed to compare exposed and non-
exposed Census tracts at delivery. First, we examined the distribution of average metal 
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concentrations across all tracts with at least ten well water measures, and calculated the 
corresponding 50th and 90th percentiles of average concentration for each metal. Then, 
we assigned an exposure status to each Census tract for each metal based on these 
percentiles as follows: residences were considered “exposed” for a given metal if the 
average concentration of the metal within the corresponding tract was equal to or greater 
than the 90th percentile of metal concentration across all tracts combined; tracts were 
considered “non-exposed” for a given metal if the average concentration of the metal 
within the corresponding tract was less than or equal to the 50th percentile of metal 
concentration across all tracts combined. Thus, the final dichotomous exposure contrast 
compared “exposed” census tracts (a tract where metal concentrations exceeded the 90th 
percentile of the distribution of metal concentrations across the state) and “non-exposed” 
census tract. The resulting 50th and 90th percentiles were as follows: 1.27 and 2.32 ppb 
for arsenic, 0.54 and 1.82 ppb for cadmium, 47.25 and 133.33 ppb for manganese, and 
3.65 and 7.80 ppb for lead.  
 
Covariates 
The following maternal and infant characteristics were obtained for cases and 
controls from the birth certificate: residence at delivery, maternal race/ethnicity, age, 
education, marital status, parity, diabetes and smoking status as well as infant birth 
weight, gestational age, gender, and date of birth. Subjects were excluded from this 
dataset if they were missing data on any covariates including maternal race, age, or 
education (n=2,092).  
 
	   40	  
Statistical analysis 
The final cohort included in the analysis comprised 686,435 births (20,094 cases 
and 666,341 controls). Estimates of the association between metal concentrations in 
drinking water and the prevalence of each birth defect within census tracts were 
calculated by log-linear regression using SAS 9.3 (SAS Institute Inc., Cary, North 
Carolina). Prevalence ratios (PRs) with 95% confidence intervals (CIs) were calculated to 
estimate the association between average concentration of each metal within census tracts 
and the prevalence of birth defects, adjusted for maternal age at delivery (continuous), 
race (categorized as non-Hispanic white, non-Hispanic Black, or Other) and education 
status (categorized as mother’s highest level of completed education as less high school, 
high school, or greater than high school). To account for multiple testing, Bonferroni-
corrected PRs with 99.9% CI estimates (alpha = 0.001) were also calculated.  
To examine potential metal-by-metal interaction, Spearman rank correlation was 
used to examine the relationship between each pair-wise metal across the ecologic unit. 
The corresponding correlation coefficient (r) and p-values were calculated.  
A multiplicative interaction effect was estimated for areas of both higher arsenic 
and manganese levels and the prevalence of each birth defect category. Specifically, the 
prevalence of birth defects among infants residing in census tracts where both arsenic and 
manganese levels were greater than or equal the 90th percentile were compared to areas 
where both arsenic and manganese were less than or equal to the 50th percentile.  
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Sensitivity analyses 
A sensitivity analysis was conducted using the census block group as the ecologic 
unit of analysis to determine whether the pattern of findings observed at the later tract 
level was robust. The analysis included 5,264 block groups across North Carolina. Using 
the smaller block group level as the unit of exposure resulted in a finer geographical 
exposure assessment, but fewer study subjects (roughly 40% of the cohort included with 
the tract ecologic unit analysis) since a larger proportion of the block groups did not have 
adequate well sampling data (>75%). Maternal residence at delivery and the private well 
locations were assigned to North Carolina block groups corresponding to the 2000 
census. Exposure levels for each metal were calculated for each block group using the 
same methods as the tract level analysis. The resulting 50th and 90th percentiles of block 
group averages were 1.24, 2.80 for arsenic, 0.5 and 1.5 for cadmium, 41.62 and 155.28 
for manganese, and 3.32 and 7.43 for lead. PRs and corresponding 95% CIs were 
calculated using log-linear regression as described in the main analysis conducted with 
the census tract ecologic unit. 
To further refine the exposure assessment, a secondary sensitivity analysis was 
conducted using a nested cohort of individuals residing outside of public water supply 
distribution areas. Using North Carolina public water supply area service data (EPA, 
2007) and the spatial overlay tool in ArcGIS, the nested analysis was limited to only 
those subjects with a geocoded maternal residence at delivery outside of a public water 
supply area. This restricted our analysis to individuals who are more likely to use private 
drinking water wells (n=117,530, ~17% of the cohort in the main analysis) infants 
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included in the analysis. PRs and corresponding 95% CIs were calculated identically to 
the main analysis using the tract and block group ecologic units.  
 
Results 
 
Study population characteristics 
Among all eligible infants identified by the BDMP and live birth certificates, 
20,151 cases and 668,371 non-malformed control infants were included in this study. 
Table 1 shows the demographic characteristics of the mothers and infants. Case and 
control subjects were similar with respect to age, race, and sex. Case infants were more 
likely to have mothers with educational attainment greater than high school. 
 
Metal levels elevated in some private wells 
From the well water database records collected between 1998 and 2010, we 
analyzed between 22,000 and 72,000 wells with geocoded locations (Supplemental 
Material, Table S1). Notably, private well metal levels that exceeded the EPA regulatory 
standard for public drinking water were detected in 1,436 (2.25%) of arsenic, 24 (0.1%) 
of cadmium, 2,563 (3.9%) of lead, and 15,031 (21.3%) of manganese samples.  
The geocoded levels of arsenic, cadmium, manganese, and lead in private wells 
were summarized to average census tract levels. The average census tract levels of each 
metal are presented in Figure 1. The range of average tract levels was 0.5 to 21.72 ppb for 
arsenic, 0.5 to 8.75 ppb for cadmium, 2.5 to 689.66 ppb for lead, and 15 to 730.91 ppb for 
manganese. The average level of each metal exceeded EPA drinking water guideline 
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levels in at least one census tract (Supplemental Material, Table S1). Notable trends of 
differential metal levels are evident across the state. Both arsenic and manganese levels 
were elevated around the central area of the state. A Spearman rank correlation showed a 
positive relationship between tract-level arsenic and manganese levels (r=0.31 p<0.001) 
(Supplemental Material, Table S2a). Additionally, cadmium levels in wells were elevated 
in areas near cities (e.g. Raleigh, Charlotte) whereas lead levels were randomly spatially 
distributed and were not strongly correlated with other metals (Supplemental Table 2a).  
To examine the spatial occurrence of each birth defect category within census 
tracts, we assigned a dichotomous exposure status based on 50th and 90th percentiles of 
average concentration for each metal. The patterns of these levels are represented in 
Figure 1, where the dark brown category represents “exposed” and the light yellow 
category represents “unexposed”. This dichotomous exposure assignment was developed 
to sharpen the exposure contrast by emphasizing the tails of the distribution of metal 
concentrations in our study area and was developed independently from EPA MCL 
guidelines for metals in public drinking water supplies. Table 2 reports the frequency of 
exposed case and control infants among the highest exposure category for each metal. A 
lower proportion of case infants were exposed to cadmium (n=288, 5.0%), compared to 
case infants exposed to arsenic (n=531, 9.3%), manganese (443, 7.8%) or lead (n=467, 
8.2%). 
  Crude and adjusted PRs and 95% CIs were calculated to estimate the association 
between average concentration of each metal within census tracts and the prevalence of 
birth defects (Supplemental Material, Table S3; Table 3). Table 3 reports the adjusted PR 
estimates comparing the prevalence among the metal- “exposed” versus “unexposed” 
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groups. An elevated PR was observed for higher arsenic exposure and the prevalence of 
conotruncal heart defects (PR: 1.3 95% CI: 0.9-1.8), but the observed 95% CI was 
consistent with unity. The highest category of cadmium exposure was associated with a 
significantly decreased prevalence of spina bifida (PR: 0.4 95% CI: 0.2-1.0) and pyloric 
stenosis (PR: 0.6 95% CI: 0.4-0.8). Notably, the highest category of manganese exposure 
was significantly associated with a higher prevalence AVSD/ECD (PR: 1.8 95% CI: 1.1-
3.1). An elevated PR was also observed for higher manganese exposure and the 
prevalence of conotruncal heart defects (PR: 1.4 95% CI: 1.0-1.9). Since manganese is an 
important essential metal, it is noteworthy that no statistically significant inverse 
relationships were observed between prevalence of any defect and elevated manganese. 
The highest quartile of lead exposure was significantly associated with a decreased 
prevalence of AVSD/ECD (PR: 0.4 95% CI: 0.1-0.9). The findings did not suggest 
patterns of association with the highest categories of cadmium or lead levels and an 
increased prevalence of any birth defects analyzed in this study. To account for multiple 
comparisons, Bonferroni corrected 99.9% CIs were calculated (Supplemental Material, 
Table S4). The protective association between cadmium exposure and pyloric stenosis 
was the only observed association that remained statistically significant after Bonferroni 
correction (PR: 0.6 99.9% CI: 0.3-1.0).  
 We examined the potential interaction between joint exposure to arsenic and 
manganese and the prevalence of each birth defect. Adjusted PR estimates and 95% CIs 
revealed elevated point estimates for the interaction effect of arsenic and manganese 
exposure with defect outcomes including spina bifida, AVSD/ECD, cleft lip with or 
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without cleft palate, and gastroschisis. However, no statistically significant associations 
were observed (Supplemental Material, Table S9).  
 
Sensitivity analyses results 
 To assess the impact of potential exposure misclassification in our ecologic 
analysis, we conducted sensitivity analyses by i) changing the ecologic unit to census 
block groups to achieve a geographically finer resolution of exposure, and ii) including 
only individuals whose maternal residence at delivery was outside public water utility 
distribution areas. The estimated PRs and 95% CIs for each sensitivity analysis and 
metal-by-outcome pair are provided (Supplemental Material, Tables S5-S8). Overall, 
similar trends were observed for analyses excluding individuals living outside of public 
distribution areas when compared to the main analyses. For both types of sensitivity 
analyses, the PR estimates had wider confidence intervals due to the reduction in sample 
size.  
The PRs and 95% CIs for selected relationships assessed in the sensitivity 
analyses are shown in Figure 2. The findings suggest patterns of association consistent 
with the highest categories of arsenic or manganese levels and conotruncal heart defects 
as well as manganese levels and spina bifida. For example, the association between 
manganese and spina bifida was estimated under six conditions including crude and 
adjusted PRs (95% CI) of 1.1 (0.6-1.8), which increased to 1.9 (0.8-4.6) when restricted 
to individuals outside of public supply areas. The same estimates using the block group 
ecologic unit estimated a crude PR (95% CI) of 2.2 (1.1-4.4), an adjusted PR (95% CI) of 
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2.1 (1.1-4.2), which increased to 2.7 (1.1-7.0) when restricted to individuals outside of 
public supply areas.  
 
Discussion 
We conducted a statewide semi-ecologic study to investigate the potential 
association between heavy metal concentrations in private well water and birth defects 
prevalence. Specifically, we examined the association between prevalence of twelve birth 
defect phenotypes and levels of arsenic, cadmium, manganese, and lead summarized at 
the census tract ecologic unit. Taken together, our analyses identified three notable 
findings: i) metal levels are elevated in private wells across the state and in some cases 
co-occur, ii) increased arsenic levels were modestly associated with conotruncal heart 
defects, and iii) increased manganese levels were modestly associated with conotruncal 
heart defects as well as spina bifida. 
 
Elevated environmental metals are spatially correlated in private wells  
Spatial trends of private well metal contamination were identified across North 
Carolina, and some concentrations exceed the EPA standard for public drinking water 
systems. The MCL for arsenic in public water supplies is 10 µg/L, and 5 µg/L for 
cadmium [33]. Lead is regulated according to a Treatment Technique (TT) which 
requires that no more than 10% of wells can exceed 15 µg/L [33]. Manganese has a 
recommended level in public water supplies as a Secondary Maximum Contaminant 
Level (SMCL) of 50 µg/L based on taste and is not federally enforceable [33].  Based on 
these standards, 1,436 (2.25%) of arsenic, 24 (0.1%) of cadmium, 2,563 (3.9%) of lead, 
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and 15,031 (21.3%) of manganese well samples exceeded guideline levels, respectively. 
The extent of samples exceeding the SMCL for manganese is substantial and supported 
by a nationwide study that demonstrated a similar proportion of wells (~21%) exceeding 
50 ppb [34]. 
North Carolina has the fourth largest state population relying on private wells for 
drinking water; the total number served is surpassed by populations in only Pennsylvania, 
California, and Michigan [27]. Arsenic has been previously recognized as a contaminant 
of concern in certain regions of North Carolina [29-31]. Notably, this study identifies at 
least one census tract and block group where the average metal levels exceed respective 
EPA standards, and we mapped spatial trends of heavy metals in wells across the state. 
These data are supported by our previous results that demonstrated arsenic contamination 
in areas along a geographic area called the Carolina terrane [29]. Here we find that 
manganese correlates spatially with arsenic. While the co-occurrence of arsenic and 
manganese has been described in North Carolina geologic conditions, a spatial 
correlation has not been previously reported with respect to private well levels. Elevated 
cadmium levels were evident near major cities including Raleigh and Charlotte. 
Urbanization and anthropogenic activities are contributing factors to groundwater 
contamination from metals including cadmium and arsenic [35]. Lead can occur at 
elevated levels in drinking water by leaching from certain faucets, fittings, or water 
systems [36], which may explain the random spatial appearance of levels across the state. 
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Arsenic levels modestly associated with heart defect prevalence 
Our findings show that residence within regions of higher arsenic levels was 
modestly associated with a higher prevalence of conotruncal heart defects at the census 
tract ecologic unit, and showed statistically significant association at the block group 
ecologic unit. While there is strong evidence of the teratogenic effects of arsenic 
compounds in animal models, currently inorganic arsenic teratogenicity in humans 
remains debated [25, 37]. Fetotoxic effects of arsenic exposure include an increase in 
spontaneous abortion and stillbirth [8, 38]. Perhaps due to early fetal loss, there are 
limited human epidemiologic studies that demonstrate a positive association between 
arsenic levels and birth defects. Previous population-based studies have shown 
associations between drinking water arsenic levels and CHDs [19-21], NTDs [22, 37], 
and increased prevalence of all birth defects [39]. Arsenic has been implicated in 
numerous studies of cardiovascular diseases in adult populations [40, 41]; however, its 
role in abnormal prenatal heart cardiac development requires further study. 
 
Manganese levels associated with heart defects and spina bifida prevalence 
Our findings support a potential association between residence in areas of highest 
manganese levels and the prevalence of conotruncal heart defects. While not statistically 
significant at the tract ecologic unit, residence in areas of highest manganese levels was 
significantly associated with increased prevalence of spina bifida at the census block 
group ecologic unit. While manganese is an essential nutrient at low doses, lifetime 
exposure to drinking water levels above the EPA health benchmark of 0.3 mg/L may 
have detrimental effects on the central nervous system [3]. No studies to date have 
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examined the relationship between drinking water manganese and birth defects in 
humans. In animals, both increased and decreased levels of manganese been associated 
with teratogenicity (reviewed in [42]). Furthermore, manganese exposure has been 
associated with several adverse newborn outcomes including infant mortality [43], 
intrauterine growth restriction [44] and lower birth weight [11, 45]. Given that 
manganese is able to cross the placental barrier and potentially bioaccumulate in fetal 
brain tissue [7], the potential association between manganese and spina bifida is 
biologically plausible. Dietary exposures and inhalation of manganese aerosols during 
showering remain important considerations exposure in addition to drinking water [46, 
47]. These data suggest that additional studies examining the health effects of manganese 
in drinking water should be carried out.  
 
Arsenic-by-manganese interaction 
We assessed a potential interaction effect between regions of higher arsenic and 
manganese with the prevalence of each defect category. The results show a potential 
interactive effect on the association with spina bifida, conotruncal heart defects, 
atrioventricular septal heart defects, and cleft lip with or without cleft palate. Specifically, 
the estimates reveal that the prevalence of these defects among infants residing in census 
tracts where both arsenic and manganese levels were greater than or equal the 90th 
percentile compared to areas where both arsenic and manganese were less than or equal 
to the 50th percentile were increased when compared to the PR estimates observed for 
either metal alone. The findings suggest a potential joint effect in areas of arsenic and 
manganese co-occurrence, but these analyses had limited power as reflected in the width 
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of the reported CIs because the total sample size was considerably reduced. This 
association has not been previously examined in studies of environmental metal 
exposures and birth defects. 
 
Cadmium and lead levels revealed reduced or null associations 
Our results suggest some associations between residence in areas of the highest 
cadmium and lead levels and a reduced birth defects prevalence. A decreased prevalence 
in pyloric stenosis was associated with residence in areas of the highest cadmium 
exposure, a relationship that remained statistically significant after Bonferroni correction. 
We also observed a protective effect of lead exposure with atrioventricular septal heart 
defects. There were no statistically significant positive relationships between birth defect 
prevalence and residence in areas of the highest cadmium or lead levels. At the time of 
this study, we are aware of only three studies that examined the relationship between 
drinking water levels of cadmium and/or lead and birth defects in humans [21, 22, 48]. 
Two studies reported null associations between drinking water levels and NTDs [22, 48], 
and the other reported an increased odds of heart defects associated with detectable lead 
levels in drinking water [21]. Blood lead levels or occupational lead exposure have been 
associated with CHDs [49, 50], NTDs [51, 52], and cleft lip [52, 53]. Further, animal 
studies confirm cadmium- and lead-induced malformations in animal models [54-57]. 
While counterintuitive, there is evidence for protective effects of maternal cigarette 
smoking, a major source of cadmium, and NTDs and conotruncal heart defects [58].  
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Study limitations and strengths 
This study had several limitations that are important when interpreting the results. 
Data on individual use of well water were unavailable; therefore, any observed 
associations are limited to the ecologic unit of analysis. Thus, the findings from this study 
cannot be applied at an individual level, but are suggestive associations that warrant 
additional follow-up. Similar ecologic approaches have been used to examine 
associations between metals in private wells and health outcomes [59, 60]. In this study, 
maternal residence at delivery rather than conception was linked to the ecologic unit for 
exposure assignment. Maternal mobility during pregnancy may introduce nondifferential 
exposure classification during pregnancy [61]; however, the effect may be tempered in 
this study as some maternal mobility could have occurred within the same ecologic unit. 
This study did not evaluate the relationship between personal water consumption patterns 
and the risk of defects. These findings require cautious interpretation and additional 
studies are needed to evaluate the link between metals and specific birth defects. 
Exposure assessment remains a challenge among epidemiological studies of birth 
defects [62, 63]. For example, there are no existing biomonitoring programs in North 
Carolina to actively assess environmental exposures during the prenatal period. As a 
result, research paradigms usually require retrospective exposure assessment that is 
clearly limited by issues of temporality. Specifically, in this study the assigned exposures 
represent a census tract average over a period of 12 years and BDMP data represent the 
location of cases at delivery. This study is clearly limited by issues of temporality and 
does not examine exposure particular to the critical periconceptional period during early 
pregnancy. Our recent study suggests that prenatal biomonitoring may be warranted in 
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North Carolina [64], especially among at-risk populations. Such a biomonitoring program 
would enable a direct assessment of the relationship between environmental exposures 
and children born with birth defects.  
A large proportion of census tracts and block groups were not assigned exposure 
status due to limited sampling (fewer than 10 wells). Clearly there may be effects of 
additional confounders that are related to geographical location such as socioeconomic 
status and/or residence in rural versus urban areas. We attempt to address this by refining 
our exposure assessment, at the expense of estimate precision, by applying two sensitivity 
analyses. A sensitivity analysis removed individuals residing in tracts and block groups 
where a proportion of the geographic area is served by public water. Given the lack of 
individual-level data, this ecologic method served as an imperfect proxy for type of water 
supply as it potentially excludes a fraction of individuals who use private wells but may 
be within the public distribution service area. The results of the sensitivity analyses are 
encouraging because for some metal-defect trends, PRs estimates using the block group 
unit and when restricted to individuals outside of public water utility areas suggest that 
exposure misclassification at the tract level may have biased associations towards the 
null. In both sensitivity analyses, the CIs reflect a loss of precision due to decreased 
sample sizes.  
This study has several strengths including an active statewide case ascertainment 
program, which provided a large sample size of cases and controls representing six years 
of birth defects surveillance in North Carolina. The outcomes we investigated included 
specific phenotypes or groups of phenotypes based on similar etiologic mechanisms. The 
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statewide surveillance program allowed exclusion of case infants born with chromosomal 
abnormalities, as this is a known risk factor for some structural defects [65].  
 
Conclusions 
 
Overall, our findings suggest evidence of a possible relationship between 
concentrations of arsenic and manganese in drinking water and specific birth defects. 
Given that our results support previous evidence of an association between metal 
exposure and conotruncal heart defects as well as spina bifida, these relationships should 
be prioritized for future studies. Ongoing research in our laboratory is directed at 
understanding the biological mechanisms that underlie metal-defect associations using 
animal and cell culture models [66]. Further studies are necessary to validate the potential 
associations observed in this study and to better understand the complex environmental 
and genetic mechanisms involved in potentially preventable environmentally-mediated 
birth defects. 
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Tables 
 
Table 2-1. Characteristics of eligible case and control infants in the study.  
Characteristic Case infants 
(n=20,151) 
Control infants 
(n=668,371) 
Infant Sex n, (%)   
Female 7,684 (38.1%) 327,514  (49.0%) 
Male 12,463 (61.8%) 340,854 (51.0%) 
Missing 4 (<0.1%) 3 (<0.1%) 
   
Maternal age (ave ± stdev) 26.8 ± 6.2 26.9 ± 6.1 
Missing 0 3 (<0.1%) 
   
Maternal Race n, (%)   
NHW 11,658 (57.9%) 381,252 (57.0%) 
NHB 4,751 (23.6%) 152,371 (22.8%) 
Othera 3,742 (18.6%) 134,748 (20.2%) 
   
Maternal Educationb n (%)   
< high school 5,035 (25.0%) 151,727 (22.7%) 
High school 5,934 (29.4%) 190,391 (28.5%) 
> high school 9,125 (45.3%) 324,225 (48.5%) 
Missing 57 (0.3%) 2,028 (0.3%) 
a Other race/ethnicity included individuals reporting Hispanic, Asian, Pacific 
Islander/Native American and Unknown race. 
b Highest year of education completed.  
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Table 2-2. Frequency of exposed case and control infants where exposed is defined as 
living in a census tract with an average metal level greater than or equal to the 90th 
percentile.  
 
 Arsenic Cadmium Manganese Lead 
1. Spina bifida (n=218) 20 5 17 21 
2. Anotia/microtia (n=94) 9 3 7 8 
3. Conotruncals (n=435) 42 28 47 37 
4. AVSD/ECD  (n=150) 14 8 19 5 
5. HLHS (n=142) 15 8 8 15 
6. Cleft palate (n=351) 40 17 26 25 
7. Cleft lip ± CP (n=516) 46 25 42 38 
8. EA/TEF (n=140) 10 6 6 9 
9. Pyloric stenosis (n=1,204) 127 40 98 106 
10. Limb reduction (n=255) 22 13 17 22 
11. Gastroschisis (n=215) 15 7 11 17 
12. Hypospadias (n=1,994) 171  128 145  164 
Total Cases (n=5,714) 531 (9.3%) 288 (5.0%) 443 (7.8%) 467 (8.2%) 
Total Controls  57,377 40,294 51,186 52,691 
 
Abbreviations: ‘Conotruncals’ consists of a group of heart defects including common 
truncus, Tetralogy of Fallot, and transposition of the great arteries; Atrioventricular 
septal/Endocardial cushion defects (AVSD/ECD); Hypoplastic left heart syndrome 
(HLHS); Esophageal atresia also called tracheo-esophageal fistula (EA/TEF); ‘Limb 
reduction’ includes reduction defects of the upper and lower limbs.  
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Table 2-3. Associationa [PR (95%CI)] between selected metals and birth defects. 
Defect As Cd Mn Pb 
1. Spina bifida 1.2 (0.7-1.9) 0.4 (0.2-1.0)* 1.1 (0.6-1.8) 1.3 (0.8-2.1) 
2. Anotia/microtia
 
1.2 (0.6-2.7) 0.5 (0.2-1.7) 0.9 (0.4-2.1) 1.0 (0.5-2.2) 
3. Conotruncals 1.3 (0.9-1.8) 1.1 (0.7-1.7) 1.4 (1.0-1.9) 1.0 (0.7-1.5) 
4. AVSD/ECD 1.0 (0.6-1.9) 0.7 (0.3-1.5) 1.8 (1.1-3.1)* 0.4 (0.1-0.9)* 
5. HLHS 0.9 (0.5-1.6) 0.8 (0.4-1.7) 0.6 (0.3-1.2) 1.4 (0.8-2.5) 
6. Cleft palate (CP) 1.1 (0.8-1.6) 0.7 (0.4-1.2) 0.8 (0.6-1.3) 0.7 (0.5-1.1) 
7. Cleft lip ± CP 1.0 (0.7-1.4) 0.8 (0.5-1.3) 1.0 (0.7-1.4) 0.9 (0.6-1.3) 
8. EA/TEF 1.0 (0.5-2.0) 0.6 (0.3-1.5) 0.6 (0.3-1.5) 1.0 (0.5-2.0)  
9. Pyloric stenosis 1.1 (0.9-1.3) 0.6 (0.4-0.8)* 1.0 (0.8-1.2) 1.0 (0.8-1.3) 
10. Limb reduction 0.8 (0.5-1.4) 0.8 (0.4-1.4) 0.8 (0.4-1.3) 1.1 (0.7-1.8) 
11. Gastroschisis
 
0.7 (0.4-1.2) 0.8 (0.4-1.7) 0.6 (0.3-1.1) 1.0 (0.6-1.6) 
12. Hypospadias 1.0 (0.8-1.2) 1.0 (0.9-1.3) 0.9 (0.8-1.1) 1.1 (0.9-1.3) 
a Prevalence ratios were adjusted for maternal age, race, and education status.  
*p<0.05 
Abbreviations: ‘Conotruncals’ consists of a group of heart defects including common 
truncus, Tetralogy of Fallot, and transposition of the great arteries; Atrioventricular 
septal/Endocardial cushion defects (AVSD/ECD); Hypoplastic left heart syndrome 
(HLHS); Esophageal atresia also called tracheo-esophageal fistula (EA/TEF); ‘Limb 
reduction’ includes reduction defects of the upper and lower limbs. 
 
	   57	  
Figures 
 
 
 
Figure 2-1. Average levels of arsenic (A), cadmium (B), manganese (C), and lead (D) 
within census tracts across North Carolina. The color gradient represents the calculated 
exposure percentile categories (≤50th; 50-75th; 75-90th; ≥90th percentiles). The association 
between birth defects prevalence was tested comparing areas with average metal levels 
greater than or equal to the 90th percentile (dark brown) versus areas with areas less than 
or equal to the 50th percentile (light yellow).    
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Figure 2-2. Sensitivity analyses plots for selected associations between residence in 
ecologic units of highest compared to lowest metal levels and prevalence of birth defects 
including the following metal-defect pairs: A) manganese and spina bifida, B) manganese 
and atrioventricular septal defects/endocardial cushion defects (AVSD/ECD), C) 
manganese and conotruncal heart defects, D) arsenic and conotruncal heart defects, E 
cadmium and pyloric stenosis, and F) lead and spina bifida.  Prevalence ratios (PRs) and 
95% confidence intervals (CIs) correspond as follows: 1. Crude, 2. Adjusted for maternal 
age, race and education status, or 3. Restricted to individuals outside public service areas 
and adjusted for maternal age, race and education status. 
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Supplemental Tables 
 
Table 2-S1. Number of geocoded wells for each metal as well as number of census tract 
and block groups with average metal levels above EPA drinking water standards for 
public distribution systems. 
 Total number 
of geocoded 
wells 
Tracts 
(nTotal=797) 
Block Groups 
(nTotal=5,264) 
EPA reference 
level 
As 46,286 3 (0.4%) 42 (0.8%) 10 ppb 
Cd 22,915 1 (0.1%) 2 (<0.1%) 5 ppb 
Mn 70,671 209 (26.2%) 531 (10.1%) 50 ppb 
Pb 76,387 19 (2.4%) 47 (0.9%) 15 ppb 
 
Table 2-S2. Spearman rank correlations comparing average (ppb) census tract metal 
levels (Table 2a) and average (ppb) census block group metal levels (Table 2b). *p<0.05 
Table 2-S2a. Tract Spearman correlations 
 Cd  Mn Pb 
As -0.11* 0.31* -0.02 
Cd  0.03 0.06 
Mn   0.18* 
 
Table 2-S2b. Block group Spearman correlations 
 Cd  Mn Pb 
As -0.03 0.25* -0.03 
Cd  0.02 0.02 
Mn   0.05 
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Table 2-S3. Crude PRs and 95% CIs using the census tract ecologic unit. 
Defect As Cd Mn Pb 
1. Spina bifida 1.2 (0.7, 2.0) 0.4 (0.2, 1.0) 1.1 (0.6, 1.8) 1.3 (0.8, 2.1) 
2. Anotia/microtia
 
1.3 (0.6, 2.7) 0.5 (0.2, 1.6) 0.9 (0.4, 2.2) 1.0 (0.5, 2.2) 
3. Conotruncals 1.3 (0.9, 1.8) 1.1 (0.7, 1.7) 1.4 (1.0, 1.9) 1.0 (0.7, 1.5) 
4. AVSD/ECD 1.0 (0.6, 1.8) 0.7 (0.3, 1.5) 1.8 (1.0, 3.0)* 0.4 (0.1, 0.9)* 
5. HLHS 0.9 (0.5, 1.6) 0.7 (0.4, 1.6) 0.6 (0.3, 1.2) 1.4 (0.8, 2.4) 
6. Cleft palate 1.2 (0.8, 1.7) 0.7 (0.4, 1.2) 0.8 (0.6, 1.3) 0.7 (0.5, 1.1) 
7. Cleft lip ± CP 1.0 (0.8, 1.4) 0.8 (0.5, 1.2) 1.0 (0.7, 1.4) 0.9 (0.6, 1.2) 
8. EA/TEF 1.0 (0.5, 2.0) 0.7 (0.3, 1.6) 0.6 (0.3, 1.5) 1.0 (0.5, 2.0) 
9. Pyloric stenosis 1.2 (1.0, 1.5) 0.4 (0.3, 0.6)* 1.0 (0.8, 1.2) 1.0 (0.8, 1.3) 
10. Limb reduction 0.9 (0.6, 1.4) 0.7 (0.4, 1.3) 0.8 (0.5, 1.4) 1.1 (0.7, 1.8) 
11. Gastroschisis
 
0.8 (0.5, 1.4) 0.5 (0.2, 1.1) 0.6 (0.3, 1.1) 1.0 (0.6, 1.7) 
12. Hypospadias 0.9 (0.8, 1.1) 1.1 (0.9, 1.3) 1.0 (0.8, 1.1) 1.0 (0.9, 1.2) 
*p<0.05 
Table 2-S4. Bonferroni corrected adjusted PRs and 99.9% CIs using the census tract 
ecologic unit. PRs were adjusted for maternal age, race, and education status. 
Defect As Cd Mn Pb 
1. Spina bifida 1.2 (0.5-2.7) 0.4 (0.1-1.8) 1.1 (0.4-2.6) 1.3 (0.6-2.9) 
2. Anotia/microtia
 
1.2 (0.3-4.5) 0.5 (0.1-3.9) 0.9 (0.2-3.7) 1.0 (0.3-3.7) 
3. Conotruncals 1.3 (0.7-2.3) 1.1 (0.5-2.2) 1.4 (0.8-2.4) 1.0 (0.6-1.9) 
4. AVSD/ECD 1.0 (0.4-2.8) 0.7 (0.2-2.5) 1.8 (0.7-4.5) 0.4 (0.1-1.6) 
5. HLHS 0.9 (0.3-2.4) 0.8 (0.2-2.8) 0.6 (0.2-1.9) 1.4 (0.5-3.7) 
6. Cleft palate 1.1 (0.6-2.1) 0.7 (0.3-1.7) 0.8 (0.4-1.7) 0.7 (0.4-1.5) 
7. Cleft lip ± CP 1.0 (0.6-1.7) 0.8 (0.4-1.7) 1.0 (0.6-1.8) 0.9 (0.5-1.6) 
8. EA/TEF 1.0 (0.3-3.2) 0.6 (0.2-2.7) 0.6 (0.1-2.6) 1.0 (0.3-3.3) 
9. Pyloric stenosis 1.1 (0.8-1.5) 0.6 (0.3-1.0)* 1.0 (0.7-1.4) 1.0 (0.7-1.5) 
10. Limb reduction 0.8 (0.4-1.9) 0.8 (0.3-2.1) 0.8 (0.3-1.9) 1.1 (0.5-2.4) 
11. Gastroschisis
 
0.7 (0.3-1.8) 0.8 (0.2-3.0) 0.6 (0.2-1.7) 1.0 (0.4-2.3) 
12. Hypospadias 1.0 (0.7-1.3) 1.0 (0.8-1.5) 0.9 (0.7-1.3) 1.1 (0.8-1.4) 
*p<0.05 
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Table 2-S5. Adjusted PRs and 95% CIs using the census tract ecologic unit and excluding 
individuals living in public distribution areas. PRs were adjusted for maternal age, race, 
and education status. 
Defect As Cd Mn Pb 
1. Spina bifida 1.4 (0.6-3.5) 1.4 (0.2-12.2) 1.9 (0.8-4.6) 1.5 (0.6-3.8) 
2. Anotia/microtia
 
1.1 (0.3-3.9) NE 0.4 (0.1-3.1) 1.5 (0.4-5.4) 
3. Conotruncals 1.4 (0.7-3.0) 0.4 (0.0-2.8) 0.7 (0.3-2.2) 1.2 (0.5-2.6) 
4. AVSD/ECD 1.1 (0.4-3.5) 0.7 (0.1-5.9) 0.4 (0.0-2.9) 0.3 (0.0-2.2) 
5. HLHS 1.2 (0.4-3.4) 0.7 (0.1-5.5) 0.8 (0.2-2.8) 0.7 (0.2-3.1) 
6. Cleft palate 1.1 (0.6-2.3) 0.6 (0.1-2.5) 0.3 (0.1-1.0) 0.5 (0.2-1.3) 
7. Cleft lip ± CP 0.9 (0.5-1.8) 1.3 (0.5-3.2) 0.7 (0.3-1.8) 0.7 (0.3-1.6) 
8. EA/TEF 1.3 (0.5-3.8) 2.4 (0.6-9.2) 0.6 (0.1-4.5) 1.4 (0.5-4.4) 
9. Pyloric stenosis 1.2 (0.8-1.7) 0.9 (0.4-1.9) 1.1 (0.7-1.7) 1.1 (0.7-1.7) 
10. Limb reduction 0.3 (0.1-1.3) 1.0 (0.2-4.3) 0.5 (0.1-2.0) 0.8 (0.2-2.6) 
11. Gastroschisis
 
1.0 (0.5-2.3) 0.6 (0.1-4.3)  0.6 (0.2-1.9) 1.1 (0.4-2.6) 
12. Hypospadias 0.9 (0.7-1.3) 1.5 (1.0-2.3) 0.7 (0.4-1.1) 0.9 (0.6-1.3) 
NE -Not estimated. 
 
Table 2-S6. Crude PRs and 95% CIs using the block group ecologic unit. 
Defect As Cd Mn Pb 
1. Spina bifida 0.9 (0.4-2.3) 1.1 (0.6-2.1) 2.2 (1.1-4.4)* 1.5 (0.7-3.4) 
2. Anotia/microtia
 
1.1 (0.3-3.7) 0.9 (0.4-2.0) 0.7 (0.2-2.9) 0.4 (0.0-2.7) 
3. Conotruncals 1.0 (0.6-1.9) 1.2 (0.8-1.8) 1.7 (1.0-3.0)* 1.1 (0.6-2.1) 
4. AVSD/ECD 1.9 (0.7-5.3) 0.4 (0.2-1.3) 1.4 (0.5-4.4) 1.2 (0.3-4.0) 
5. HLHS 1.0 (0.3-2.8) 0.7 (0.3-1.7) 0.5 (0.1-1.9) 2.0 (0.9-4.4) 
6. Cleft palate 0.8 (0.4-1.7) 0.9 (0.5-1.4) 0.5 (0.2-1.2) 0.8 (0.4-1.5) 
7. Cleft lip ± CP 1.4 (0.8-2.4) 0.9 (0.6-1.3) 0.7 (0.3-1.4) 1.2 (0.7-2.1) 
8. EA/TEF 1.3 (0.5-3.3) 0.7 (0.3-1.6) 1.3 (0.5-3.4) 1.1 (0.4-3.3) 
9. Pyloric stenosis 1.2 (0.8-1.7) 0.5 (0.4-0.7)* 1.0 (0.7-1.5) 0.9 (0.6-1.3) 
10. Limb reduction 0.7 (0.2-2.0) 0.7 (0.4-1.4) 1.3 (0.6-2.6) 1.2 (0.5-2.8) 
11. Gastroschisis
 
0.3 (0.1-1.2) 0.4 (0.2-1.0) 0.8 (0.3-2.2) 1.2 (0.5-2.8) 
12. Hypospadias 0.9 (0.6-1.2) 1.1 (0.9-1.3) 0.9 (0.7-1.2) 0.8 (0.6-1.1) 
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Table 2-S7. Adjusted PRs and 95% CIs using the block group ecologic unit. PRs were 
adjusted for maternal age, race, and education status. 
Defect As Cd Mn Pb 
1. Spina bifida 0.9 (0.3-2.2) 1.2 (0.6-2.3) 2.1 (1.1-4.2)* 1.5 (0.7-3.3) 
2. Anotia/microtia
 
1.0 (0.3-3.4) 0.9 (0.4-2.2) 0.7 (0.2-2.9) 0.4 (0.0-2.7) 
3. Conotruncals 1.0 (0.6-1.9) 1.2 (0.8-1.8) 1.7 (1.0-3.0) 1.1 (0.6-2.0) 
4. AVSD/ECD 1.8 (0.7-5.0) 0.5 (0.2-1.5) 1.5 (0.5-4.7) 1.3 (0.4-4.5) 
5. HLHS 0.9 (0.3-2.6) 0.8 (0.3-1.7) 0.5 (0.1-2.0) 2.1 (0.9-4.5) 
6. Cleft palate 0.8 (0.4-1.6) 0.9 (0.6-1.5) 0.5 (0.2-1.2) 0.8 (0.4-1.6) 
7. Cleft lip ± CP 1.3 (0.8-2.3) 0.9 (0.6-1.4) 0.7 (0.3-1.4) 1.3 (0.7-2.2) 
8. EA/TEF 1.3 (0.5-3.4) 0.7 (0.3-1.5) 1.3 (0.5-3.4) 1.1 (0.4-3.3) 
9. Pyloric stenosis 1.1 (0.7-1.5) 0.7 (0.5-0.9)* 1.0 (0.7-1.4) 0.9 (0.6-1.3) 
10. Limb reduction 0.7 (0.2-1.9) 0.8 (0.4-1.7) 1.2 (0.6-2.5) 1.0 (0.4-2.4) 
11. Gastroschisis
 
0.3 (0.1-1.0) 0.7 (0.3-1.7) 0.8 (0.3-2.1) 1.2 (0.5-2.7) 
12. Hypospadias 0.9 (0.7-1.2) 1.1 (0.9-1.3) 0.9 (0.7-1.2) 0.9 (0.6-1.2) 
*p<0.05 
 
Table 2-S8. Adjusted PRs and CIs at the block group level excluding individuals living in 
public distribution areas. PRs were adjusted for maternal age, race, and education status. 
Defect As Cd Mn Pb 
1. Spina bifida 0.9 (0.2-4.2) 2.0 (0.7-5.6) 2.7 (1.1-7.0)* 1.9 (0.7-5.5) 
2. Anotia/microtia
 
NE 0.9 (0.2-4.3) NE NE 
3. Conotruncals 2.4 (1.1-5.5)* 0.8 (0.3-2.4) 2.3 (1.0-5.5) 0.8 (0.3-2.4) 
4. AVSD/ECD 1.2 (0.3-5.7) 0.4 (0.1-3.4) 1.1 (0.2-5.2) NE 
5. HLHS 2.2 (0.7-7.0) 1.2 (0.3-4.1) 0.6 (0.1-4.4) 1.6 (0.5-4.9) 
6. Cleft palate 0.8 (0.2-2.6) 0.7 (0.2-2.0) 0.6 (0.2-1.9) 1.1 (0.4-2.6) 
7. Cleft lip ± CP 1.1 (0.5-2.5) 1.3 (0.6-2.8) 0.4 (0.1-1.5) 0.7 (0.2-1.9) 
8. EA/TEF 1.9 (0.5-7.2) 1.4 (0.4-5.2) 0.5 (0.1-4.1) 1.0 (0.2-4.7) 
9. Pyloric stenosis 1.0 (0.6-1.7) 0.9 (0.5-1.5) 1.1 (0.6-1.8) 1.0 (0.6-1.7) 
10. Limb reduction 1.2 (0.3-4.0) 0.8 (0.2-2.9) 0.9 (0.3-2.7) 1.2 (0.3-4.1) 
11. Gastroschisis
 
0.5 (0.1-2.0) 0.5 (0.1-2.2) 1.0 (0.3-2.9) 0.9 (0.3-2.7) 
12. Hypospadias 0.9 (0.5-1.3) 1.1 (0.8-1.5) 0.8 (0.5-1.3) 0.8 (0.5-1.2) 
NE -Not estimated. 
*p<0.05 
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Table 2-S9. Crude and adjusted PRs and 95% CIs estimate arsenic-by-manganese 
interaction using the tract level ecologic unit. PRs were adjusted for maternal age, race, 
and education status. 
Defect As*Mn Crude As*Mn Adjusted 
1. Spina bifida 2.1 (0.3-16.1) 2.0 (0.3-15.1) 
2. Anotia/microtia
 
0.4 (0.0-4.1) 0.4 (0.0-3.8) 
3. Conotruncals 1.1 (0.3-3.5) 1.2 (0.4-3.7) 
4. AVSD/ECD 1.3 (0.2-8.3) 1.3 (0.2-8.2) 
5. HLHS 4.6 (0.3-66.0) 4.5 (0.3-65.8) 
6. Cleft palate 1.1 (0.3-4.6) 1.1 (0.3-4.5) 
7. Cleft lip ± CP 3.0 (0.8-11.5) 2.9 (0.8-11.0) 
8. EA/TEF NE NE  
9. Pyloric stenosis 1.1 (0.5-2.3) 1.0 (0.5-2.1) 
10. Limb reduction 1.2 (0.2-5.6) 1.5 (0.3-8.0) 
11. Gastroschisis
 
6.4 (0.3-144.1) 6.0 (0.3-134.6) 
12. Hypospadias 0.7 (0.4-1.3) 0.7 (0.4-1.4) 
 NE -Not estimated. 
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CHAPTER 3: miRNA-DEPENDENT AND INDEPENDENT CADMIUM-
INDUCED SIGNALING IN HUMAN CARDIOMYOCYTES 
 
Overview 
Cadmium is a toxic metal with widespread human exposure resulting from diet, 
air, and drinking water. Despite the strong evidence of cadmium-associated 
cardiovascular disease, the mechanisms that underlie metal-induced cardiovascular 
endpoints remain largely unknown. MicroRNAs (miRNAs) are post-transcriptional 
regulators of gene expression that influence heart development and function, but the role 
of miRNAs remains unstudied as a potential mechanism of cadmium-associated disease. 
This is the first study to assess cadmium-induced changes in miRNA levels in human 
cardiomyocytes. The objective of this study was to assess miRNAs as potential 
epigenetic modifiers of gene expression in human cardiomyocytes exposed to cadmium. 
We exposed human-derived induced pluripotent stem cell cardiomyocytes to 0.5 µM of 
cadmium chloride (56.3 ppb) for 24 hours. Micro (mi) RNAs and messenger (m) RNAs 
were isolated and analyzed for differential expression analysis using genome-wide 
microarrays. A non-cytotoxic dose of 0.5 µM cadmium chloride increased the expression 
levels of eight miRNAs. Network analysis of the miRNAs revealed that cadmium 
potentially alters signaling pathways associated with cancer, connective tissue disorders, 
and inflammatory disease. Analysis of messenger RNA (mRNA) expression showed 31 
genes were upregulated in cadmium-exposed cardiomyocytes, and eight (26%) matched 
to predicted targets of the identified differentially expressed miRNAs. The miRNA-
	   71	  
associated mRNAs mapped to signaling pathways including gene expression, embryonic 
development, and organismal development. miRNA-independent mRNA changes were 
seen for 21 genes including a family of metallothionein genes showing increased 
transcript levels. Cadmium alters miRNA patterns in cardiomyocytes that regulate gene 
expression and potentially play a role in metal-induced cardiovascular disease.  
 
Introduction 
Cadmium is a carcinogen of the liver, kidney, and pancreas as well as a known 
risk factor for cardiovascular disease [1, 2]. Numerous poor cardiovascular endpoints are 
associated with cadmium exposure including coronary heart disease [3], peripheral artery 
disease [4, 5], myocardial infarction [6], as well as stroke and heart failure [7, 8]. 
Cadmium is a cardiovascular risk factor even at low chronic exposure levels [9, 10]. It is 
estimated that the Disability Adjusted Life Years (DALYs) due to cardiovascular disease 
will be 169 million (11% of estimated global DALYs) by 2020 [11]. Cadmium is 
therefore an environmental risk factor of considerable potential global disease burden 
[12, 13]. 
Human exposure to cadmium occurs primarily through diet and cigarette smoke 
[2, 14]. There is evidence that cadmium can accumulate in the human heart at levels 
higher than observed in many other organs [15]. In addition to cadmium-associated heart 
disease later in life, early life exposure to cadmium is associated with altered cardiac 
development in animal models [16-19], but to date this has not been examined in humans. 
Despite the strong evidence of cadmium-associated adverse cardiovascular endpoints, an 
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exact molecular mechanism that links cadmium to heart disease is currently unknown. 
The suggested impacts of cadmium exposure include inhibition of DNA repair, 
generation of reactive oxygen species, and perturbation of cell cycle progression or 
apoptosis (reviewed in [20]). Cadmium is believed to act as an epigenetic or indirectly 
genotoxic metal [21]. The relationship between transcriptional mediators and gene 
expression is understudied and few studies have investigated the complex interplay 
between the toxicogenomic and potential epigenetic mediators of cadmium-associated 
heart disease. Indeed, animal studies confirm that cadmium exposure alters cardiac gene 
expression [16, 17, 22], and we have shown that low dose cadmium exposure in human 
lymphoblast cells alters genes enriched for biological functions including cancer and 
cardiovascular disease [23]. Expanding this work, here we examine the transcriptional 
effects in cardiomyoctyes, with a particular focus on microRNA (miRNAs) as mediators. 
We hypothesize that metal-induced miRNA changes are a potential epigenetic 
mechanism that may control downstream gene expression that leads to altered cardiac 
function or disease.   
miRNAs are short single-stranded RNAs approximately 20 nucleotides in length 
that post-transcriptionally regulate gene expression through silencing. miRNAs are 
involved in a number of cell proliferation, apoptosis, and developmental processes [24-
26]. Currently over 1,100 human miRNAs have been identified [27], and are believed to 
target approximately 60% of genes [28]. miRNA control of gene expression in heart cells 
is involved in both heart development and failure (reviewed in [29, 30]). Specifically, 
miR-133 and miR-1 are miRNAs involved in the regulation of a large number of cell 
division and maintenance processes, which contribute to altered gene expression and 
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dysregulated cardiac function and/or development. No studies to date have examined 
cadmium-induced changes in miRNA levels in human cardiomyocytes. 
In the present study, we examine the effects of cadmium at the genomic (mRNA) 
and epigenetic (miRNA) levels to identify potential mechanisms of metal-perturbed heart 
function using in vitro cardiomyocyte culture. Given that alterations in cardiomyocyte 
signaling can lead to abnormal heart development or function, this work represents novel 
insight into miRNA-mediated metal-induced disease.  
 
Methods 
Cardiomyocyte culture 
iCell® cardiomyocytes derived from human induced-pluripotent stem cells were 
purchased from Cellular Dynamics International (Madison, WI). Cells were stored and 
thawed according to the manufacturer’s protocol. The iCell® cardiomyocytes were plated 
at a density of 15,000 cells per well (~47,000 cells/cm2) in a 24-well plate that was pre-
treated with 0.1% gelatin. Cells were initially maintained in iCell Cardiomyocytes Plating 
Medium then transferred into iCell Cardiomyocytes Maintenance Medium every 48 hours 
after. Cells were incubated at 37C and 7% CO2 for 144 hours until they reached a state of 
synchronous beating. After 144 hours of incubation, cells were exposed to cadmium or 
received a mock control. Treatment groups included the untreated control and cadmium 
chloride treatments selected based on environmental relevance. Cadmium chloride 
solutions were prepared fresh from stock at the following final test concentrations: 0.05 
µM (5.6 ppb), 0.1 µM (11.3 ppb), and 0.5 µM (56.3 ppb). 
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Cytotoxicity analysis 
A 96-well plate seeded with iCell Cardiomyocytes at the same density (~47,000 
cells/cm2) was examined for cytotoxicity. After 120 hours incubation, cells received 
culture medium with or without cadmium chloride treatment for 24 hrs. Treatment groups 
were divided as follows: the (i) untreated control, (ii) 0.1 mM staurosporin positive 
control, and (iii) cadmium chloride treatment. Cadmium chloride solutions were prepared 
fresh from stock at the following final test concentrations: 0.01 µM, 0.05 µM, 0.1 µM, 
0.5 µM, 1.0µM, 5.0 µM, 10.0µM, and 50.0µM.  
After 24-hour exposure to cadmium chloride, cardiomyocyte viability was 
assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570; 
Madison, WI). The assay quantifies adenosine triphosphate (ATP), which signals the 
presence of metabolically active cells. Luminescence was measured in relative light units 
(RLU) on the GloMax®-96 Microplate Luminometer (Promega, Madison, WI). 
Luminescence fold change was calculated as the mean luminescence for cadmium- or 
staurosporin- exposed samples divided by untreated control values. Mean luminescence 
was calculated from six replicates under each treatment condition after subtraction of the 
average background luminescence. 
 
RNA and miRNA isolation  
After 24-hour exposure to cadmium chloride, cells were lysed and stored at -80 
using the Qiagen AllPrep® DNA/RNA/Protein Mini Kit for simultaneous purification of 
genomic DNA, total RNA, and total protein from human cells according to kit 
specifications (Qiagen, Valencia, CA). Simultaneous mRNA (>200 nucleotides) and 
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miRNA (18-200 nucleotide length) extraction was performed using the supplementary 
protocol for purification of miRNA and the RNeasy® MinElute® Cleanup Kit (Qiagen, 
Valencia, CA). miRNA and mRNA were quantified using a NanoDrop 
spectrophotometer 2000c (Thermo Scientific, Wilmington, DE). mRNA quality was 
assessed using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Samples 
used for mRNA microarray analysis were required to have an RNA Integrity Number 
(RIN) value above 9.6. 
 
Microarray analysis 
 A starting material of 20 ng of the collected small RNA fraction (18-200 
nucleotides) was labeled and hybridized to the Agilent Human miRNA Microarray 
release 16.0, which measures the expression levels of 1,348 human miRNAs across 
53,880 probesets (Agilent Technologies, Santa Clara. CA). Three samples the 0.5 µM 
cadmium chloride-exposed and three unexposed control samples were hybridized using 
20 ng input small RNA per sample.  
 Three samples exposed to 0.5 µM cadmium chloride and three unexposed control 
samples were amplified, fragmented, and hybridized to Affymetrix GeneChip Human 
Gene 2.0 ST Arrays (Affymetrix, Santa Clara, CA) using 50 ng input RNA per sample. 
The Nugen Ovation Pico WTA system V2 and the Nugen EncoreTM Biotin module 
(Nugen, San Carlos, CA) were used to prepare RNA for hybridization. Briefly 50 ng of 
total RNA was converted into amplified SPIA cDNA using the Nugen Ovation Pico 
WTA system V2 and accompanying user guide. The amplified SPIA cDNA was purified 
using the Qiagen QIAquick PCR purification kit. Five µg of SPIA cDNA was fragmented 
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and labeled using the Nugen Encore Biotin module and accompanying user guide.  The 
hybridization cocktail for hybridization onto Affymetrix GeneChip Human Gene 2.0 ST 
arrays was prepared using the Nugen Encore Biotin module user guide’s cocktail 
assembly table. The hybridization cocktails were denatured and hybridized onto 
Affymetrix GeneChip Human Gene 2.0 ST arrays for 18 hours at 45°C in an Affymetrix 
GeneChip Hybridization Oven 640.  After 18 hours, the arrays were washed and stained 
in the Affymetrix Fluidics Station 450.  The arrays were scanned using the Affymetrix 
GeneChip Scanner 3000 7G Plus with autoloader. The Affymetrix GeneChip Human 
Gene 2.0 ST Array contains 53,617	   probesets corresponding to over 25,000 RefSeq 
(Entrez) genes.  
 
Statistical analysis 
Microarray data were normalized using Robust Multi-Chip Average (RMA) [31]. 
miRNA data were extracted using Agilent Feature Extraction software and probes with 
signal intensities with an absolute expression level above a background level 
(background was set to 26.5, the median signal per array) in all conditions were removed 
from the analysis to eliminate background noise. Differential expression was defined as a 
significant difference in mRNA or miRNA expression levels between exposed and 
unexposed samples, where the following two statistical requirements were met: (i) fold 
change of ≥ 1.5 or ≤ -1.5 (average exposed versus average unexposed); (ii) p-value < 0.01 
(ANOVA). Analysis of variance (ANOVA) p-values were calculated using Partek® 
Genomics SuiteTM software (St. Louis, MO). To control the rate of false positives, false 
discovery rate q-values were calculated [32]. Data will be submitted to the National 
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Center for Biotechnology Information’s Gene Expression Omnibus repository [33] and  
the accession numbers will be provided here for the mRNA and miRNA datasets. 
 
Pathway enrichment analysis of cadmium-altered miRNA and mRNA 
transcripts 
 
We performed enriched biological functions and network analyses using the 
Ingenuity Pathway Analysis (IPA) tool (Ingenuity® Systems, Redwood City, CA). IPA is 
a proprietary database that curates gene-phenotype associations, molecular interactions, 
regulatory events, and chemical knowledge to provide a global molecular network. The 
set of differentially expressed miRNAs were uploaded into the IPA core pathway analysis 
module and overlaid onto this global molecular network. Related networks were 
algorithmically constructed based on connectivity.  
Putative miRNA-mRNAs relationships were identified using the IPA microRNA 
Target Filter. Given the list of cadmium-altered miRNAs, mRNA targets were identified 
based on a knowledgebase of predicted and experimentally observed relationships. An 
independent miRNA database was used to verify the predicted mRNA targets [34]. 
We compared our experimentally identified differentially expressed mRNAs with 
the list of putative mRNA targets matching the set of differentially expressed miRNAs. 
This resulted in classification of two distinct subsets of differentially expressed mRNA in 
samples exposed to cadmium. The miRNA-associated gene set as well as the miRNA-
independent geneset was overlaid onto the global molecular network.  
Functional analysis was carried out to identify biological functions and disease 
signatures most significantly associated with the observed differentially expressed 
miRNAs, as well as the miRNA-associated and miRNA-independent genesets. Statistical 
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significance of each biological function or disease was calculated using Fisher’s exact 
text with an alpha set at 0.05. 
Upstream transcriptional regulators were identified using IPA for each 
differentially expressed mRNA gene list. The upstream regulator analysis uses prior 
knowledge of to identify potential regulating molecules involved in signaling cascades 
that may explain observed gene expression changes. Statistically significant overlap p-
values between the uploaded geneset and genes known to be modified by a 
transcriptional regulator were calculated using Fisher’s exact text with an alpha set at 
0.05. Each list of transcriptional regulator was filtered for molecules that correspond to 
known transcription factors.   
  
 
Results 
Cadmium exposure modulates miRNAs in human cardiomyocytes 
In this study, we set out to determine whether cadmium exposure alters miRNA 
expression levels in human cardiomyocytes. Human-derived iCell cardiomyocytes were 
exposed to 0, 0.05, 0.1 or 0.5 µM cadmium chloride. None of the doses tested resulted in 
significant cytotoxicity to the cardiomyocytes (Supplemental Material, Table S1). After 
exposure, we collected small RNAs (miRNAs) and measured their relative abundances 
using the Agilent Human miRNA Microarray (version 16.0). A total of 33,573 of 53,880 
total probesets were detectable above background levels in these cells. A total of 56 
probesets corresponding to nine unique miRNAs were upregulated in cadmium-exposed 
samples compared with control samples (Table 1; Supplemental Material, Table S2). 
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There were no miRNAs with significantly decreased expression levels in response to 
cadmium. The nine significantly differentially expressed miRNAs included miR-1, miR-
125b-5p, miR-130a-3p, miR-20a-5p, miR-21-5p, miR-22-3p, miR-27b-3p, miR-30e-5p, 
and miR-1274a (Table 1).  
 
Upregulated miRNAs integrated into biological networks 
To identify potential biological pathways impacted by the cadmium-altered 
miRNAs, we overlaid the nine differentially expressed miRNAs onto molecular pathway 
maps using IPA. Eight miRNAs constructed a single network that was enriched for 
functions including cancer, connective tissue disorders, and inflammatory disease 
(p<1x10-23) (Figure 1). These miRNAs have known links to tumor suppressor gene p53 
(TP53). To note, miR-1274a was not recognized by IPA and was excluded from further 
analysis. 
 
Cadmium exposure modulates gene expression in human cardiomyocytes 
To test whether cadmium alters mRNA expression levels, we assessed mRNA 
abundance in cardiomyocytes. A total of 83 probesets corresponding to 31 unique genes 
were differentially expressed in cadmium-exposed samples compared with control 
samples (Figure 2; Supplemental Material, Table S3). Only five of the 31 genes (16%) 
showed decreased expression among the cadmium-exposed samples. Among the 
remaining 26 genes showing increased expression in the cadmium-exposed samples, a 
family of ten metallothionein (MT) genes was significantly upregulated including MT1A, 
MT1B, MT1CP, MT1E, MT1F, MT1G, MT1H, MT1L, MT1M, MT1L, and MT1X 
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(Supplemental Material, Table S3). Taken together, all 31 significantly differentially 
expressed genes were mapped to signaling pathways including renal and urological 
disease, cellular compromise, and psychological disorders (p<1×10-26) (Supplemental 
Material, Table S4).  
 
Conservation of predicted and observed mRNA targets 
To understand downstream genomic changes regulated by the eight cadmium-
altered miRNAs, we computationally predicted putative mRNA targets. We identified 
6,735 predicted mRNA targets. We compared the list of 6,735 predicted mRNA targets 
with the 31 significantly differentially expressed genes. There was an overlap between 
eight (26%) of our experimentally observed differentially expressed genes and the 
predicted miRNA targets (Table 2). Specifically, the microarray analysis confirmed 
differential expression of ALX homeobox 4 (ALX4), malic enzyme 1 (ME1), MT1F, 
MT1G, MT1H, DNA-directed RNA polymerase III subunit G (POLR3G), solute carrier 
family 30 member 2 (SLC30A2), and sushi domain containing 5 (SUSD5). Among these 
modulated mRNAs, multiple miRNAs were common regulators of transcription. 
POLR3G was predicted to be the target of miR-17-5p, miR-27a-3p, and miR-30c-5p. 
ALX4 was a predicted target of both miR-17-5p and miR-21-5p (Table 2). 
The eight miRNA-associated mRNA transcripts were mapped in IPA to signaling 
pathways including gene expression, embryonic development, and organismal 
development (p<1×10-16) (Supplemental Material, Table S4). The remaining miRNA-
independent genes (n=23) were mapped to signaling pathways including cell signaling, 
nucleic acid metabolism and small molecule biochemistry (p<1×10-41) (Supplemental 
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Material, Table S4).  
 
Enrichment of transcription factor binding sites in cadmium-associated genes  
The mRNA transcripts modified by cadmium independently of miRNAs (n=23) 
as well as those potentially under miRNA control (n=8) were examined for enrichment of 
upstream transcriptional regulators. This analysis demonstrated enrichment for a set of 
eight and 16 upstream regulators, respectively between the two lists (Table 3). Notably, 
three transcription factors were common to both lists including metal regulatory 
transcription factor 1 (MTF1), lysine (K)-specific demethylase 5B (KDM5B), and histone 
deacetylase (hdac). 
 
Discussion 
Cadmium is a known risk factor for cardiovascular disease [1, 2]; however, the 
mechanism by which cadmium impacts cardiac function is understudied. This is the first 
study to assess miRNA expression as a key transcriptional regulator in cardiomyocyte 
response to cadmium. miRNAs regulate gene expression by post-transcriptional 
degradation of mRNA or reducing translational efficiency. Each miRNA can regulate the 
expression of several hundred target genes [28]. Thus, miRNAs represent potential 
epigenetic modulators that control the downstream expression of genes that may lead to 
altered cardiac function or disease state. Here, we exposed human cardiomyocytes to 0.5 
µM cadmium chloride for 24 hours and assessed genome-wide changes in miRNA and 
mRNA expression profiles.  
 The expression levels of over 1,000 miRNA were measured and compared 
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between cadmium-exposed and unexposed cardiomyocytes. A total of nine miRNAs 
were identified with altered expression. Network analysis identified that eight of the 
miRNAs are linked to the p53 tumor suppressor gene. The p53 gene encodes the p53 
protein which is a critical transcription factor involved in tumor suppression and under 
normal conditions is protective of cancer progression [35]. Increased levels of p53 are 
linked to cardiomyocyte apoptosis, which may lead to fatal ischemic heart injury [36, 37].   
The individual identified miRNAs included miR-1, miR-20a-5p, miR-21-5p, 
miR-22-3p, miR-27b-3p, miR-30e-5p, miR-125b-5p, miR-130a-3p, and miR-1274a. 
Many of the cadmium-responsive miRNAs have known links to cardiac development or 
function. More specifically, miR-1, miR-21, miR-22, miR-27b, and miR-125b have been 
shown to have altered expression in tissues exhibiting cardiac conditions such as 
arrhythmia and hypertrophy compared to normal tissues [38-44]. Of note, miR-1 
overexpression negatively regulates cardiac growth, in part by targeting and 
downregulating heart and neural crest derivatives-expressed protein 2 (Hand2), a 
transcription factor that promotes cardiomyocyte expansion [45]. In addition, miR-20a 
belongs to a cluster of miRNAs known as miR-17~92 that are oncogenic [46]; mice 
deficient in miR-17~92 developed fatal ventricular septal heart defects [47]. Both miR-
130a and miR-30e are known regulators of cardiac development [48, 49], but have not 
been previously associated with abnormal cardiac function or disease states.  
To date, only three studies have examined cadmium-associated miRNA changes 
in human tissues or cell lines [50-52]. Increased expression of miR-146a in peripheral 
blood leukocytes was associated with occupational cadmium exposure [50]. Decreased 
expression of miR-21 in urine samples was associated with increased levels of urinary 
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arsenic and lead, but not cadmium in a cohort of children [52]. A previous in vitro study, 
noted twelve miRNAs down regulated in human hepatoblastoma cells exposed to 10 µM 
cadmium [51]. The authors identified differential expression of miR-130a in cadmium-
treated cells [51], however expression levels were decreased in contrast to the increased 
miR-130a expression observed in the present study. No previously known relationship 
exists between cadmium and the other miRNAs identified in this study.  
 miRNAs are potential regulators of mRNA abundance. To examine the potential 
impact of the modulation of the eight miRNAs, mRNA expression levels were examined 
in the cardiomyocytes. A total of 31 genes showed altered expression among the 
cadmium-exposed samples compared to controls. Among these, a family of ten MT genes 
was identified. Induction of MT gene expression by cadmium has been shown in vitro 
[51], in vivo [53], and in human samples [54, 55]. MTs are involved in cellular protection 
against metal toxicity as well as the homeostasis of essential metals [56].   
We predicted miRNA-mRNA interactions then compared the predicted targets to 
our list of 31 differentially expressed genes. Eight of these were predicted to be regulated 
by the cadmium-modulated miRNAs. These miRNA-associated mRNAs were enriched 
for signaling pathways involved in gene expression, embryonic development, and 
organismal development. Paradoxically, all eight of the miRNA-associated mRNAs 
showed increased expression levels in the cadmium-exposed samples. Although binding 
of miRNA typically negatively regulates gene expression, recent evidence demonstrates 
that some miRNA act by increasing target gene expression [57]. It is suggested that 
factors other than miRNA binding might promote or inhibit miRNA-mRNA interactions 
[24]. miRNA-mediated upregulation of target genes can occur by upregulation of 
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previously suppressed target genes or by decreased expression of other inhibitory 
proteins and/or transcription factors.  
This study also identified upstream regulators of the differentially expressed 
genes. Notably, the MT genes were enriched for upstream regulation by transcription 
factors such as MTF1. MTF1 is a transcription factor associated with metal detoxification 
that coordinates induction of MT gene expression in multiple species. Andrews et al. 
suggested the other signal transduction cascades might be involved in MT gene 
expression activated by MTF-1 in cadmium-treated cells [58]. The present study provides 
evidence that miRNAs, such as miR-1, may partially play a role as mediators of signal 
transduction.  
Cardiomyocytes are the dominant cell type in the heart, including the septa [59], 
which are the most common site of cardiac defects in humans. Pathways that regulate 
early cardiomyocyte differentiation are also involved in processes that lead to adult heart 
disease [30], and animal models have shown that embryonic or early life cadmium 
exposure may influence cardiomyocyte cell fate and function in postnatal life [16, 17].  In 
general, cultured induced pluripotent stem cells mimic phenotypic properties of 
embryonic cells and are similar to embryo-derived stem cells [60, 61]. Human induced 
pluripotent stem cell-derived cardiomyocytes provide a superior in vitro model for 
cadmium toxicity studies over previous heart cell lineages because they exhibit 
spontaneous contractility and electrophysiological properties of main cardiac cell types 
[62, 63]. These properties enable in vitro culture of cells capable of mimicking acute 
cardiac dysfunction including arrhythmias [63]. Despite these advantages, it remains 
unclear how miRNA behavior in induced pluripotent stem derived cardiomyocytes 
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compares to that of primary cardiomyocytes [61, 64]. The future characterization of 
miRNA control of gene expression in primary cardiomyocytes and in vivo models will 
provide information on how normal heart cells respond to cadmium. 
In this study, we examined human cardiomyocytes miRNA and mRNA responses 
to acute environmentally relevant levels of cadmium. Further studies comparing the acute 
versus chronic miRNA response to exposure, as has been shown for other environmental 
exposures [65], will be useful in understanding these relevant differences as population 
tend to experience low-level chronic cadmium exposure. These miRNAs may potentially 
serve as novel biomarkers of exposure or metal-associated disease in future studies. 
 
Conclusions 
This study demonstrates that miRNAs are altered in cardiomyocytes exposed to 
cadmium. miRNAs are predicted to control mRNA transcript levels, and we demonstrate 
that these potentially regulate a set of eight differentially expressed mRNAs in human 
cardiomyocytes. Taken together, these findings support a role of miRNAs as a potential 
mechanism of cadmium-associated functional changes in human heart cells. More 
research is needed to examine the biological effects of cadmium exposure in vivo and 
among populations suffering from cadmium-associated cardiovascular disease. 
Understanding the pathophysiological role of cadmium in the heart can inform the 
mechanism of cadmium-associated cardiovascular disease and aid in the potential 
treatment of metal-associated disease.  
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Tables 
Table 3-1. Cadmium exposure to cardiomyocytes significantly increased the 
expression of nine unique miRNAs corresponding to 56 probesets. Significant 
differential expression between exposed and unexposed samples was defined by a fold 
change (FC) ≥ |1.5| and a p-value < 0.01.   
 
miRNA N Probesets p-value range Ave FC 
miR-1 17 9.97E-04 – 9.43E-03 2.03 
miR-20a-5p 1 4.37E-03 1.54 
miR-21-5p 13 1.81E-03 – 9.95E-03 1.98 
miR-22-3p 7 1.00E-03 – 7.34E-03 1.69 
miR-27b-3p 1 3.67E-03 1.51 
miR-30e-5p 1 9.85E-03 1.58 
miR-125b-5p 10 1.37E-03 – 9.74E-03 1.62 
miR-1274a_v16.0 3 5.77E-03 – 5.77E-03 1.56 
miR-130a-3p 3 1.11E-05 – 3.60E-03 1.55 
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Table 3-2. Eight miRNA predicted mRNA targets were confirmed experimentally 
by microarray analysis of mRNA transcript levels in samples exposed cadmium. 
Significant differential mRNA transcript expression between exposed and unexposed 
samples was defined by a fold change (FC) ≥ |1.5| and a p-value < 0.01.   
 
miRNA Confidence Gene Symbol mRNA FC p-value 
miR-1  Moderate (predicted) MT1F 4.47 2.08E-07 
miR-1  Moderate (predicted) MT1G 68.99 2.10E-06 
miR-1  Moderate (predicted) MT1H 148.52 2.69E-05 
miR-17-5p  High (predicted) ALX4 1.51 4.68E-03 
miR-17-5p High (predicted) POLR3G 1.57 3.04E-03 
miR-21-5p  High (predicted) ALX4 1.51 4.68E-03 
miR-27a-3p  Moderate (predicted) POLR3G 1.57 3.04E-03 
miR-27a-3p  High (predicted) SUSD5 1.63 2.57E-03 
miR-30c-5p  High (predicted) ME1 1.51 3.56E-03 
miR-30c-5p  High (predicted) POLR3G 1.57 3.04E-03 
miR-30c-5p  Moderate (predicted) SLC30A2 2.04 1.65E-03 
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Table 3-3.  Transcriptional regulators (TR) known to influence the differentially 
expressed mRNA transcripts were identified for the miRNA-associated genes and 
miRNA-independent genes. P-values represent a statistically significant overlap 
between the cadmium-associated geneset and genes known to be modified by a upstream 
transcriptional regulator (p<0.05). 
 
Upstream 
Regulator 
miRNA-target 
associated Molecule Type Target molecules p-value  
MUC1 TR MT1G, MT1H 5.26E-05 
KDM5B TR MT1F, MT1H 8.96E-04 
Hdac group MT1F, MT1H 1.14E-03 
HDAC1 TR MT1G, MT1H 1.32E-03 
MTF1 TR MT1G 2.00E-03 
HAND2 TR ALX4 5.98E-03 
BACH1 TR ME1 7.97E-03 
E2F5 TR MT1G 8.76E-03 
SUPT16H TR POLR3G 8.76E-03 
ELF4 TR MT1G 1.23E-02 
NCOR1 TR ME1 1.79E-02 
E2F2 TR MT1G 2.41E-02 
HDAC2 TR MT1H 2.49E-02 
RBL1 TR MT1G 2.57E-02 
E2F3 TR MT1G 2.80E-02 
NR3C2 
ligand-dependent 
nuclear receptor MT1H 3.50E-02 
 
 
   
Upstream 
Regulator miRNA-
independent 
Molecule Type Target molecules p-value  
MTF1 TR MT1E, SLC30A1 3.89E-06 
KDM5B TR MT1E, MT1X 2.45E-03 
Hdac group MT1B, MT1E 3.12E-03 
TP73 TR MT1B, MT1L 5.75E-03 
SMARCA4 TR MT1E, MT1L 1.52E-02 
NRF1 TR MT1E 2.95E-02 
CTNNB1 TR ASCL2, MT1L 4.58E-02 
USF1 TR MT1E 4.70E-02 
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Figures 
 
 
 
Figure 3-1. Significant molecular network of eight miRNAs differentially expressed 
in cadmium-exposed cardiomyocytes. Tumor suppressor protein p53 (TP53) appears as 
a central node. The network was enriched for signaling pathways associated with cancer, 
connective tissue disorders, and inflammatory disease (p<1x10-23). Colors represent 
increased expression of miRNA (red symbols) or associated proteins (clear symbols).  
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Figure 3-2. Heatmap of 31 differentially expressed mRNA transcripts. Data were 
mean standardized and hierarchical clustering was performed. Blue indicates relative low 
expression, and red indicates relative high expression.  
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Figure 3-3. Significant molecular network of miRNA-associated proteins (red color) 
and miRNA-independent proteins (green color). Networks display interactions of 
proteins encoded by genes that were differentially expressed in cadmium-exposed 
cardiomyocytes.  
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Supplemental Tables 
 
Table 3-S1. Cadmium chloride was not cytotoxic to cardiomyocytes after 24-hour 
exposure. Luminescence fold change was calculated as the mean luminescence for 
cadmium- or staurosporin- exposed samples divided by untreated control values. Each 
treatment group included six replicates. 
 
Treatment Condition Fold change  
Staurosporin (positive control) 0.01 
0.01 µM CdCl2 1.20 
0.05 µM CdCl2 1.13 
0.1 µM CdCl2 1.20 
0.5 µM CdCl2 1.25 
1.0 µM CdCl2 1.34 
5.0 µM CdCl2 1.18 
10.0 µM CdCl2 1.08 
50.0 µM CdCl2 1.07 
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Table 3-S2. Cadmium exposure to cardiomyocytes significantly increased the 
expression of nine unique miRNAs corresponding to 56 probesets. Significant 
differential expression between exposed and unexposed samples was defined by a fold 
change (FC) ≥ |1.5| and a p-value < 0.01.   
 
miRNA Probeset ID p-value q-value FC 
miR-1 44458 9.97E-04 0.49 1.75 
miR-1 19282 1.02E-03 0.49 1.72 
miR-1 4289 1.13E-03 0.50 1.91 
miR-1 28368 2.28E-03 0.60 1.87 
miR-1 8669 3.28E-03 0.65 2.17 
miR-1 61032 3.61E-03 0.65 2.10 
miR-1 30149 4.10E-03 0.67 2.29 
miR-1 53139 4.26E-03 0.67 1.96 
miR-1 46440 4.38E-03 0.67 2.27 
miR-1 39526 4.51E-03 0.67 2.01 
miR-1 41053 5.18E-03 0.69 1.99 
miR-1 14899 5.45E-03 0.70 2.13 
miR-1 33250 6.13E-03 0.70 1.87 
miR-1 37885 7.77E-03 0.73 2.07 
miR-1 20269 7.83E-03 0.73 1.88 
miR-1 57664 8.50E-03 0.74 2.15 
miR-1 17168 9.43E-03 0.75 2.32 
miR-20a-5p 58184 4.37E-03 0.67 1.54 
miR-21-5p 5799 1.81E-03 0.57 2.10 
miR-21-5p 28018 2.97E-03 0.65 2.09 
miR-21-5p 59575 3.10E-03 0.65 2.02 
miR-21-5p 18483 3.34E-03 0.65 2.16 
miR-21-5p 35083 3.68E-03 0.66 2.06 
miR-21-5p 25570 4.82E-03 0.67 2.15 
miR-21-5p 20794 5.46E-03 0.70 2.03 
miR-21-5p 9456 6.29E-03 0.71 1.87 
miR-21-5p 26951 6.53E-03 0.71 1.92 
miR-21-5p 10775 6.70E-03 0.71 1.85 
miR-21-5p 9322 8.66E-03 0.74 1.90 
miR-21-5p 51597 9.89E-03 0.75 1.87 
miR-21-5p 43392 9.95E-03 0.75 1.73 
miR-22-3p 28021 1.00E-03 0.49 1.60 
miR-22-3p 32003 1.04E-03 0.49 1.73 
miR-22-3p 2399 2.69E-03 0.63 1.67 
miR-22-3p 11673 3.39E-03 0.65 1.69 
miR-22-3p 9068 4.15E-03 0.67 1.67 
miR-22-3p 10971 5.70E-03 0.70 1.74 
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miR-22-3p 56058 7.34E-03 0.72 1.71 
miR-27b-3p 23533 3.67E-03 0.66 1.51 
miR-30e-5p 25735 9.85E-03 0.75 1.58 
miR-125b-5p 15935 1.37E-03 0.53 1.73 
miR-125b-5p 37771 4.37E-03 0.67 1.57 
miR-125b-5p 43022 4.38E-03 0.67 1.65 
miR-125b-5p 17949 5.53E-03 0.70 1.65 
miR-125b-5p 41051 5.67E-03 0.70 1.68 
miR-125b-5p 20012 6.90E-03 0.71 1.51 
miR-125b-5p 55379 7.54E-03 0.72 1.62 
miR-125b-5p 28571 8.12E-03 0.74 1.53 
miR-125b-5p 53702 8.56E-03 0.74 1.60 
miR-125b-5p 43869 9.74E-03 0.75 1.64 
miR-1274a_v16.0 23273 5.77E-03 0.70 1.55 
miR-1274a_v16.0 2371 5.81E-03 0.70 1.61 
miR-1274a_v16.0 21226 9.43E-03 0.75 1.53 
miR-130a-3p 3655 1.11E-05 0.10 1.51 
miR-130a-3p 1878 2.07E-04 0.35 1.52 
miR-130a-3p 20288 3.60E-03 0.65 1.62 
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Table 3-S3. Cadmium exposure to cardiomyocytes significantly altered the 
expression of 31 mRNA transcripts (FC ≥|1.5| and p-value<0.01). Five of the 
transcripts showed decreased expression in samples exposed to 0.5 µM cadmium 
chloride.  
 
Gene Symbol p-value FDR q-value Fold Change 
MT1H 2.69E-05 2.24E-01 148.52 
MT1A 1.39E-04 4.29E-01 93.61 
MT1L 8.25E-06 8.25E-02 87.13 
MT1M 7.28E-06 8.25E-02 85.76 
MT1G 2.10E-06 5.26E-02 68.99 
MT1E 2.58E-04 5.38E-01 7.64 
MT1B 7.14E-05 3.57E-01 7.55 
MT1F 2.08E-07 1.04E-02 4.47 
MT1CP 1.44E-04 4.29E-01 3.95 
SLC30A1 9.48E-05 4.29E-01 2.81 
MT1X 1.42E-04 4.29E-01 2.48 
F2RL2 5.50E-03 8.56E-01 2.26 
SLC30A2 1.65E-03 8.56E-01 2.04 
SUSD5 2.57E-03 8.56E-01 1.63 
ASCL2 9.69E-03 8.60E-01 1.60 
ACTR5 8.73E-03 8.56E-01 1.59 
POLR3G 3.04E-03 8.56E-01 1.57 
LOC100132472 8.16E-03 8.56E-01 1.54 
OR10AD1 7.89E-03 8.56E-01 1.53 
FAM27L 4.55E-03 8.56E-01 1.53 
OR1E2 4.77E-03 8.56E-01 1.52 
C1QL1 8.31E-03 8.56E-01 1.51 
ME1 3.56E-03 8.56E-01 1.51 
PPIP5K1 4.58E-03 8.56E-01 1.51 
ALX4 4.68E-03 8.56E-01 1.51 
ASIP 9.61E-03 8.60E-01 1.51 
LOC440895 6.64E-03 8.56E-01 -1.55 
LOC441728 3.58E-03 8.56E-01 -1.57 
C12orf36 6.40E-03 8.56E-01 -1.64 
MIR570 7.26E-03 8.56E-01 -1.64 
SNORD63 8.08E-03 8.56E-01 -2.11 
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Table 3-S4. Differentially expressed mRNA transcripts that were i) miRNA-
associated, ii) mRNA-independent, or iii) both were mapped to signaling pathways. 
Gene names in bold correspond to the 31 mRNA genes with altered expression in 
cadmium-exposed samples compared to unexposed controls. 
ID Molecules in miRNA-associated networks P-value Top Functions 
1 
ALX4, ATP7B, BACH1, BOP1, DLX2, DLX5, 
E2F5, ELF4, ERCC8, GARS, GATA4, 
GORASP2, GSTM3, GTF2A1, GTF3C1, 
HAND2, HOXA11, HOXD13, LDB1, ME1, 
MT1F, MT1G, MT1H, POLR3C, POLR3D, 
POLR3G, POLR3H, SOX10, SPINK7, 
STK17A, TBCD, TOM1, UBC, UGDH, VTA1 10-16 
Gene Expression, 
Embryonic 
Development, 
Organismal 
Development 
2 CREB3, SLC30A2 10-3 
Molecular Transport, 
Cancer, Cellular 
Development 
3 ACVR1, SUSD5, TGFB1 10-3 
Inflammatory 
Disease, 
Inflammatory 
Response, Skeletal 
and Muscular 
Disorders 
    
ID Molecules in miRNA-independent networks P-value Top Functions 
1 
ACTR5, ACTR8, ASCL2, ASIP, ATRN, beta-
estradiol, C1QL1, EGFR, eumelanin, F2RL2, 
FAM168A, FOS, GPR50, HTR1B, INO80C, 
MC1R, MC2R, MC3R, MC4R, MC5R, mir-
548, MT1A, MT1B, MT1E, MT1L, MT1M, 
MT1X, MTF1, NFRKB, POMC, PPIP5K1, 
SLC30A1, STK17A, TMC6, UBC 10-41 
Cell Signaling, 
Nucleic Acid 
Metabolism, Small 
Molecule 
Biochemistry 
2 OR1E2, RAD21 10-3 
Cellular Assembly 
and Organization, 
DNA Replication, 
Recombination, and 
Repair, Cellular 
Function and 
Maintenance 
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ID All 31 mRNA molecules in networks P-value Top Functions 
1 
ACTB, ACTR5, ACTR8, APP, C1QL1, 
CXXC1, DIRAS3, EGFR, F2RL3, FSH, 
GDF15, glutathione disulfide, GSTM3, GSTT1, 
Hdac, HNF4A, INO80, MT1A, MT1B, MT1E, 
MT1F, MT1H, MT1L, MT1M, MT1X, 
MTF1, NFRKB, nitrogen, PNPLA8, POLR3C, 
POLR3G, SRD5A1, STK17A, TFPT, TNF 10-26 
Renal and Urological 
Disease, Cellular 
Compromise, 
Psychological 
Disorders 
2 
ALX4, ASCL2, ASIP, ATRN, beta-estradiol, 
BOP1, CXXC1, DNMT1, F2RL2, GARS, 
GATA4, HAND2, HOXC4, HOXD13, HTR1B, 
KDM6A, MC1R, MC2R, MC3R, MC4R, 
MC5R, ME1, mir-548, MLL3, MT1G, MTF1, 
NFRKB, PHLDA2, PPIP5K1, SETD1A, 
SLC30A1, TBCD, TMC6, UBC, VTA1 10-21 
Cell Signaling, 
Nucleic Acid 
Metabolism, Small 
Molecule 
Biochemistry 
3 CREB3, SLC30A2 10-3 
Molecular Transport, 
Cancer, Cellular 
Development 
4 OR1E2, RAD21 10-3 
Cellular Assembly 
and Organization, 
DNA Replication, 
Recombination, and 
Repair, Cellular 
Function and 
Maintenance 
5 ACVR1, SUSD5, TGFB1 10-3 
Inflammatory 
Disease, 
Inflammatory 
Response, Skeletal 
and Muscular 
Disorders 
 
 
Note: References for Chapter 3 appear after the appendices.
 
 
 
 
 
 
CHAPTER 4: CONCLUSIONS AND IMPLICATIONS 
Summary 
The majority of birth defects have no known cause whether environmental, 
genetic, or combination of these factors. Toxic metals are likely contributors to birth 
defects in humans, yet the biological pathways that underlie these relationships remain 
largely unknown. The studies presented herein examined i) the epidemiologic association 
between toxic metal exposure and CHDs at the population and ii) transcriptional 
regulation and epigenetic modifiers using cardiomyocyte cultures exposed to cadmium in 
vitro.  
In the second chapter of this dissertation, we evaluated the associations between 
arsenic, cadmium, manganese, and lead levels in private well water with the prevalence 
of specific birth defects using six years of data collected by the North Carolina Birth 
Defects Monitoring Program. We estimated the association between prevalence of birth 
defects and residence in census tracts with the highest average metal levels and compared 
to residence in areas with the lowest average metal levels. Our exploratory study suggests 
ecologic associations between concentrations of toxic metals in drinking water and the 
prevalence of specific birth defects.  
Next, we applied an in vitro approach to identify biological pathways that 
underlie exposure to metals and their potential association with altered signaling in the 
heart. We exposed human-derived cardiomyocytes to low-levels of cadmium and 
	   99	  
assessed genome-wide miRNA and mRNA expression levels. We identified sets of 
miRNA-dependent and -independent genes that were differentially expressed in 
cardiomyocytes exposed to cadmium compared to unexposed controls. 
 
Public health implications 
Taken together the body of my doctoral research examines the potential health 
effects of metals in North Carolina and contributes to the overarching goal of protecting 
the health of susceptible populations by raising public health awareness of the global 
burden and potential impacts of toxic metals. Our studies have demonstrated that 
detectable metal levels were present in private well across the state and showed that 
further monitoring of levels of toxic metals North Carolina populations was prudent 
particularly for pregnant women. The epidemiologic study in Chapter Two contributes to 
the body of literature that describes the potential relationship between metal leveling in 
drinking water and CHDs. The toxicological study presented in Chapter Three describes 
a potential epigenetic mechanism, namely miRNA regulation of gene expression, which 
may contribute to metal-induced heart defects.   
In addition to targeted biomonitoring programs, public health strategies to prevent 
exposure such as raising awareness among pregnant mothers may be vital to protecting 
the health of newborns. Informing pregnant women of the sources of toxic metals such as 
diet (including drinking water), cigarette smoke, and other environmental sources will 
help to reduce exposures. Increased education about the potential risks of environmental 
contaminants including toxic metals will be key to reducing and preventing harm to 
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infants. The evidence provided by the environmental and biomonitoring studies herein 
have provided impetus for targeted biomonitoring programs and public health campaigns 
in North Carolina, specifically related to well water testing and monitoring prenatal lead 
exposure.  
 
Recommendations for future studies 
Our study contributes to the growing body of epidemiological literature on metal 
exposure and the relationship to birth defects. Direct biological monitoring of maternal 
and fetal exposures during the periconceptional period would greatly improve potential 
exposure misclassification issues in studies of environmental causes of birth defects. 
Further epidemiologic investigations should incorporate individual-level assessment of 
maternal drinking water quality and consumption. The results from this study suggest that 
research aimed at identifying metal-induced health outcomes should consider the likely 
presence of multiple metals. Moreover, studies examining the relationship between metal 
exposures in North Carolina and other metal-mediated health end points are needed. 
The research presented here used acute exposure and exposure response to a 
specific metal. Moving forward it will be important to understand the effects of chronic 
exposure and to assess long term alterations in miRNA expression levels. Moreover, 
studies examining the mechanistic responses to metal mixtures will be of interest since 
metal exposure rarely occurs in isolation. Further, use of an in vivo model or direct 
human biological sampling would allow increased translatability of this work the 
understanding of metal-induced disease. There is growing evidence that links miRNAs 
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and environmental exposures, and miRNAs have potential use as diagnostic biomarkers. 
Understanding the mechanisms that underlie metal-induced miRNA alteration are 
important for the development of more effective preventions strategies for 
environmentally-mediated diseases.  
It is likely a complex interplay of transcriptional regulators, including multiple 
epigenetic and genetic factors that will ultimately help researchers achieve a better 
understanding of metal-mediated disease. Taken together, the findings presented in this 
dissertation contribute to the understanding of potentially preventable environmentally-
mediated birth defects. Identifying environmental causes of adverse birth outcomes is 
important for the prevention of birth defects. 
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ABSTRACT 
Arsenic is a known human carcinogen and relevant environmental contaminant in 
drinking water systems. We set out to comprehensively examine statewide arsenic trends 
and identify areas of public health concern. Specifically, arsenic trends in North Carolina 
private wells were evaluated over an eleven-year period using the North Carolina 
Department of Health and Human Services database for private domestic well waters. We 
geocoded over 63,000 domestic well measurements by applying a novel geocoding 
algorithm and error validation scheme. Arsenic measurements and geographical 
coordinates for database entries were mapped using Geographic Information System 
techniques. Furthermore, we employed a Bayesian Maximum Entropy (BME) 
geostatistical framework, which accounts for geocoding error to better estimate arsenic 
values across the state and identify trends for unmonitored locations. Of the 
approximately 63,000 monitored wells, 7,712 showed detectable arsenic concentrations 
that ranged between 1 and 806 µg/L. Additionally, 1,436 well samples exceeded the EPA 
drinking water standard. We reveal counties of concern and demonstrate a historical 
pattern of elevated arsenic in some counties, particularly those located along the Carolina 
terrane. We analyzed these data in the context of populations using private well water and 
identify counties for targeted monitoring, such as Stanly and Union Counties. By 
spatiotemporally mapping these data, our BME estimate revealed arsenic trends at 
unmonitored locations within counties and better predicted well concentrations when 
compared to the classical kriging method. This study reveals relevant information on the 
location of arsenic-contaminated private domestic wells in North Carolina and indicates 
potential areas at increased risk for adverse health outcomes.  
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INTRODUCTION 
Ingestion of arsenic through drinking water is implicated in heart disease, 
neurological abnormalities, as well as cancers of the skin, lung, kidney, and bladder 
(NRC 2001). The United States Environmental Protection Agency (EPA) regulates 
arsenic in public drinking water supplies at a maximum contaminant level (MCL) of 10 
µg/L (EPA 2010).  Although this standard is enforceable in public water systems via the 
Safe Drinking Water Act, there is no federal regulatory standard for domestic well 
waters. Approximately 14 percent (about 42 million people) of the U.S. population 
obtains water from unregulated private domestic wells (Kenny et al. 2009).  It is 
estimated that domestic well users in the U.S. carry an excess lifetime risk of bladder and 
lung cancer of 66 people per million people, almost five times higher than that estimated 
for public well users (Kumar et al. 2010).  
 
Although arsenic exposure through drinking water is documented worldwide 
(Mukherjee et al. 2006), there is a paucity of data in the U.S.. For example, in a survey of 
U.S. drinking water supplies, many of the Mid-Atlantic states had insufficient data with 
less than 10% of counties represented (Welch et al. 1999).  To help fill this void, regional 
evaluations of groundwater arsenic in Appalachia (Shiber 2005), Idaho (Hagan 2004), 
Maine (Yang et al. 2009), Michigan (Kim et al. 2002), Nevada (Shaw et al. 2005; Walker 
et al. 2006), New England (Ayotte et al. 2003), and New Hampshire (Peters et al. 1999) 
have provided data beyond those collected in nationwide studies and have demonstrated 
contamination of drinking sources at spatial scales finer than the county level. In 
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addition, while the USGS provides routine ambient well monitoring nationwide, data 
gathered currently represent only a small fraction of groundwater sources. Domestic 
wells are not often monitored in such nationwide programs and may more adequately 
reflect exposure to unregulated contaminated water.  
 
It is known that areas of North Carolina contain naturally occurring arsenic 
deposits including the geological region of Carolina terrane (or Carolina slate belt) 
making it an ideal area for further investigation and public health efforts (Foley et al. 
2001). An initial study by Pippin et al., (2005), characterized arsenic occurrence in North 
Carolina groundwater between 1996-2004 and employed classic kriging techniques to 
map arsenic probabilities in the state. More recently, Kim et al. (in press), characterized 
geologic determinants of arsenic in Orange County, North Carolina. Our work builds 
upon earlier characterization of arsenic in North Carolina wells by developing methods to 
map historical contamination for the purposes of protecting public health. Importantly, 
the number of individuals in North Carolina currently using domestic wells for drinking 
water is estimated at 2.3 million (Kenny et al. 2009). North Carolina has the fourth-
largest state population in the U.S. using private groundwater wells as a drinking source 
and is exceeded only by Michigan, California, and Pennsylvania (Kenny et al. 2009).  
Many states, such as North Carolina, still remain understudied for the presence of arsenic 
in drinking water at a statewide level. Here, we present results obtained from a statewide 
program to monitor unregulated private domestic wells.  
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Given the known health risks and occurrence of arsenic in drinking water, we set 
out to identify areas of concern and quantitatively assess concentrations in domestic wells 
throughout North Carolina. To assess arsenic trends in monitored private domestic wells, 
we applied a novel geocoding scheme and mapped arsenic levels in wells using standard 
Geographical Information System (GIS) techniques (Nuckols et al. 2004; Miranda et al. 
2002; Holton 2002; Bellander et al. 2001). To estimate arsenic values at unmonitored 
locations, we then applied a novel Bayesian Maximum Entropy (BME) framework 
(Christakos 1990, 2000; Serre and Christakos 1999; De Nazelle et al. 2010) to predict 
arsenic contamination across the state and to examine areas of interest. These analytical 
techniques were applied to more than 60,000 domestic well water arsenic measures 
collected by the North Carolina Department of Health and Human Services (NCDHHS) 
dating back to 1998. In this work, we identify spatial and temporal arsenic trends in 
North Carolina domestic wells and indicate specific locations and populations of concern. 
Importantly, the geocoding and geostatistical methods presented here can be applied to 
track contaminant trends in other states.  Our results indicate a large number of 
contaminated wells in North Carolina and suggest that ongoing monitoring of well water 
contaminants is prudent. Moreover, these data provide new information of specific areas 
in North Carolina where targeted well monitoring programs can be used in a cost-
effective manner. 
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MATERIALS AND METHODS 
Data collection 
Domestic well water samples were collected by the NCDHHS Division of Public 
Health (DPH) State Laboratory of Public Health and Epidemiology Section which 
provides groundwater monitoring assistance to North Carolina homeowners. Following 
DPH guidelines, local health department officials collected water from homeowners’ 
indoor, outdoor, or well tap after allowing the water to run for 5-10 minutes. Arsenic 
analyses were performed by the NCDHHS Laboratory for Environmental Inorganic 
Chemistry.  Samples were transported to the DPH State Laboratory of Public Health and 
analyzed within 48 hours as per EPA Method 200.8 Revision 5.4 via inductively coupled 
plasma mass spectrometry (ICP-MS) with adherence to formal quality assurance/quality 
control (QA/QC) protocols (EPA 1994). Sample aliquots were acidified with nitric acid 
to below a pH of 2.0 for at least sixteen hours prior to ICP-MS analysis. A 50-mL 
subsample was then digested at 95ºC for at least 2 h.  For samples with high amounts of 
undissolved particulates, the digestate was filtered through a 0.45 µm filter to prevent 
damage to the analytical instrumentation. This method detects for total arsenic; species of 
As(III) and As(V) were not differentiated. The NCDHHS detection limit for arsenic had 
shifted in the past decade. In early 2000, the detection limit decreased from 10.0 to 1.0 
µg/L. More recently, the detection limit was raised to 5.0 µg/L – the level at which the 
laboratory presently operates. The laboratory maintains QC requirements of Fortified 
Blank recoveries of 95 – 105% and reagent blanks must show no contamination. In all lab 
analyses yttrium, rhodium, lutetium were included as internal standards to account for 
instrument drift and physical interferences. Every QC requirement must be met for the 
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sample analysis to be approved by the laboratory manager. Analyses were then entered 
into an extensive electronic database maintained by the State Laboratory of Public 
Health.  
Electronic database formatting 
Results from arsenic well water analyses were housed in an electronic database 
containing informational fields for arsenic concentration, well location ID, county name, 
global positioning system (GPS) location (if available), well owner address, and date 
collected. We analyzed 68,836 electronically available well water records of measured 
arsenic concentrations collected between October 19, 1998 and February 25, 2010. Data 
cleaning of the arsenic database excluded entries with insufficient information on 
location or those with improper/incomplete chemical analysis. We required that entries 
included in this study provided the following minimum information: a county name, a 
valid sampling date, and an approved laboratory chemical analysis for arsenic. The 
resulting comprehensive database of 63,856 well measures was used for all subsequent 
analyses.  
 
Descriptive statistics, heat map generation, and county ranking 
For all analyses, arsenic measurements below the detection limit (DL) were 
treated as 0.5 times the DL (0.5 × DL). Descriptive statistics were calculated using 
Spotfire DecisionSite 8.1 (TIBCO, Palo Alto, CA) for each of the 100 North Carolina 
counties. Heat maps to visualize temporal county trends were prepared using Partek 
Genomics Suite 6.4 (St. Louis, Missouri). Hierarchical cluster analysis using Euclidean 
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distance as a measure was used to identify relationships over time among the top 35 
counties exceeding the standard (Eisen et al. 1998). Furthermore, counties were ranked 
by 1) the percentage of wells exceeding the EPA standard over the full time period 
examined, and 2) the percentage of wells exceeding the EPA standard multiplied by the 
percentage of county population using self-supplied domestic wells (data reported by 
Kenny et al. 2009). We considered the current EPA MCL of 10 µg/L as the threshold, 
although the regulatory standard (originally 50 µg/L) was lowered over the course of data 
collection in this study. 
 
Four-class geocoding algorithm and error validation scheme  
A geocoding algorithm was developed to extract spatial coordinates and associated 
location error for the 63,856 private well measurements contained in the database. A 
four-class strategy, detailed below, was used to assign each data entry, l, with a spatial 
coordinate sl=(s1,s2)l, where s1 and s2 were the longitude and latitude best-representing the 
well location given the level of recorded information: GPS, street address, zip code, or 
county. The first of the four classes (Class I) was represented by data entries with 
available GPS coordinates, sl(GPS). For wells with reported GPS locations, geographical 
coordinates were standardized to decimal degrees format.  Standardized GPS coordinates 
were visualized in ESRI ArcGISTM software Version 9.0 (Redlands, CA). Well locations 
were classified as Class I when GPS coordinates were available and within the 
longitude/latitude boundaries of North Carolina. The second class (Class II) assigned 
geocoded owner address (GOA) coordinates, sl(GOA), to data entries based on street 
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address. To geocode the data, we applied a multi-stage geocoding process in which a 
series of local and national reference files were used sequentially in order from most 
comprehensive spatial detail to least as follows: a North Carolina point reference file 
(courtesy of NCDHHS Spatial Analysis Group), followed by a North Carolina 
Department of Transportation line reference file, then followed by a U.S. Street Address 
line reference file (Tele Atlas Dynamap Transportation, 2003). Resulting from this 
process, match scores of 0-100 were associated with each successfully geocoded address 
coordinate, sl(GOA).  To determine a match score threshold at which each reference file 
provided acceptable coordinates, we developed a method using one-way analysis of 
variance (ANOVA) to select acceptable match scores based on the distance between GPS 
and geocoded coordinates, dl=||sl(GPS)-sl(GOA)||. We calculated the average distance, dl, for 
wells with match score of 100 (perfectly matched addresses) to serve as the referent 
group. The remaining wells with a geocoded location were binned into deciles according 
to match score (e.g. 99-90, 89-80, 79-70 and so on) and the average distance dl was also 
calculated for each match score decile. We used ANOVA to compare the average 
distance dl to identify which match score deciles had an average distance dl that was not 
statistically significantly different (=0.05) from the average distance dl obtained with a 
match score of 100. Using this criterion, point file match scores of 70 and higher and line 
file match scores of 60 and above were considered acceptable for describing geocoded 
well locations. A data point was classified as Class II when it was not a Class I, was 
successfully geocoded by a given reference file with a match score above the match score 
threshold, and the county name included in the owner address matched the recorded 
county of sampling location. Class II data entries were assigned a single coordinate pair 
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representing the geocoded owner address coordinates sl(GOA) resulting from the multi-
stage geocode process.  The third class (Class III) included zip code centroid coordinates 
calculated and assigned using ArcGISTM. A well location was categorized as Class III 
when it was neither a Class I or Class II, was inside the North Carolina boundary and 
county of well location and a zip code was available to geocode. Class III data entries 
were assigned zip code centroid coordinates. The fourth class (Class IV) included county 
centroid coordinates for each of the 100 counties in North Carolina. A well location was 
considered Class IV when it did not meet the requirements of any of the previous classes, 
but a county centroid coordinate was available. Class IV data entries were assigned 
county centroid coordinates. Each entry in the database was categorized as one of the 
four aforementioned classes and the resulting four-class geocoded data was used in all 
subsequent analyses. In summary, the geocoding process assigned one of each of the 
following four classes to every arsenic measure in the database: Class I (GPS location), 
Class II (street address), Class III (zip code centroid), Class IV (county centroid). Wells 
with assigned geographic coordinates and corresponding arsenic concentration data were 
visualized using ArcGISTM ESRI version 9.0 software. 
 
The four-class geocoding scheme enabled maximum incorporation of spatial 
information contained in the private well database. Next, we assessed error associated 
with each of the four classes to account for uncertainty introduced by the geocoding 
process. For Class I, GPS device positional error resulted from inaccuracies in satellite 
triangulation.  Positional error associated with GPS instrumentation found by others was 
between 5 and 25 meters (Wing and Eklund 2007; Hulbert and French 2001). Without 
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rigorous quantification of GPS device error by the NCDHHS, a conservative Class I error 
of 50 m was estimated for the GPS coordinates sl(GPS). For Class II, the location error of 
geocoded street address coordinates sl(GOA) was considered to be a combined effect of two 
error sources: character-matching error as captured by the match score and inaccuracy in 
reference file coordinates. For Class II data entries we estimated the location error as the 
distance dl=||sl(GPS)-sl(GOA)|| between the well GPS location and the street address 
geocoded location. Class II location error was described as a function of match score 
grouped into deciles (e.g. 100, 90-99, 80-89, 70-79). The location error for a geocoded 
owner address coordinate sl(GOA) corresponding to a given match score was assigned the 
median of the distances dl in the corresponding match score bin (Supplemental Figure 
S3). For Classes III and IV, entries provided limited locational information, thus data 
entries were assigned an error estimate of the median radius of zip code or county, 
respectively.  
 
Spatiotemporal geostatistical estimation of arsenic concentrations 
In addition to mapping the actual historical arsenic measures contained in the 
database, a BME geostatistical framework was applied to estimate concentrations for 
locations at which no data were available. We let X(s’,t) be a space/time random field 
(S/TRF) representing the yearly arsenic concentration at location s’ and year t. We 
defined the yearly county arsenic concentration at location s and time t as the areal 
average of X(s’,t) over an area the size of a county around s, i.e. 
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€ 
ZR (s,t) =
1
AR
ds'X(s',t)
AR (s)
∫ 	   (1) 
where AR(s) was an area of radius R around s, and the subscript R in ZR emphasized the 
county level observation scale over which arsenic was estimated, which in this work 
corresponded to the median county radius in North Carolina (approximately 11 km). 
 
First, kriging principles were applied to estimate arsenic concentrations across 
space and time using only the county averages. The average arsenic concentrations were 
calculated within the boundary of any county i. This county average provided an exact 
(hard) value zhard(i,t) for the S/TRF Z(si,t) at the centroid si of county i.  These hard data 
were processed with the well-documented kriging method (Cressie 1990) to model the 
mean trend (assumed constant) and covariance cZ(p,p’) of the S/TRF Z(s,t) where p=(s,t) 
was the space/time coordinate and obtain kriging estimates of county arsenic 
concentrations at a grid of unmonitored locations.  
To incorporate the geocoded information and refine the spatial resolution of our 
arsenic estimate, we developed a BME framework to account for errors associated with 
geocoded classes by generating soft data. The soft data for yearly arsenic county 
concentrations were constructed at soft data points located on a static fine resolution grid 
across the state. The mean µj (Equation 2) and variance  (Equation 3) for the yearly 
county arsenic concentration incorporated geocoding distance error and assigned weight 
wl (Equation 4). As such, the arsenic value at a given soft data point sj was assigned a 
mean and variance calculated as the weighted sample average and sample variance, 
2
jσ
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respectively, of the geocoded private well data that were within a distance R of sj, where 
the weights decreased as a function of increased geocoding location error, i.e. 
         (2) 
 
€ 
σ j
2 =
wl∑ (Asl −µ j )2
wl∑
n       (3) 
where Asl and n served as the l-th and total number of measured arsenic values within R 
of sj, respectively, and wl described a weight that was inversely related to the location 
error l of the l-th arsenic data point. Weights were calculated as 
	          (4) 
which captured the chance that well l was correctly placed within a circle of radius R 
despite its location error εl. To prevent the probability of estimating a negative 
concentration, we defined the soft data using a Gaussian probability distribution function 
truncated below zero, with mean and variance calculated from Equations 2 and 3. 
Equations (2-4) provided values for the soft data points sj, which together with the hard 
data zhard(i,t) at the county centroids si, constituted the site specific knowledge S that was 
incorporated to produce refined estimates of yearly county arsenic concentrations using 
the BME method (Christakos 1990, 2000; De Nazelle et al. 2010) and its BMElib 
numerical implementation  (Serre and Christakos 1999; Christakos et al. 2002). The 
estimated values were mapped using ArcGISTM ESRI version 9.0 software. 
∑
∑=
l
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µ
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Lastly, to quantitatively evaluate the difference in performance of the kriging and 
BME methods for accurate estimation of arsenic concentrations, we applied a cross-
validation approach.  Each data point was sequentially removed from the estimation 
scheme and then re-estimated using the remaining space/time data points (Money et al. 
2009). Mean square error (MSE) was then derived from this cross-validation process and 
calculated as the sum of the squared differences between the re-estimated and original 
values.  
 
USGS and EPA database retrieval 
Archived arsenic monitoring data from the online Water Quality section of the National 
Water Information System (NWIS) and STORET database were obtained electronically 
(USGS 2010).  Basic statistics were compared from the NCDHHS database with the field 
sample dataset from the NWIS in North Carolina. 
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RESULTS 
Arsenic levels exceed EPA standard in North Carolina monitored wells 
 
The historical database of monitored well data revealed increased well sampling 
in recent years. Prior to 2008 the NCDHHS sampled over 4,000 wells per year with a 
notable increase to over 10,000 wells per year from 2008 to present (Supporting 
Information Table S1). Across the state, a total of 1,436 well measurements (2.25%) 
exceeded the current standard of 10 µg/L and 233 exceeded 50 µg/L (Table 1; Supporting 
Information Table S1 and Table S2).  Over the 11-year period, 7,713 samples measured 
above the detection limit, representing approximately 12% of all private wells tested 
(Table 1). The remaining domestic well water records were below the detection limit 
(Supporting Information Table S2).  
 
To systematically determine counties with elevated arsenic levels, counties were 
ranked by the percentage of wells that exceeded the EPA standard across the eleven-year 
period (Figure 1; Table 1; Supporting Information Table S1). The top ten counties with 
the highest percentage of wells containing elevated arsenic levels were in order: Stanly, 
Union, Anson, Montgomery, Dare, Randolph, Davidson, Alexander, Cleveland, and 
Currituck (Supporting Information Table S1). Of the measured wells that exceeded the 
EPA standard, nearly 70% were within these ten counties. The remaining 30% of wells 
that exceeded the EPA standard were collected from the remaining ninety North Carolina 
counties (Table 1). To identify counties that might exhibit similar arsenic trends over 
time, cluster analysis was performed. Members of the top ten counties (e.g. Union, 
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Stanly, Alexander) had statistical temporal relationships in arsenic levels across the 11-
year period (Supporting Information Figure S1). This comprehensive temporal 
assessment revealed a historical pattern of arsenic levels in counties along the Carolina 
terrane, demonstrating that some counties appear to have been high for over a decade. 
 
Table 1 also reports the demographics of county and state population (and percent 
of total) using private domestic well water (Kenny et al. 2009). Notably, in some of the 
highly ranked counties, such as Randolph County, nearly 48% of the county population 
uses private domestic wells as a primary water source. Counties were assigned a second 
ranking based on the percentage of population using self-supplied domestic wells 
multiplied by the percentage of wells exceeding the EPA standard.	  The following top ten 
counties were identified: Stanly, Union, Montgomery, Randolph, Lincoln, Pender, Dare, 
Moore, Person, and Transylvania.	  	  	  
	  
A four-class geocoding algorithm increased spatial information 
The geocoding scheme developed in this work categorized the data into four 
classes (Supporting Information Figure S2). Approximately 3.6% (2,295 well measures) 
of the database had original GPS coordinates available and represent Class I. Geocoded 
well locations representing Class II comprised 68.9% (43,991 well measures) of the 
database. The remaining well locations were categorized as Class III (13.3%) and Class 
IV (14.2%) by assigning zip code and county centroid coordinates, respectively.  
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A geocoding location error was assessed for each geocoding class (Supporting 
Information Table S3). A conservative estimate of 50 m location error for Class I was 
established based on previously reported quantification of GPS error (Wing and Eklund 
2007; Hulbert and French 2001). Class II location errors were determined as a function of 
match score. Acceptable geocoding match scores were established at 60-100 and the 
corresponding median location error ranged between 78 meters and 758 meters 
(Supporting Information Figure S3, Table S3). Location error for Class III and Class IV 
was approximated as half the median radius of a zip code or county, 3,500 and 11,000 m, 
respectively.  
 
Mapping of arsenic in monitored private domestic wells 
We applied the results of our four-class geocoding process to map arsenic levels 
in monitored wells and identify regions of arsenic contamination in North Carolina 
(Figure 2). As an example, we show locations of the geocoded wells and those that 
exceeded the EPA standard in 2009 (Figure 2A).  Notably, wells exceeding the EPA 
standard were located primarily in the south-central region of the state. The calculated 
county averages for 2009 are also provided (Figure 2B). The highest county average was 
observed in Stanly County, where the average of 89 domestic well records approached 
the 10 µg/L EPA standard.   
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Spatiotemporal modeling of estimated arsenic concentrations 
Next, we set out to refine the spatial scale and apply the results of the geocoding 
process using two geostatistical estimation methods, namely 1) the classical kriging 
method and 2) our novel BME framework. Using the classical method that incorporates 
no distance error information, the spatial distribution of kriging estimates of county 
arsenic concentrations across North Carolina is represented (Figure 2C). The kriging 
estimates correspond to the spatial interpolation of county averages assigned to their 
county centroid. In comparison, the BME framework with a county-level observation 
scale (Figure 2D) interpolated data in between county averages. The county observation 
scale enabled estimates of aggregated arsenic concentrations across a ~11 km radius. This 
map incorporated estimated distance errors associated with the geocoded data to obtain 
less biased predicted arsenic values. From this BME map we identified regions within 
counties where elevated arsenic is endemic. For example, southeastern Union County and 
the border between Stanly and Montgomery Counties are areas of special concern (Figure 
2-D1). The BME estimates reveal that in these areas the arsenic concentration may reach 
18 µg/L. Cross-validation analysis indicated that the BME framework better estimated 
arsenic concentrations than the kriging method. The MSE for the BME method was 41% 
lower than that of kriging (Supporting Information Table S4). In total, the geocoded data 
and the rigorous processing of location errors through the BME method significantly 
improved our understanding of arsenic distributions across unsampled areas of North 
Carolina.   
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DISCUSSION 
Arsenic is a known human carcinogen and relevant environmental contaminant in 
drinking water systems. Publicly available data at the NCDHHS represent a volume of 
historical arsenic analyses in North Carolina domestic well waters performed under 
stringent EPA guidelines that remain largely unanalyzed. A primary goal of this research 
was to identify trends in areas of North Carolina with elevated arsenic concentrations in 
monitored domestic well waters. We revealed arsenic trends by county in monitored 
wells over time as well as estimated concentrations in unmonitored locations. The 
geocoding methods developed in this study data enabled a comprehensive report of over 
4,000 yearly arsenic measurements with geographical coordinates from 1998-2007 and 
over 10,000 from 2008 to present, a substantial increase relative to the USGS and EPA 
ambient monitoring systems. Specifically, the number of records analyzed represents a 
600-fold increase from samples collected by the USGS (USGS 2010) and more than three 
times the number of records analyzed in other studies North Carolina wells (Pippin 2005; 
Kim et al. in press). The substantial increase in recent well sampling is likely due to state 
legislation adopted in 2008 that requires every newly constructed well be tested. These 
types of monitoring programs, as evidenced here, are successful to ensuring increased 
awareness of well water contaminants and protected health of individual homeowners.  
 
A notable result of this study is the surprisingly high levels of arsenic (up to 806 
µg/L) that were detected in some homeowners’ domestic wells. In addition, more than 
1,436 (2.25%) of wells exceeded the EPA standard. Some of the top-ranked counties 
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identified here as most frequently exceeding the EPA MCL have not previously been 
highlighted in nation- or statewide studies (Welch et al. 1999) including Anson, 
Montgomery, Dare, Alexander, Cleveland, and Currituck Counties. We identify historical 
trends in counties along the Carolina terrane and through comprehensive temporal 
assessment reveal that arsenic levels have been elevated for over a decade. In some of 
these counties, greater than 50% of the population use domestic wells (Kenny et al. 
2009). Importantly, some of the identified counties of concern have rapidly growing 
populations (US Census Bureau 2006), which compounded by an arsenic-prone geology 
may have public health implications for residents. Simultaneously, rural areas are more 
likely to lack connection to a municipal drinking water system. By ranking based on 
percentage of population at risk we identify counties where county-level well monitoring 
programs may be cost-effective. By integrating information on population size in these 
counties, we show Union and Stanly continue to rank among the most at-risk county 
populations. Our data confirm increased concentrations of arsenic in counties located 
along the Carolina terrane and highlight elevated levels over a decade-long period. In 
addition, the counties of Stanly and Union have large populations (roughly 26,000 and 
49,000 individuals) relying on private well water sources. Currently, no epidemiologic 
literature has investigated the health impact of arsenic in these populations. 
 
This study presents a new approach to assigning geographical coordinates when 
sample locations are described by inconsistent recorded information. It was evident from 
the spatial locations of GPS data that GPS device use was not uniform across the state. It 
was necessary, therefore, to increase the number of geocoded locations using additional 
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information (Classes II-IV) to avoid bias and provide more accurate spatial 
representations. As such, we applied a four-step geocoding process and error estimation 
scheme that increased the available geographic coordinates of ~3,000 to more than 
63,000 well analyses. We increased the knowledgebase using available locational 
information to assign geographic coordinates of domestic wells based on four spatial 
classes: GPS, street address, zip code, and county. As an example, we tripled the number 
of successfully geocoded points used in previous analyses over comparable geographic 
areas and timeframes (Pippin 2005; Kim et al. in press). Additionally, while others have 
shown that multi-stage geocoding methods improved the match rate compared to single-
step methods (Lovasi et al. 2007), to our knowledge, the present study is one of the first 
to use GPS locations to systematically quantify and account for geocoding location error. 
We present a widely applicable method of systematically determining acceptable match 
scores resulting from the multi-stage address geocoding procedure that serves as an 
alternative to a minimum match score determined a priori (Yang et al. 2004). 
 
The general BME framework has been applied to arsenic levels in Bangladesh 
groundwaters to estimate aqueous concentrations where data are not available (Serre et 
al. 2003). In this study, we apply the BME framework to U.S. groundwaters and 
incorporate location error into a novel arsenic estimation process, which aggregates 
monitored arsenic levels to a county level observation scale (~11km). To the best of our 
knowledge, this is the first study that accounts for locational error. The cross-validation 
analysis shows that the BME approach presented in this work more accurately predicts 
arsenic than conventional modeling approaches. Within this framework, the county 
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observation scale refines well-to-well variation and we would not expect to find the high 
concentrations seen in individual monitored wells (e.g. up to 806 µg/L). By narrowing the 
scope to counties of interest in the southwestern Piedmont we identified southeastern 
Union County and the border between Stanly and Montgomery Counties as areas of 
special concern. The levels documented in this study indicate areas of arsenic 
contamination at nearly twice the EPA standard-a level estimated to double the risk of 
bladder and lung cancer (NRC 2001).  The local observation scale enables our predictive 
maps to be useful for public health screening purposes by identifying areas where the risk 
of arsenic exposure is high and by providing a science-based criterion for cost-effective 
monitoring of wells.  
 
Through our analyses of over 60,000 geocoded well locations we were able to 
more accurately assess spatial and temporal arsenic trends in both monitored wells and 
estimates at unmonitored locations across North Carolina. We found that areas near the 
eastern coast and along the Carolina terrane have high prevalence of arsenic 
contamination in private wells. The presence of arsenic in the Carolina terrane has been 
confirmed by geological studies in this area (Foley et al. 2001) and is supported by 
models that incorporate geologic determinants (Kim et al. in press). Abundant literature 
details the sources of groundwater arsenic contamination through anthropogenic factors 
including agricultural or industrial practices (Foley and Ayuso 2008; Jackson et al. 2006; 
Appleyard et al. 2004; Embrick et al. 2005), yet, much of arsenic contamination  
highlighted in this study is thought to be naturally occurring due to the underlying 
geology (Foley et al. 2001; Welch et al. 2000; Duker et al. 2005). The Carolina terrane, 
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however, does not underlie each of the top ten counties (Pender, Dare, and Currituck 
Counties for instance) and it is possible that a combination of anthropogenic and natural 
sources may contribute to arsenic contamination, however additional studies are 
warranted. Currently, no EPA Superfund National Priorities List or Toxic Release 
Inventory sites are listed in these three counties that would indicate substantial 
anthropogenic contribution to environmental arsenic concentrations. Moreover, while an 
EPA superfund site is located in Haywood County with reported historical use of 
arsenical pesticides, no wells in that county that exceeded the EPA standard.  
 
Studies like this one represent a major step towards arsenic surveillance in 
contaminated areas. To lessen the risk of exposure to arsenic in drinking water, 
recommended preventative measures include point-of-use removal, modification of well 
depth, and/or use of an alternate water source (Alaerts and Khouri 2004; Pratson et al. 
2010). These solutions are rarely cost-effective, however, and may not be feasible in rural 
areas. Simple cost-effective technologies for mitigating arsenic are not widely available, 
and, in lieu of federal or state water quality regulation of domestic wells, the best 
mitigation is in the form of well water testing programs. Trivalent (As3+: arsenite) and 
pentavalent (As5+: arsenate) arsenic most commonly occur in natural waters (Duker et al. 
2005; Feng et al. 2001). Due to the variable toxicity of arsenic species (As3+ being more 
toxic), additional studies are warranted to determine the distribution of individual arsenic 
species in drinking water. Targeted monitoring is crucial in reducing the financial cost of 
testing for speciated arsenic in every monitored well and the methods developed here can 
be applied to this end towards arsenic in other regions as well as to other contaminants of 
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concern to public health.   
The compounding of environmental and social factors means residents could be at 
increased risk for health effects from arsenic. Additional studies are warranted to further 
ascertain the sources of and biogeochemical behavior of arsenic in unstudied regions of 
North Carolina and to help reduce exposures among at risk populations. By identifying 
regions of contamination through studies such as this one, cost-effective monitoring 
programs can target at risk populations to protect public health and help to shape state 
and local water monitoring policies (Miranda et al. 2011).  Moving forward we anticipate 
research that will integrate these findings with biomonitoring and health outcome data to 
substantiate risks posed to populations in arsenic endemic areas. The next steps to 
protecting individuals include community education in at risk areas and biomonitoring of 
those populations most at risk including children and pregnant women.  
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FIGURES 
 
Figure 1. The top thirty-five counties that exceed the EPA standard (10 µg/L). Counties 
are ranked by the percent of wells that exceed the EPA standard and are represented in a 
heat map. Counties with percent of wells exceeding the statewide 2.25% appear in red-
scale, while those below the statewide percent appear in blue-scale. Counties with no 
information available appear in white.  
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12.  Moore 
13.  Gaston 
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Figure 1. 
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Figure 2. Geocoded arsenic concentrations in 2009. (A) Samples exceeding the EPA 
standard are shown in black. Well locations of samples below the standard appear in 
gray. (B) County averages are displayed in grayscale and the number of arsenic analyses 
in 2009 appear within each county.  *No wells were sampled in Chowan County in 2009. 
(C) A classical kriging method estimated arsenic distribution across the state at 
unmonitored locations. (D) The Bayesian Maximum Entropy framework estimated 
arsenic distribution across the state at unmonitored locations.  
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TABLES 
Table 1. Top 25-rankeda North Carolina counties.  
Ranka County  
Total 
no. of 
wells 
sample
d 
No. of 
wells that 
exceed 
EPA 
standard 
(%) 
No. of wells 
above detect 
(%) 
Pop. using 
domestic wells, 
in thousands 
(%)b 
Pop. 
at 
risk 
rankc 
1 Stanly 849 176 (20.73) 485 (57.13) 25.947 (44.00) 1 
2 Union 3250 634 (19.51) 
1454 
(44.74) 49.197 (30.20) 2 
3 Anson 98 10 (10.20) 34 (34.69) 2.704 (10.60) 11 
4 Montgomery 372 34 (9.14) 120 (32.26) 8.213 (30.06) 3 
5 Dare 572 36 (6.29) 137 (23.95) 8.091 (23.87) 7 
6 Randolph 1595 72 (4.51) 394 (24.70) 66.845 (48.31) 4 
7 Davidson 552 23 (4.17) 106 (19.20) 36.893 (23.86) 13 
8 Alexander 128 5 (3.91) 30 (23.44) 6.818 (19.21) 15 
9 Cleveland 269 9 (3.35) 37 (13.75) 9.234 (9.39) 29 
10 Currituck 153 5 (3.27) 24 (15.69) 3.492 (15.11) 23 
11 Lincoln 990 31 (3.13) 139 (14.04) 39.858 (57.06) 5 
12 Moore 1093 33 (3.02) 206 (18.85) 34.920 (42.75) 8 
13 Gaston 1697 47 (2.77) 278 (16.38) 57.915 (29.53) 14 
14 Cabarrus 626 15 (2.40) 98 (15.65) 37.367 (24.87) 21 
15 Pender 800 19 (2.38) 115 (14.38) 33.179 (71.46) 6 
16 Watauga 671 15 (2.24) 77 (11.48) 11.970 (28.18) 20 
17 Nash 1137 25 (2.20) 145 (12.75) 4.870 (5.33) 43 
18 Transylvania 424 9 (2.12) 24 (5.66) 15.156 (51.16) 10 
19 Chatham 1404 26 (1.85) 455 (32.41) 32.080 (55.31) 12 
20 Person 847 15 (1.77) 165 (19.48) 25.605 (68.80) 9 
21 Catawba 454 8 (1.76) 42 (9.25) 62.709 (41.35) 17 
22 Bladen 114 2 (1.75) 7 (6.14) 13.898 (42.19) 16 
23 Duplin 240 4 (1.67) 13 (5.42) 15.305 (29.44) 24 
24 Avery 261 4 (1.53) 28 (10.73) 8.291 (47.00) 18 
25 
New 
Hanover 1449 22 (1.52) 248 (17.12) 16.371 (9.12) 41 
-- 
Other 
counties 43811 157 (0.36) 2852 (6.51) 
1668.398 
(24.95) 
-- 
Total -- 63856 1436 (2.25) 
7713 
(12.08) 2295.33 (26.43) 
-- 
aRank based on tendency of wells to exceed the EPA standard throughout an 11-year period; 
bData from (Kenny et al. 2009); cRank based on composite of percentage of wells that exceed the 
EPA standard through the 11-year period and percentage of county residents using private 
domestic well water.  
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ABSTRACT 
 
Exposure to toxic metals during the prenatal period carries the potential for adverse 
developmental effects to the fetus, yet such exposure remains largely unmonitored in the 
United States. The aim of this study was to assess maternal exposure to four toxic metals 
(arsenic (As), cadmium (Cd), mercury (Hg), and lead (Pb)) in a cohort of pregnant 
women in North Carolina. We analyzed blood samples submitted to the North Carolina 
Department of Health and Human Services for blood typing to assess toxic metal levels 
in pregnant women (n=211) across six North Carolina counties. Whole blood metal 
concentrations were measured by inductively coupled plasma mass spectrometry. The 
association between maternal characteristics, including county of residence, age, and 
race, and metal exposure was analyzed using multiple linear regression analysis. A large 
fraction of the blood samples showed detectable levels for each of the four metals. 
Specifically, As (65.7%), Cd (57.3%), Hg (63.8%), and Pb (100%) were detected in 
blood samples. Moreover, compared with adult females participating in the Fourth 
National Report on Human Exposure to Environmental Chemicals and guidelines for 
pregnant women, some women in the sample population exceeded benchmark levels of 
Cd, Hg, and Pb. Evidence from this pilot study indicates that pregnant women in North 
Carolina are exposed to As, Cd, Hg, and Pb and suggests that factors related to maternal 
county of residence and race may impact maternal exposure levels. As increased levels of 
one or more of these metals in utero have been associated with detrimental 
developmental and reproductive outcomes, further study is clearly warranted to establish 
the impacts to newborns.  
	   135	  
INTRODUCTION 
Arsenic (As), cadmium (Cd), mercury (Hg), and lead (Pb) are metals ranked 
among the top ten most toxic substances by the Agency for Toxic Substances and Disease 
Registry [1]. Maternal exposures to toxic metals may result from diet, air, drinking water, 
occupational exposures, and/or tobacco use. Evidence suggests that each of these metals 
is able to cross the placental barrier resulting in prenatal exposure [2,3,4,5] and maternal 
blood levels of these contaminants correlate with umbilical cord blood levels [5,6]. 
Biologically, prenatal exposure to metals is of concern for a variety of reasons. For 
example, prenatal exposure to arsenic is associated with later life health effects in adults 
[7,8,9] including increased mortality and increased risk of lung and liver cancer 
[10,11,12]. In addition, in utero exposure to arsenic has been shown to alter genomic 
signaling of key biological pathways [13]. Furthermore, maternal exposures to toxic 
metals can increase the risk for poor birth outcomes, including low birth weight 
[3,14,15], reduced fetal growth [16], and reproductive and cognitive deficits in 
adolescents [17,18,19].  
Toxic metal exposures in utero and during childhood may result in significant 
health effects to individuals that manifest cumulatively to the detriment of populations. 
U.S. annual economic losses due to decreased productivity from environmental exposure 
to Hg and Pb were estimated as $8.7 and $43.4 billion respectively [20,21]. In spite of 
strong evidence to indicate the adverse health effects of metals to susceptible populations 
such as newborns, few statewide biomonitoring programs are in place. For example, 
while North Carolina has established a successful program for childhood lead screening 
[22], there remains no prenatal assessment of environmental contaminants. This is of 
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concern in North Carolina because the occurrence of metals including As, Pb, and Hg has 
been reported in environmental reservoirs with the potential for human exposure 
[23,24,25].  
Known health risks are associated with exposure to heavy metals, particularly 
during the periconceptional and prenatal periods. Established recommended advisory 
blood levels of 5.8 µg/L Hg and 10.0 µg/dL Pb are considered protective of human health 
for the general population [26,27]. However, because cord blood levels of Hg and Pb 
have been found to exceed maternal blood levels, the maternal blood levels of 3.5 µg/L 
Hg and 5.0 µg/dL Pb are recommended for the protection of fetal health [26,28,29]. 
Blood levels in individuals exceeding these reference concentrations are associated with 
decreased IQ and cognitive function [20,26]. Despite evidence of associated detrimental 
health effects, there are currently no biological advisory levels pertaining to As or Cd for 
pregnant women or the general population.  
The major aim of this pilot study was to assess blood levels of As, Cd, Hg, and Pb 
in pregnant women residing in six North Carolina counties and to examine associations 
of metal levels according to maternal age, race, and county of residence. Evidence 
gathered in this study will be used to further assess maternal and prenatal exposures in 
future studies and to provide impetus for targeted biomonitoring programs or public 
health campaigns in North Carolina. Biomonitoring of maternal levels of toxic metals in 
targeted populations may help reduce prenatal exposures and subsequently the potential 
for future adverse developmental effects.  
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METHODS 
Study Design 
 To assess blood levels of toxic metals in pregnant women, we analyzed blood 
samples submitted to the North Carolina Department of Health and Human Services 
(NCDHHS) State Laboratory of Public Health for blood group typing. Residual volumes 
of blood originally submitted for group typing were analyzed for As, Cd, Hg, and Pb. 
Data were provided under the context of a data use agreement for a limited data set using 
a data custodian as an intermediary to protect identifiable information. This study was 
reviewed by the UNC Public Health-Nursing IRB (#09-1399) and was determined to be 
exempt from review according to regulatory category 4 under the National Institutes of 
Health description on Research on Human Specimens (44 CFR 46.101(b)). Similar 
strategies that assess metal levels in samples collected under the auspices of existing 
public health monitoring programs have been used to establish environmental 
contaminant levels in individuals [30].  
Women in this study were North Carolina residents in their third trimester of 
pregnancy and receiving prenatal care at local health departments. The mothers’ venous 
blood samples were collected between October 2009 and January 2011. Bladen, 
Cumberland, Richmond, Stanly, Union, and Wake Counties were selected for analysis 
based on trends in private well water metal levels reported in publicly available data [31]. 
Throughout the remainder of the manuscript county identities are coded and designated 
as A-F, using random assignment. Data collected included: (1) pregnant women’s 
(n=211) whole blood level of As, Cd, Hg, and Pb, (2) county of residence, (3) age, and 
	   138	  
(4) race. No additional demographic information on subjects was requested in accordance 
with the limited data use agreement.  
 
Blood Analysis  
The North Carolina Department of Health and Human Services (NCDHHS) for 
blood typing group is certified by the U.S. DHHS as compliant with the 1988 Clinical 
Laboratory Improvement Amendment (CLIA). In accordance with CLIA certification, 
the laboratory adheres to quality assessment/quality control (QA/QC) requirements with 
oversight by the Centers for Medicare and Medicaid Services. Blood samples from non-
fasting pregnant women were collected into phlebotomy tubes containing 
ethylenediaminetetraacetic acid (EDTA) as an anticoagulant and stored at 4°C prior to 
processing at the Division of Public Health State Laboratory. Whole blood analysis was 
performed via Inductively Coupled Plasma Dynamic Reaction Cell Mass Spectrometry 
(ICP/DRC/MS) according to the US CDC laboratory methods for metals in whole blood, 
DLS Method code CTL-TMS 3.01 [32,33]. The samples were analyzed on a Perkin 
Elmer Elan DRC II ICP/MS instrument. Arsenic was measured in blood using the DRC 
mode to remove isobaric interference from Argon Chloride at mass 75. Iridium was used 
as an internal standard for all elements. The limits of detection (LODs) were 0.23 µg-
As/L, 0.11 µg-Cd/L, 0.23 µg-Hg/L, and 0.13 µg-Pb/dL. The results represent levels of 
total metal concentrations; speciation of metals was not performed. The ICP-MS analyses 
for Cd, Hg, and Pb were similar to those used in the Fourth National Report on Human 
Exposure to Environmental Chemicals (NHANES IV).  
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Statistical analysis 
Statistical analysis was conducted with the statistical package SAS 9.2 (SAS 
Institute Inc., Cary, North Carolina). Blood samples with metal levels below the LOD 
were assigned an imputed value equal to LOD/√2, as in NHANES IV [34]. The data were 
log-transformed to address the non-normal distribution of metal concentrations. 
Spearman’s correlation coefficient estimates among metal pairs and corresponding p-
values were calculated. Linear regression was performed on every pairwise metal 
combination by adjusting for maternal age to test for associations between blood metal 
levels and race (NHW served as the referent group). Additional multivariate analyses 
were performed adjusting for maternal age, race, and categorized county of residence to 
assess the relationship between metal levels and residence in individual counties. 
Furthermore, differences between the mean metal levels of individual counties were 
compared using Scheffe’s test (α=0.05). 
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RESULTS 
 
Here we monitored metal levels in blood samples collected from pregnant women 
(n=211) residing in North Carolina between October 2009 and January 2011. Study 
participant characteristics are presented in Table 1. The average woman’s age was 25 
years and ranged from 15 to 43 years. The study population was 2% Asian, 38% non-
Hispanic Black (NHB), 6% Hispanic, and 55% non-Hispanic White (NHW). The 
monitored women were residents of County A (n=50), County B (n=28), County C 
(n=50), County D (n=13), County E (n=25), and County F (n=45) in North Carolina. 
From the 211 individuals in the sample population, blood metal levels were 
detected among 138 for As (65.7%), 121 for Cd (57.3%), 134 for Hg (63.8%), and 211 
for Pb (100%) samples. Descriptive statistics of metal levels are presented in Table 2. 
The 95th percentile whole blood Cd, Hg, and Pb levels among women of childbearing age 
(age 16-49) participating in NHANES IV (n=4,241) were reported as 1.60 µg/L, 4.40 
µg/L, and 3.50 µg/dL, respectively [34]. A total of three (1.4%), five (2.4%), and four 
(1.9%) women in the study population exceeded these levels for Cd, Hg and Pb, 
respectively. Arsenic in whole blood was not measured in NHANES IV and therefore 
could not be compared to these data. However, three (1.4%) women here had levels of As 
comparable to those reported for an environmentally exposed cohort of pregnant women 
[2]. Blood Cd levels were within previously reported ranges for pregnant women, 
however, some Hg and Pb levels exceeded reported levels [35]. Specifically, of the 
pregnant women sampled, four women (1.9%) had Hg concentrations above the EPA 
blood guideline of 5.8 µg/L and two women (0.94%) had Pb levels above 5.0 µg/dL (the 
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CDC blood lead advisory level for pregnant women) [26,27] (Figure 1). Additionally, 
five women (2.3%) had blood Hg levels above the 3.5 µg/L level of concern during 
pregnancy [28,29]. 
Our analysis revealed relationships among some sample population characteristics 
and maternal metal levels. Table 3 shows the unadjusted Spearman correlation 
coefficients computed for each pairwise combination of metals.  Notably, maternal levels 
of As and Hg positively covaried in the study population (r=0.45, p<0.001). This suggests 
that for some pregnant mothers, As and Hg are elevated in tandem. Specifically samples 
collected from Counties A, C, and F demonstrated a significant positive correlation 
between maternal As and Hg (p<0.05, data not shown). No other metal pair correlations 
were statistically significant at the α=0.001 significance level. 
Our data also indicate that maternal race and residence in certain counties were 
associated with elevated body burden of some toxic metals. Linear regression of maternal 
race on metal levels adjusted for maternal age is presented in Table 4. The results reveal 
that NHB maternal race was associated with increased blood As (p<0.05) and Cd levels 
(p<0.001) when compared to NHW mothers. Asian women in this study also appear to 
have elevated levels of As, Cd, and Hg, although the sample size was small and 
additional study is needed to verify this trend.  
 Table 5 shows the geometric mean metal levels by coded maternal county of 
residence. The compared differences among average metal levels in individual counties 
using Scheffe’s test after adjusting for maternal age and race are also displayed. The 
highest geometric mean As level (0.87 µg/L) was in County F. The As levels in samples 
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collected from Counties C and F were significantly elevated when compared to at least 
one other county (Scheffe’s p<0.05; Table 5). Cd levels in samples collected from 
Counties A and C were significantly elevated when compared to at least one other county 
(Scheffe’s p<0.05), and the highest geometric mean level of Cd (0.27 µg/L) was in 
County A. Among Hg levels, samples from County F had the highest geometric mean Hg 
(0.87 µg/L), and average levels in Counties D and F were significantly elevated when 
compared to one or more other counties (Scheffe’s p<0.05; Table 5). Finally, maternal 
blood levels of Pb in County C had the highest geometric mean (1.28 µg/L), and were 
significantly elevated compared individually to those from Counties A, E, and F 
(Scheffe’s p<0.05). Notably, samples collected from County C had the highest levels of 
As, Cd, and Pb. Samples collected from County F had elevated average levels of As and 
Hg. Counties A and D had elevated average levels of Hg and Cd, respectively.  Average 
Pb and Hg levels exceeded those reported for women participating in NHANES IV in 
County C and County F, respectively (Table 5) [34]. 
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DISCUSSION 
Pregnant women are exposed to toxic metals 
The aim of this study was to assess toxic metal exposure in pregnant mothers in 
North Carolina. The data suggest that indeed pregnant women in North Carolina are 
exposed to toxic metals. For each of the four toxic metals studied, more than 50% of the 
women had detectable blood levels. Specifically, depending on the metal detectable 
blood levels were found in 57-100% of the samples. Most of the metal measurements 
revealed levels of exposure that did not fall outside regulated limits. For some 
individuals, however, blood levels of toxic metals exceeded the 95th percentile of Cd, Hg, 
and Pb reported in the U.S. population. Moreover, a few women had metal levels above 
current guideline levels adopted for health protection. Specifically, some women had 
blood metal levels above reference values indicative of a threshold for adverse health 
effects: five women (2.3%) had blood Hg levels above 3.5 µg/L and two women (0.94%) 
had Pb levels greater than 5.0 µg/dL (the CDC blood lead advisory). Since no current 
threshold levels exist for As in blood we compared our findings with a previous study by 
Concha et al [2]. Three women in our study showed levels similar to those reported 
among As-exposed pregnant women served by contaminated public water supplies 
containing up to 200 µg/L As (blood range: 5.6-13 µg/L) [2]. In addition, thirty-seven 
women had blood levels greater than 1 µg/L, a level previously associated with known 
exposure to As in drinking water [36].  
 
As and Hg are positively correlated in pregnant mothers’ blood  
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Environmental exposures in the general public more commonly occur as mixtures 
than as single-contaminant exposures. Contaminant mixtures can contribute to an 
individuals’ susceptibility and potentially have synergistic effects resulting in disease 
manifestation [37,38].  Here we examined the correlation of the four toxic metals among 
the pregnant women. Notably, we report a relationship between maternal As and Hg 
blood levels. An implication of this finding is that maternal and fetal body burden may 
result from combined or interactive effects of more than one metal. Thus, concomitant 
exposure is an important consideration in future studies that assess in utero health 
outcomes from metal exposure.  
 
Non-Hispanic Black maternal race is associated with increased Cd  
The findings also highlight associations between blood metal levels and maternal 
race. Our data suggest that across the sample population NHB maternal race was 
associated with increased Cd exposure compared to NHW women. To our knowledge 
this association has not been previously reported. Poor birth outcomes in North Carolina 
and across the U.S. disproportionately affect infants born to NHB mothers [39,40], 
despite the lack of a definitive causal mechanism. Our findings suggest that the role of 
maternal race in birth outcome etiology may be confounded by metal exposure, and 
further investigation of social, environmental, and genetic factors disproportionately 
affecting NHB mothers is needed. 
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County of residence is associated with mothers’ metal levels 
This initial study suggests that on average, women residing in various North 
Carolina counties experience differential exposure to toxic metals during pregnancy. We 
show that on average, pregnant women residing in Counties C and F were likely to have 
higher levels of As when compared to women residing in the other counties. Exposure to 
As primarily occurs through ingestion of food and drinking water [41]. In public drinking 
water supplies, allowable levels of As can range up to the EPA Maximum Contaminant 
Level (MCL) of 10 µg/L. As such, individuals can be exposed to detectable levels of As 
that are still within regulatory guidelines. We have shown recently that in North Carolina, 
some counties have elevated levels of As in unregulated private well water [23]. Here we 
show that women living in Counties C and F have elevated blood As, two counties that 
were not identified as particular outliers in the well water analysis. This could suggest an 
alternate route of exposure among residents, perhaps through diet. In addition, this study 
did not select for individuals based on their type of drinking water source. Taken 
together, these results suggest that a future study of women supplied by private drinking 
water sources may be prudent.   
We also found that on average, pregnant women residing in Counties D and F 
also had elevated levels of blood Hg. Most Hg exposures in the U.S. are attributable to 
diet, particularly fish consumption [42]; however, dental amalgams [4] and some 
industrial processes also contribute to human exposure [43]. In North Carolina, a 
statewide freshwater fish advisory for mercury (specifically in largemouth bass) has been 
in effect since 2009. A recent study in Durham County, North Carolina found that the 
type of fish consumption and corresponding Hg content varied among different 
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demographic groups of pregnant women [24]. There are no reports of public or private 
well drinking water Hg levels above acceptable EPA MCL standard of 2 µg/L in either of 
these counties. 
Cadmium exposure commonly occurs through food consumption or inhalation of 
cigarette smoke, although minor exposure can occur from byproducts of industrial 
processes [44]. Previous studies have shown Cd levels in maternal and cord blood are 
higher in smokers [45], and that Cd levels among smokers were reportedly 4-5 times 
higher than nonsmokers [46]. Moreover, Cd levels in pregnant women exposed to 
second–hand smoke were double that of nonsmokers [6]. In our study, residence in 
County A was associated with increased maternal blood Cd levels; yet, the smoking rate 
in this county is lower than the statewide rate (20.9% of adults) [47].  Detectable levels of 
Cd in public drinking water can range up to 5.0 µg/L (the EPA MCL) and may 
potentially contribute to low-level exposure in the general population. Further research is 
needed to establish the source of maternal Cd exposure.  
Exposure to Pb can result from various environmental sources such as 
contaminated dust or soil, drinking water, lead-based paint, cigarette smoke, as well as 
byproducts of industrial processes [48]. Elevated maternal blood levels of Pb were 
associated with residence in County C. Similar to the other metals, Pb levels in public 
drinking water supplies can range up to the 15 µg/L and up to 10% of samples can exceed 
this level under EPA guidelines. Currently, no evidence indicates that North Carolina 
public water sources contain endemic levels of lead. While drinking water is a potential 
route of lead exposure, rural counties may experience additional risk factors for Pb 
exposure such as older housing and low socioeconomic status that may put mothers at 
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risk [49].  
Although the design of this study did not allow us to ascertain exposure sources, 
both anthropogenic and environmental sources can contribute to an individuals’ toxic 
metal exposure. Body weight, race, occupational factors, duration of residence, 
socioeconomic status, smoking status, gestational time during pregnancy, and genetic 
factors can affect the body burden of metals. It is likely that multiple exposure routes and 
sources may have contributed to the metal levels assessed in this study and warrant future 
follow-up. 
 
Biomonitoring programs may reduce the risk of prenatal metal exposure 
Despite evidence that adverse health effects are attributable to in utero metal 
exposure, currently Minnesota, New York City, and New York State are the only 
jurisdictions that have active guidelines for monitoring maternal blood lead levels in the 
U.S. [26]. The initiation of statewide metal biomonitoring programs in the U.S. may be 
accomplished through collaborations with state programs to better protect public health, 
particularly in susceptible populations such as pregnant women and children. This study 
demonstrates that detectable metal levels were present in maternal blood and suggests 
that further biomonitoring of blood levels of toxic metals in susceptible North Carolina 
populations is prudent. Furthermore, in lieu of existing targeted biomonitoring programs, 
public health strategies to prevent exposure such as raising awareness among pregnant 
mothers may be vital to protecting the health of newborns.   
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In conclusion, this study demonstrates that the pregnant women under study were 
exposed to four toxic metals at detectable levels. Specifically, we show evidence of 
elevated levels of As, Hg, and Pb among some women in the third trimester of 
pregnancy. In addition, we identified statistically significant relationships between 
maternal As and Hg in blood levels. Furthermore, we report associations between 
maternal blood metal levels and maternal race as well as county of residence. The 
increased levels of one or more of these metals are associated with detrimental 
neurological and physiological developmental outcomes. Informing pregnant women of 
the sources of toxic metals such as diet (including drinking water), cigarette smoke, and 
other environmental sources may help to reduce exposures. Targeted national, statewide, 
and community level programs promoting mothers’ awareness of metals exposure and in 
utero effects would each help to protect human health and lessen the economic burden of 
metal exposure. Biomonitoring programs in North Carolina and other at-risk areas can 
help to protect the health of expectant mothers and their children. 
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FIGURES 
 
 
Figure 1. Boxplots of blood levels of As, Cd, Pb, and Hg in 211 pregnant women 
residing in North Carolina. Solid horizontal lines indicate guideline values believed to 
be protective of fetal health. Dashed lines represent established guideline levels for the 
general public. No values have been established for As or Cd. The center horizontal line 
in each box blot corresponds to the sample median and the central plus sign corresponds 
to the sample mean. Horizontal lines also represent the 25th and 75th percentiles as well as 
minimum and maximum measured values. *Lead units are expressed in µg/dL. 
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TABLES 
  
Table 1. Characteristics of the pregnant women (n=211) in the third trimester of 
pregnancy. 
 
Maternal age (years), mean±SD (range) 25.0±5.7 (15-43) 
Race/ethnicity, n (%)  
Asian 4 (2%) 
Non-Hispanic Black 79 (38%) 
Hispanic 13 (6%) 
Non-Hispanic White 115 (55%) 
County of residence, n (%)  
County A 50 (24%) 
County B 28 (13%) 
County C  50 (24%) 
County D 13 (6%) 
County E 25 (12%) 
County F 45 (22%) 
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Table 2. Detectable levels and geometric averages of the four toxic metals in women. 
 
Blood Metals  n % Detected Geometric Meana (range) 
Arsenic 210 65.7 0.445 (<0.23 - 8.58) µg/L 
Cadmium 211 57.3 0.181 (<0.11 - 2.79) µg/L 
Mercury 210 63.8 0.453 (<0.23 - 11.78) µg/L 
Lead  211 100 0.890 (0.19 - 7.72) µg/dL 
aThe geometric mean was calculated with measures <LOD assigned values of LOD/√2 
[35].  
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Table 3. Spearman’s rank correlation coefficients for metals in blood of North 
Carolina pregnant women (n=211). 
 As Cd Hg Pb 
As 1. -0.14* 0.45** 0.12 
Cd  1 -0.21* 0.07 
Hg   1 0.19*  
Pb    1 
*P<0.05; **P<0.001; Data below detect were assigned imputed values of LOD/√2 
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Table 4. Linear regression of age-adjusted maternal race on blood metal levels (Beta 
coefficient and 95% CI). NHW served as the referent group. 
 Asian Hispanic NHB NHW (ref) 
As 0.51 (0.14-0.88)* -0.13 (-0.35-0.08) 0.12 (0.02-0.23)* -- 
Cd 0.39 (0.01-0.77)* 0.20 (-0.02-0.41) 0.25 (0.15-0.36)** -- 
Hg 0.64 (0.23-1.05)* -0.07 (-0.31-0.16) 0.01 (-0.11-0.12) -- 
Pb -0.01 (-0.24-0.22) -0.08 (-0.21-0.05) -0.07 (-0.13- -0.00)* -- 
* p<0.05; ** P<0.001; Metal levels were log-transformed.  
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Table 5. Concentration of As, Cd, Hg, and Pb in maternal blood collected from women 
residing in selected North Carolina counties – reported as the geometric mean. 
 
 Maternal blood concentrationa (µg/L)* 
 As Cd Hg Pb 
County A (n=50) 0.29 0.27B 0.28 0.70 
County B (n=28) 0.36 0.14 0.39 0.89 
County C (n=50) 0.49A 0.23B 0.40 1.28D 
County D (n=13) 0.33 0.09 0.70C 1.02 
County E (n=25) 0.39 0.11 0.45 0.69 
County F (n=45) 0.87A 0.17 0.87C 0.86 
Total (n=211) 0.44 0.18 0.45 0.89 
NHANES IV NA 0.33 0.78 1.22 
Abbreviations: NA not available; NHANES: Geometric mean levels (2003-2004) 
reported for women (n=4,241) participating in NHANES IV [35]. 
a Concentration reported as the geometric mean blood levels collected from women in the 
third trimester of pregnancy. 
*Units of Pb are expressed in µg/dL 
AArsenic levels in County C were significantly elevated compared individually to County 
A (Scheffe’s p<0.05). As levels in County F were significantly elevated compared to 
each of the other five counties individually (Scheffe’s p<0.05). 
B Cadmium levels in County A were significantly elevated compared individually to 
County B, D, and E (Scheffe’s p<0.05). Cd levels in County C were significantly 
elevated compared individually to County D and E (Scheffe’s p<0.05) 
C Mercury levels in County F were significantly elevated compared individually to 
County A, B, and C (Scheffe’s p<0.05).  Hg levels in County D were significantly 
elevated compared individually to County A (Scheffe’s p<0.05). 
D Lead levels in County C were significantly elevated compared individually to County 
A, E, and F (Scheffe’s p<0.05).  
APPENDIX THREE: CADMIUM-ASSOCIATED PATTERNS OF DNA 
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ABSTRACT  
Cadmium is prevalent in the environment and understudied as a developmental toxicant. 
It can cross the placental barrier from mother to fetus and is linked to detrimental effects 
in newborns. This study examines the relationship between maternal exposure to 
cadmium and leukocyte DNA methylation patterns in seventeen mother-newborn pairs. A 
methylated cytosine-guanine (CpG) island recovery assay was used to assess over 4.6 
million sites spanning 16,421 CpG islands. Exposure to cadmium was classified for each 
mother-newborn pair according to maternal blood levels and compared to levels of 
cotinine. Comparative methylation analysis was performed to identify genes with 
differential methylation levels. DNA motifs that were overrepresented among the 
differentially methylated genes were identified. Subsets of genes were identified that 
showed altered DNA methylation levels in fetal DNA associated with exposure to 
cadmium (n=61), cotinine (n=366), or both (n=30). In maternal DNA, several 
differentially methylated genes were associated with cadmium (n=92) and cotinine 
(n=134) exposure. Relative differences in DNA hyper- or hypo- methylation in selected 
maternal samples were reproducible using an alternate technology. While the gene sets 
were largely distinct between mothers and newborns, functional similarities at the 
biological pathway level were identified including transcriptional regulation and 
apoptosis. Furthermore, conserved DNA motifs with sequence similarity to specific 
transcription factor binding sites were identified within the CpG islands of the gene sets. 
This pilot study provides evidence for distinct patterns of DNA methylation alterations or 
“footprints” in fetal and maternal DNA associated with exposure to cadmium.  
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INTRODUCTION  
Cadmium (Cd) is a heavy metal that ranks among the top ten chemicals in the 
Agency for Toxic Substances and Disease Registry priority list of hazardous substances 
[1]. Cd is a known lung carcinogen and a putative carcinogen in other tissues including 
the liver, prostate, kidney, bladder, stomach, and pancreas [2-4]. Cd is widespread in the 
environment and is found in byproducts of industrial processes, contaminated water or 
soil, certain foods such as shellfish, and tobacco products [5]. Cd in the blood has a half-
life of approximately 3-4 months and can range up to 10 years [6]. 
  Environmental and low level health effects of Cd are of growing interest in the 
environmental health field, particularly among susceptible populations such as pregnant 
women and children [7]. Of concern, among pregnant women (n=253) studied in the 
Fourth National Report on Human Exposure to Environmental Chemicals (NHANES 
IV), 66% had detectable blood Cd levels with an average level of 0.22 µg/L [8].  Given 
that fetal levels correlate with maternal levels [9, 10], we sought to determine the impact 
of Cd exposure on DNA methylation patterns in a cohort of mother-baby pairs in Durham 
County, North Carolina.  
Cd is a component of cigarette smoke and concurrent exposure is common. In 
utero exposure to both Cd and cigarette smoke is associated with lower newborn birth 
weight [9, 11, 12]. Further, Cd has been suggested to be the component of cigarette 
smoke that affects fetal skeletal growth [13]. Prenatal tobacco smoke exposure is a 
known modifier of DNA methylation patterns [14-16] and is therefore an important 
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consideration in this study. Cotinine, the primary metabolite of nicotine and biomarker of 
cigarette smoke exposure, is a reliable measure of actual dose received with a half-life of 
less than one day [17, 18]. Thus, cotinine is a general measure of recent exposure to 
tobacco products, whereas Cd can represent long term and historic tobacco exposure. In 
addition, diet is the major source of Cd exposure among non-smokers [6]. Therefore, in 
this study we measured maternal cotinine and Cd levels to compare and contrast the 
methylation levels associated with either contaminant and to differentiate Cd-specific 
patterns in DNA methylation from those associated with cotinine.  
Prenatal Cd exposure has been inversely associated with fetal growth parameters 
such as newborn length, weight, height, and head circumference [9, 12, 19-24], as well as 
adverse cognitive developmental effects later in life [23, 25]. The modes of action of 
health effects related to prenatal Cd exposure are not well established. An epigenetic 
mechanism has been hypothesized [26], but is understudied in human populations. DNA 
methylation is an epigenetic mechanism that may play a key role in mediating biological 
processes [27], possibly contributing to subsequent health effects resulting from 
environmental toxicant exposure. Indeed there is evidence from animal and cell culture 
studies that Cd alters DNA methyltransferase activity and subsequently DNA methylation 
[2, 26, 28-33]. Thus, in an effort to understand potential impacts of prenatal Cd exposure, 
we assess DNA methylation in blood leukocytes and distinguish between Cd- and 
cotinine-associated changes. Here we examine genome-wide site-specific DNA 
methylation changes associated with in utero and maternal Cd exposure. 
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RESULTS 
This study consisted of 34 subjects, 17 mother-newborn pairs, selected as a nested 
cohort from the CEHI Healthy Pregnancy, Healthy Baby study in Durham, North 
Carolina. Maternal and infant characteristics are presented in Table 1. The average 
maternal age was 28 years. Most of the women had more than one child (n=13; 76.5%), 
including the infants described in this study. There were similar proportions of male 
(n=9; 52.9%) and female children (n=8; 47.1%).  All newborns, with one exception, had 
a birth weight greater than 2500 g with a range of 2495 to 3740 g. Levels of maternal Cd 
ranged from below detect to 1.05 µg/L with an average maternal blood concentration of 
0.44 µg/L. Ten mothers in the study had Cd levels above the NHANES median level in 
pregnant women and were classified as the “higher cadmium-exposed” group (See 
Methods and Materials). Maternal cotinine levels ranged from below detect to 166.96 
µg/L with an average of 14.5 µg/L. Eleven mothers had a detectable level of cotinine and 
were classified as “cotinine-exposed”. Of the mothers with detectable blood levels of 
cotinine, only two women had levels above 10 µg/L (a level associated with active or 
passive smoking activity [17]).  
Linear regression analysis revealed that maternal Cd or cotinine levels did not 
vary significantly with respect to maternal age, race, parity, child’s sex or birth weight. 
Exclusion of the low birth weight infant from the dataset did not significantly affect 
regression analyses (data not shown). Generally, younger mothers had higher levels of 
Cd, but this finding was not statistically significant (p>0.05). A linear relationship 
between maternal serum cotinine and Cd levels was not observed (p=0.6); however, 
Spearman rank correlation revealed a positive association (r=0.62, p=0.008).  
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Cd-associated gene-specific DNA methylation  
Methylated DNA collected from each newborn and mother was isolated using 
Methyl-CpG-binding domain protein 2 (MBD2) and hybridized onto Affymetrix Human 
Promoter 1.0R arrays. This resulted in the assessment of 4.6 million sites that were 
bioinformatically analyzed in the context of human CpG islands enriched in the promoter 
regions of 16,421 genes as in our recent publication [34] (see Methods and Materials).  
Prior to analysis for the exposures of interest, differences in average methylation 
levels associated with maternal age, race, and infant sex were identified. Analysis of 
DNA methylation patterns from maternal DNA revealed there was a significant 
difference in gene specific methylation levels associated with mothers’ age (n= 596 
genes) and race (n=83 genes). In fetal DNA, there was significant difference in gene 
specific DNA methylation levels associated with maternal age (n=39 genes), race (n=949 
genes), and infant sex (n=176 genes) (Supplemental Material, Table S1).  
In relation to newborn environmental exposures of Cd and cotinine, two gene sets 
were identified with significantly different average methylation abundances in fetal DNA 
that were Cd-associated (n=61 genes) or cotinine-associated (n=366 genes) (Figure 1A-B, 
Supplemental Material, Table S2). For the fetal DNA assessment, one gene was 
hypomethylated with increasing Cd, and five were hypomethylated with respect to 
increasing cotinine (Figure 1C). A total of 30 hypermethylated genes overlapped between 
the Cd and cotinine gene sets (Figure 1C, Supplemental Material, Table S2).  
In maternal DNA, distinct sets of Cd-associated (n=92) or cotinine-associated 
genes (n=134) were identified (Figure 1A-B, Supplemental Material, Table S3). For the 
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maternal DNA assessment, eleven of the 92 Cd-associated differentially methylated 
genes were hypomethylated, whereas four of 134 cotinine-associated genes were 
hypomethylated. There were no overlapping genes between differentially methylated Cd- 
or cotinine-associated genes in maternal DNA (Figure 1D). None of the Cd-associated 
genes were the same between mothers and newborns. Very few (n=12) of the cotinine-
associated genes were differentially methylated in both newborns and mothers. The 
majority of differentially methylated genes had increasing promoter methylation with 
increasing Cd or cotinine level for both fetal and maternal DNA.   
An independent technology was used for validation analyses to assess methylation 
levels, namely, the Illumina HumanMethylation450 BeadChip (450K). Maternal DNA 
from two mothers was selected based on stratified Cd-exposure status. Eighty-three of the 
92 Cd-associated differentially methylated islands identified in maternal DNA with the 
MIRA assay were also contained on the Illumina 450K platform. A total of 68 out of the 
83 CpG islands (82%) showed concordant hyper- or hypo- methylation between the two 
platforms (Supplemental Material, Table S3). The data also showed a statistically 
significant Spearman rank correlation (r=0.35; p=0.0009) comparing average methylation 
levels at CpG islands contained on both platforms.  
In addition to identifying genes that are differentially methylated and associated 
with Cd or cotinine levels, a comparison was also performed between the DNA 
methylomes of mothers and newborns. Regardless of environmental exposure, this 
comparison of the 34 individuals’ methylomes showed that there were 12,820 genes 
significantly differentially methylated between fetal and maternal DNA that were not due 
to differences in maternal age, race, or infant sex (Supplemental Material, Figure S1). All 
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of the 12,820 genes showed lower average methylation abundance in maternal DNA 
when compared to fetal DNA.  
Biological functions are enriched among differentially methylated genes 
The Cd- and cotinine-associated gene sets in mother-baby pairs were analyzed to 
determine whether they encode proteins that play a similar role in the cell. Each of the 
gene sets was analyzed for enriched biological functions using two independent methods 
(see Materials and Methods). The most significant enriched biological functional 
categories were gene expression, cell cycle, cell death, and nervous system development 
(Table 2). Interestingly, while there was no overlap between the individual gene sets, 
genes that encode proteins that play a role in regulation of transcription were enriched 
among Cd-associated genes in both fetal and maternal DNA (p<0.001). Apoptosis was an 
enriched biological process in mothers and newborns for genes associated with either Cd 
or cotinine levels (p<0.05).  
 
Common DNA motifs identified in gene sets 
We hypothesized that the identified genes may contain common underlying 
sequences or motifs. To examine this, the individual promoter regions of CpG islands for 
each differentially methylated gene were analyzed for statistically enriched common 
sequence patterns (e.g. motifs). The motifs were then compared with known transcription 
factor binding sites. Among the Cd- and cotinine-associated gene sets, significantly 
enriched motifs of conserved DNA sequences were identified (Figure 2). The conserved 
motifs showed sequence similarity to binding sites for several transcription factors 
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including: transcription factor 7-like 1 (TCF7L1 also known as TCF3), metal-responsive 
transcription factor-1 (MTF-1), transcription factor AP-2-eplison (TCFAP2E) and serum 
response factor (SRF) (Table 3). Notably, for the Cd-associated gene sets identified in 
maternal and fetal DNA, the enriched motifs had significant sequence similarity to the 
binding sites of MTF-1 and TCF7L1.  
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DISCUSSION 
There is growing evidence that the prenatal environment may influence the 
burden of disease in adult life, and that this relationship is strongly associated with 
epigenetic modifications induced during the prenatal period [27, 35]. Given the 
relationship of Cd with birth outcomes in humans [9, 12] and its known role as a 
mediator of DNA methyltransferase activity [26], we set out to identify patterns of 
differential methylation in newborn and maternal leukocyte DNA associated with 
exposure to Cd. The data were compared to cotinine-associated patterns of differential 
methylation.  
The data from this study support that there are marked differences between the 
leukocyte methylomes of mothers and their newborns, and that the methylation patterns 
are largely distinct based on the environmental exposure to Cd or cotinine for both 
mothers and their babies. Notably, the genes that are identified as differentially 
methylated for both of the environmental exposures contain common DNA 
motifs/sequence and the CpG islands in their promoter regions encode proteins with 
conserved biological processes in the cell.  
The suggested impacts of Cd exposure include enzyme inhibition, generation of 
reactive oxygen species, and perturbation of apoptosis or cell cycle [36]; however, the 
ability to create genomic instability without genotoxic action has strongly suggested an 
epigenetic mechanism of Cd toxicity [26]. Cd-associated genome-wide DNA methylation 
has not been previously assessed in human samples. Here sets of genes with altered 
methylation levels that were associated with in utero exposure to Cd- (n=61) and 
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cotinine- (n=366) were identified. Only thirty of the genes overlapped between the Cd- or 
cotinine associated gene sets in newborns. Among mothers, the  Cd- (n=92) and cotinine-
associated (n=134) gene sets were identified. There was no overlap between the Cd- or 
cotinine associated gene sets in the maternal DNA. When the Cd- and cotinine-specific 
gene sets were contrasted between mothers and newborns, we found that these sets were 
largely distinct; none of the Cd-associated genes, and very few (n=12) of the cotinine-
associated genes, were similar between mothers and newborns. Overall, the majority of 
the differentially methylated genes showed increased average methylation levels with 
increasing exposure. Similar to the findings here, previous in vitro and ex vivo 
experiments showed that Cd exposure led to hypermethylation of DNA after prolonged 
chronic exposures, however hypomethylation was present after acute Cd exposure [26, 
29, 30]. A study of adult non-smoking women in Argentina found no significant 
association between blood Cd and global or site-specific methylation levels within 
promoter regions of two candidate genes; however, global hypomethylation was 
associated with urinary Cd levels [37].   
The Illumina 450K platform was used as an alternate technology to substantiate 
methylation levels across the Cd-associated gene set (n=92) for which 83 CpG islands 
were contained on both arrays. Validation was performed on two maternal DNA samples 
stratified by Cd-exposure status. A significant Spearman rank trend was observed 
between the MIRA and 450K platform methylation levels (R=0.35; p=0.0009). A 
majority of the CpG islands (82%) had concordant relative hyper- or hypo- methylation 
on the 450K platform in the Cd-exposed versus unexposed mothers.  
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A larger number of genes with differential DNA methylation were associated with 
cotinine exposure in maternal DNA (n=134 genes) and fetal DNA (n=366 genes), 
compared to the number of Cd-associated genes. Three previous studies of prenatal 
cigarette smoke exposure examined gene-specific DNA methylation [14-16]. One study 
reported global hypomethylation with gene-specific hypermethylation of eight genes 
investigated [14] while the other found largely gene-specific hypomethylation among 38 
total genes [15]. The third study reported 26 significant CpGs mapped to 10 genes with 
both hyper- and hypomethylation associated with plasma cotinine levels [16]. None of 
the genes identified were common between the three studies and none are similarly 
reported in the present study. There are several factors that could potentially influence 
differences in observed methylation patterns that include exposure type, exposure 
duration, tissue type (i.e. buccal vs. placental vs. cord blood), subject’s age at sampling, 
type of assay used or other unaccounted for co-exposures.  
These data also highlight that regardless of exposure, there were significantly 
different methylation profiles between mothers and newborns that were not due to 
differences in maternal age, race, or infant sex. This is supported by a recent study that 
compared to newborn DNA, less methylation is observed among CpG island promoters 
in older individuals [7]. The increased methylation levels in newborns has relevance for 
developmental biology, and further evaluation of these basic processes may increase our 
understanding of how early life exposure resulting in epigenetic shifts can have long-term 
health effects. 
To classify the differentially methylated genes by known ontologies, two 
independent enrichment analyses were used. Transcription regulatory processes emerged 
	   172	  
as significantly enriched among the Cd gene lists in both fetal and maternal DNA. Cell 
death, specifically apoptosis, was a significantly enriched function for each gene list. Cd 
has been shown in vitro to perturb pathways involved in inflammatory response, cell 
survival, apoptosis, tumorigenesis, and oxidative stress [26, 38-41]. In animal models, in 
utero exposure to Cd is associated with a wide range of cell cycle and proliferative 
genomic responses [42]. These data support an epigenetic mechanism, namely DNA 
methylation, by which genes involved in transcriptional regulation and apoptosis may be 
altered by Cd exposure. RNA is not available for the specific study subjects analyzed 
here for gene expression analysis at a functional level. Therefore, these data are 
interpreted with caution, as it is not anticipated that all of the changes in DNA 
methylation will impact gene expression. 
Of interest, many of the genes contained in the Cd and cotinine gene sets showed 
common patterns in DNA sequence in the CpG islands within promoters. Among these 
conserved motif regions, binding sites for a common set of transcription factors were 
identified. The specific binding of transcription factors to target sites is a recognized 
mechanism that protects CpG islands from methylation [43, 44]. Recent studies have 
demonstrated that transcription factor binding results in local regions of low methylation 
and in contrast, absence of DNA-binding factors triggers the remethylation of local 
promoter regions [45, 46]. The identified conserved motifs showed sequence similarity to 
several binding sites including TCF7L1, MTF-1, TCFAP2E and SRF. Notably, MTF-1 is 
known to respond to changes in cellular concentrations of multiple metals and coordinate 
expression of genes protective against metal toxicity [47, 48]. The motifs with sequence 
similarity to TCFAP2E and SRF binding sites were found only in gene sets identified in 
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newborns, but not mothers. All of the identified transcription factors are known to 
regulate developmental processes within cells and are worthy of future investigation [49-
52].  Taken together, these results suggest that patterns of DNA methylation that are 
associated with Cd may represent “footprints” indicating transcription factor presence or 
absence that occur during periods of DNA methylation. Further research is needed to 
validate this hypothesis.  
The cord blood sampling done here is representative of newborn leukocyte DNA 
rather than potential target organ systems such as the kidney, liver, or bone. There are 
obvious ethical and technical reasons to use leukocyte DNA as a proxy for target tissue 
analysis. Peripheral blood leukocyte patterns of DNA methylation have not been shown 
to differ greatly among cell types [16, 53]. Moreover, the use of circulating white blood 
cells as proxies for disease has been shown [54, 55]. In addition, there is increasing 
evidence that there are contaminant-specific changes to DNA methylation associated with 
various environmental contaminant exposures [34, 56, 57]. Future studies should aim to 
investigate tissue-specific differences as they relate to contaminants of interest. In this 
study, RNA was not available to confirm gene expression levels in the cord blood. In 
future studies, genomic examination of the epigenetic gene targets identified here will aid 
understanding of how methylation may alter gene expression and subsequent disease 
manifestation. 
This study provides evidence of Cd- and cotinine-associated DNA methylation 
changes in the leukocyte DNA of newborns and their mothers. This study identifies 
genome-wide site-specific DNA methylation changes associated with in utero Cd 
exposure, and distinguishes these from methylation changes attributable to cotinine 
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exposure, a general proxy measure for exposure to tobacco products. These distinct 
patterns of environmentally-associated DNA methylation alterations or footprints in fetal 
and maternal DNA may have functional consequences in the cell and warrant further 
research. Maternal metal exposure continues to be an important area of public health 
concern for both maternal and child health. Increased education about the potential risks 
of environmental contaminants including Cd and cigarette smoke will be key to reducing 
and preventing harm to infants. 
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MATERIALS AND METHODS 
Study participants 
The Children’s Environmental Health Initiative (CEHI) conducted a prospective 
cohort study of pregnant women living in Durham County, North Carolina from 2005-
2011. This study is a key component of the Southern Center on Environmentally-Driven 
Disparities in Birth Outcomes (SCEDDBO), an interdisciplinary center aimed at 
understanding how environmental, social, and host factors jointly contribute to health 
disparities (http://cehi.snre.umich.edu/projects/sceddbo/). The CEHI Healthy Pregnancy, 
Healthy Baby study was reviewed and approved by the Institutional Review Boards at 
Duke University (Pro00007633) and the University of North Carolina (#09-0866). All 
women participating in this study consented for maternal venous and newborn cord blood 
collection for chemical and genetic analysis.  
Women receiving prenatal care at either the Duke Obstetrics Clinic or the Durham 
County Health Department Prenatal Clinic were eligible to participate if they planned to 
deliver at Duke University Medical Center, were at least 18 years of age, were English-
literate, lived in Durham County, and did not have a multi-fetal gestation or any known 
fetal genetic or congenital anomalies. Additional methods on subject recruitment, 
enrollment, and data collection have been described previously [58]. Women were 
enrolled between 18 and 28 weeks of pregnancy, and demographic data were collected 
including maternal age, race, and parity, as well as child’s sex and birthweight. At 
delivery, biological samples including maternal venous blood and newborn cord blood 
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were collected. From the CEHI study, we selected a nested subcohort of 17 mother-infant 
pairs stratified by maternal Cd level (see Supplemental Material).  
 
Methylated CpG island recovery assay (MIRA)  
Venous maternal blood and newborn cord blood samples were obtained at 
delivery. DNA was extracted using Qiagen’s PAXgene Blood DNA kit (Qiagen, 
Valencia, CA) according to manufacturer’s protocol. DNA was re-suspended in nuclease-
free water and stored at -80C prior to DNA methylation assessment. CpG methylated 
DNA was collected using the MethylCollector Ultra Kit (Active Motif Carlsbad, CA) and 
enriched DNA was amplified using the WGA2 kit (Sigma, St Louis, MO) according to 
manufacturer instructions. Amplified DNA was then hybridized to the Affymetrix 
Human Promoter 1.0R arrays (Affymetrix, Santa Clara, CA) which quantitates 
methylation at over 4.6 million probe sites. 
 
Statistical analyses  
 Linear regression analyses were performed using the statistical package SAS 9.3 
(SAS Institute Inc, Cary, NC) to examine relationships between maternal blood Cd 
levels, serum cotinine levels and demographic characteristics for women and children. 
Maternal demographics included age, race, and parity, and children’s demographics 
included sex and birthweight. The relationship between Cd and cotinine was assessed 
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with linear regression as well as Spearman rank correlation. Cd and cotinine levels below 
detect were treated as zero.  
The study subjects’ data for each of the 4.6 million probe sets resulting from the 
MIRA assay were normalized using robust multi-chip average then summarized at a 
gene-specific CpG island level based on the reference Human Genome 18 (HG18) [59]. 
The resulting average methylation abundances for 16,421 CpG islands were compared 
using ANOVA (Partek Genomic Suite 6.4, St Louis Missouri). Differential methylation 
was assessed for each island and statistically defined as: (i) average island promoter 
methylation with a minimum absolute change of 30%; and (ii) a p-value < 0.05. 
Additionally, a false discovery rate (FDR) corrected q-value estimate was calculated and 
is reported. After identifying covariate-associated DNA methylation within CpG islands 
(see Supplemental Material), differential methylation was also examined according to 
sample type (maternal versus newborn), higher versus lower Cd-exposed, and cotinine-
exposed versus cotinine-unexposed (see Supplemental Material). The same statistical 
requirements were applied to all analyses.  
 
Gene ontology/pathway enrichment analysis 
Gene ontology/pathway enrichment analysis was performed using two independent 
methodologies. The differentially methylated genes were analyzed in the context of 
interacting networks using Ingenuity Pathway Analysis Software (Ingenuity Systems, 
Inc., Redwood City, CA) and functional clustering using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (available 
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online: http://david.abcc.ncifcrf.gov/tools.jsp). Methods are provided in Supplemental 
Material. Pathway enrichment analysis was performed for the exposure-specific gene lists 
for both mothers and newborns to identify biological pathways significantly associated 
with the differentially methylated gene sets. 
 
 
Enriched DNA motif identification 
CpG island sequences were retrieved from the UCSC genome browser website 
[60] for each exposure-associated methylated gene set. These sequences are 
representative of CpG islands within promoter regions. Position specific letter probability 
matrices, also known as motifs, were identified using Multiple Em for Motif Elicitation 
(MEME) version 4.8.1 [61]. A first order Hidden Markov Model and negative position 
specific priors were calculated from a background set of 200 randomly selected CpG 
island sequences that were not differentially methylated. Additional parameter 
specifications are reported in the Supplemental Material. The motif with the highest 
significance (p-value) for each group of differentially methylated genes was compared to 
known transcription factor binding sites using TOMTOM [61].  
 
Illumina Methylation 450K BeadChip Validation 
 Additional DNA methylation analysis was performed on two maternal DNA 
samples stratified by maternal blood Cd levels (0.8 µg/L vs. below detect) and matched 
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on maternal race, age and insurance status. Bisulfite conversion was performed using the 
Zymo EZ DNA Methylation kit (Zymo Research, Irvine, CA) according to manufacturers 
instructions. Methylation was assessed at 485,577 CpGs in maternal DNA using the 
Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, CA). 
BeadChip processing was performed at Expression Analysis Inc. (Durham, NC; 
www.expressionanalysis.com) and processed with Illumina’s GenomeStudio Methylation 
module Version 1.8 (Illumina Inc., San Diego, CA). The proportion of methylation (β) 
for each CpG was calculated as the ratio of methylated signal intensity divided by the 
sum of both methylated and unmethylated signals.  
For statistical comparison, the 92 differentially methylated Cd-associated genes in 
maternal DNA were extracted from the Illumina 450K results. Because the MIRA 
technology enriches for promoter regions, the 450K data were filtered for probe sets 
positioned in islands. For quality control, probes with a detection p-value greater than 
0.0001 were removed prior to analysis. This resulted in 83 genes for comparison between 
the two platforms. Average β values for island-associated CpG sites were calculated and 
a β value ratio equal to the average β for the Cd-exposed mother divided by the 
unexposed mother was calculated for each gene. To compare relative differences in 
methylation across the platforms, the β value ratio was converted to a log2 fold change. A 
Spearman rank correlation and corresponding p-value were calculated to compare the 
450K β ratio to the MIRA fold changes across the two platforms.  
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FIGURES 
 
 
Figure 1. Heat map of differentially methylated genes in fetal and maternal DNA 
associated with Cd (A), or cotinine (B). Venn diagram representing the total number 
of Cd-or cotinine-associated differentially methylated genes among newborns (C) or 
mothers (D). Heat maps represent average DNA methylation levels of exposure-
associated gene sets (p<0.05). Data are z-score normalized for each gene. Individuals are 
ordered form left to right based on increasing level of exposure. Red color indicates a 
relative increase in average DNA methylation and blue color represents a relative 
decrease in average DNA methylation. In Venn diagrams, number in parentheses 
indicates the number of hypomethylated genes contained in each set. Abbreviations: LE – 
lower exposed, HE – higher exposed, UE – unexposed, E – exposed. 
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Figure 2. Significantly enriched DNA motifs identified within the Cd and cotinine-
associated gene lists in fetal DNA (A) and maternal DNA (B) as identified by 
MEME. The motifs shown have standard orientation 5' to 3'. Estimates of sequence 
conservation at each nucleotide position within the motif are shown where a higher bit 
score is represented by increased font size.  
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TABLES 
 
Table 1. Characteristics of mother-newborn pairs (n=34 subjects) from Durham, 
North Carolina.  
 Mean ±  SD (range) / N (%) 
Maternal cadmium (µg/L) 0.44 ± 0.31 (0 - 1.05) 
  
Maternal cotinine (µg/L) 14.5 ± 42.23 (0 - 166.96) 
  
Maternal age (years) 28 ± 7 (19-42)    
  
Maternal race*  
NHB / 12 (70.6) 
NHW / 4 (23.5) 
Other / 1 (5.8) 
  
Parity  
First / 4 (23.5) 
Second / 5 (29.4) 
Third or higher / 8 (47.1) 
  
Child’s Sex  
M / 9 (52.9) 
F / 8 (47.1) 
  
Birth weight (g) 3210 ± 377 (2495-3740) 
*This study intentionally over-sampled NHB mothers. 
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Table 2. Enriched biological functions within the differentially methylated gene sets 
(p<0.05).   
  Fetal DNA Maternal DNA 
Category Function 
Annotation 
Cd a Cotinine a Cd a Cotinine a 
Gene expression Regulation of 
transcription 
0.001* 
[0.01] 
-- 0.001* 
[0.001] 
-- 
Tissue 
morphology 
Adipose tissue 
quantity 
0.004 -- -- -- 
Cancer  Hyperplasia 0.004 -- -- -- 
Lipid metabolismb Lipid 
accumulation 
0.005 -- -- -- 
Cell death Apoptosis 0.02 
[0.05] 
0.001* 1.2×10-4* 
[0.04] 
0.05 
Cell cycle Delay in G1, 
interphase 
-- 3.0×10-5* 
[0.003] 
-- -- 
Nervous systemc Neuronal 
quantity 
-- 0.002 
[0.03] 
5.2×10-5* 
[0.03] 
-- 
Cell proliferation Tumor 
proliferation 
-- 0.002  -- 0.03 
Protein 
degradation 
Proteolysis -- 0.003 
[0.003] 
-- 0.01 
Infectious disease Replication of 
virus 
-- -- -- 0.01 
Neurological 
disease 
Movement 
disorder 
-- -- -- 0.02 
*p<0.001; [ ] = p-value of gene ontology terms in DAVID. 
a Associated contaminant exposure in fetal or maternal DNA 
b Lipid metabolism, molecular transport, small molecule biochemistry 
c Nervous system development and function 
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Table 3. Transcription factor binding sites showed sequence similarity to the 
identified motifs within each Cd- or cotinine-associated gene set. 
 Fetal DNA Maternal DNA 
Transcription 
Factor 
Cd a Cotinine a Cd a Cotinine a 
TCFAP2E 2.3×10-5* 9.2×10-4* -- 4.9×10-3 
TCF7L1 6.7×10-5* 2.0×10-5* 5.1×10-4*	   1.5×10-4* 
SRF 2.2×10-4* 3.2×10-4* 1.5×10-3	   5.0×10-3 
MTF1 3.1×10-4* 1.6×10-4* 3.5×10-4*	   2.0×10-3 
* p< 0.001 
a Associated contaminant exposure in fetal or maternal DNA 
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